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ABSTRACT 
Beckwith Wiedemann syndrome (BWS) and Birt-Hogg-Dube syndrome (BHD) are two 
examples of genetic conditions that are associated with an increased risk of renal neoplasia 
(Wilms tumour and renal cell carcinoma (RCC) respectively). BWS is a model imprinting 
disorder characterised by overgrowth, developmental defects, predisposition to embryonal 
tumours and results from disordered expression of imprinted genes on chromosome 
11p15.5. There is an association between the use of assisted reproductive technologies 
(ART) and BWS. BHD is an autosomal dominantly inherited condition characterised by 
cutaneous fibrofolliculomas, lung cysts predisposing to spontaneous pneumothorax and an 
increased lifetime risk of RCC and is caused by germline mutations in the FLCN gene. Both 
BWS and BHD show phenotypic variation in their manifestation. The clinical and molecular 
genetic investigations described in this thesis aimed to uncover factors influencing variation 
in phenotypic expression in these two conditions. Conclusions: Phenotypic variation in BWS 
can result from locus heterogeneity, epigenetic and environmental modifiers. Phenotypic 
variation in BHD may reflect allelic heterogeneity and the presence of genetic modifiers. 
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CHAPTER 1. GENERAL INTRODUCTION 
For the purpose of this thesis I will give a brief general introduction in this section on the 
epidemiology of renal cancer followed by an introduction to renal cell carcinomas and 
Wilms tumour, the two renal tumour types that are associated with Birt-Hogg-Dube 
syndrome and Beckwith-Wiedemann syndrome respectively. As I am using the two 
conditions to investigate factors that affect variability of phenotypic expression, I will 
present my investigation of the conditions in separate chapters for each syndrome. 
Therefore for each chapter, I will give a detailed introduction to the syndrome, the sub-aims 
of the chapter, the material and methods of investigation, the results and discussion. At the 
end of the thesis, I will present the overall conclusions and future directions with this 
research. 
1.1 RENAL CANCER 
1.1.1 EPIDEMIOLOGY OF RENAL CANCER 
In the UK, renal cancer is now the 8th commonest cancer in men and the 9th commonest in 
women(Cancer Research UK, http://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/kidney-cancer, Accessed May 2016). Renal cancer 
affecting adults includes malignant tumours arising from the renal parenchyma and renal 
pelvis. The predominant renal cancer arises from the renal parenchyma and is mainly 
adenocarcinoma or better known as renal cell carcinoma. Renal cell carcinoma (RCC) 
accounts for around 80% of all renal cancers in the UK. Renal pelvis cancers are mostly 
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transitional cell cancers. It is rare for people under the age of 40 years to develop renal 
cancer.  However, Wilms tumour (nephroblastoma), an embryonal malignant tumour 
usually occurs in children (Curado et al., 2007).  
1.1.2 AETIOLOGY OF RENAL CANCER 
Risk factors for the development of renal cancer include 
 Smoking 
 Obesity 
 Hypertension 
 Genetic predisposition or Family history 
 Predisposing renal disease that requires dialysis 
 Hepatitis C infection 
 Previous treatment for testicular or cervical cancer  
 
There is evidence that cigarette smoking increases the risk of renal cell carcinoma by 50% 
and may account for about one third of cases of renal cancer (Chow et al., 2010). The risk 
increases in a dose-dependent manner with the amount of cigarette smoked. Cessation of 
smoking reduces this risk only in quitters of ten years or more (Hunt et al., 2005). Cigarette 
smoking is postulated to increase the risk of renal cancer by chronic tissue hypoxia as a 
result of carbon monoxide exposure and smoking related disease such as chronic 
obstructive pulmonary disease (COPD) (Sharifi et al., 2006). In addition, there are higher 
levels of DNA damage in the peripheral blood lymphocytes due to tobacco-specific N-
nitrosamine in renal cell cancer patients compared to normal controls (Clague et al., 2009). 
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Obesity is another risk factor for the development of renal cancers with a linear relationship 
with increasing body weight. This effect is seen more prominently in women (Renehan et 
al., 2008). Although several mechanisms to explain how obesity is associated with this 
increased risk have been postulated, direct evidence in humans is lacking. These 
mechanisms include insulin resistance and compensatory hyperinsulinaemia, tissue hypoxia, 
hormonal imbalance, obesity related inflammatory response and oxidative stress 
(Klinghoffer et al., 2009). 
Other risk factors that are associated with an increased risk of renal cancers include 
hypertension, pre-existing renal disease, previous chemotherapy for treatment for other 
cancers, and other medications such as phenacetin containing analgesics (Chow et al., 
2010). I will be discussing the genetic factors that can increase the risk of renal cancers in 
relation to renal cell carcinomas and Wilms tumour below.  
1.2 RENAL CELL CARCINOMA 
1.2.1 EPIDEMIOLOGY OF RENAL CELL CARCINOMA 
RCCs are heterogeneous tumours of the renal tubular epithelium. The highest incidence of 
RCC occurs between the ages of 50 and 70 years. 
1.2.2 SUB CLASSIFICATION OF RENAL CELL CARCINOMA 
RCC can be subclassified depending on their location within the nephron and the cell types 
from which the tumour originates.  
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Clear cell RCC and papillary RCC originate from the epithelial cells of the proximal tubules 
whereas chromophobe and collecting duct tumours originate from the collecting duct 
(Thoenes et al., 1986). 
Histologically, there are 5 major subtypes of RCC: Clear cell (conventional) RCC (accounts for 
70-80%), papillary (chromophile) (10-15%), chromophobe (3-5%), collecting duct (1%) and 
unclassified (1%).  
The Heidelberg classification subdivides renal cell tumours into benign or malignant 
tumours and where possible, each category is linked to the most commonly documented 
genetic abnormalities (Kovacs et al., 1997). This is represented schematically in Figure 1-1. 
 
 
Figure 1-1 Schematic representation of the different subtypes of RCC according to the ‘Heidelberg’ 
classification in relation to their positions within the nephron and collecting tubule of the kidney 
(Bodmer et al., 2002) by permission of Oxford University Press 
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1.2.3 INHERITED FORMS OF RCC  
Characteristic features of inherited forms of RCC include a younger age of diagnosis, 
tumours occurring in both kidneys (bilateral) or multiple tumours in the kidneys at the same 
time (multifocal). Inherited forms of RCC account for about 3-4% of all RCC. The majority of 
the inherited RCC cancer predisposition syndromes are inherited in an autosomal dominant 
manner. The histology of the tumour can often provide clues into the likely inherited cause. 
Table 1 summarises the main RCC predisposing genetic conditions. 
The studies of inherited RCC predisposition syndromes have provided important insights 
into the molecular basis of tumourigenesis in renal cancer. An example of this is the study of 
von Hippel-Lindau disease (VHL) which is the commonest inherited renal cancer 
predisposition syndrome. The VHL gene was identified in 1993 and researchers were then 
able to study the VHL protein that functions as a tumour suppressor and its involvement in 
the regulation of hypoxia-response genes in the HIF (hypoxia-induced factor) pathway that 
affects proliferation and angiogenesis (Kondo et al., 2002; Latif et al., 1993; Maxwell et al., 
1999). The finding that sporadic clear cell RCC also frequently showed acquired somatic 
mutations in VHL meant that the understanding of the pathways involved in rare cancer 
predisposition syndromes have implications on more common sporadic tumours (Maher, 
2004). An example is the development of novel drugs to target the downstream targets of 
the HIF pathway now in use for the treatment of metastatic RCC (Motzer et al., 2006). 
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Table 1. Inherited disorders predisposing to RCC 
Disorder MIM Type of RCC Associated tumours and 
other features 
Gene and location 
von Hippel-Lindau 
Disease  
193300 Clear cell Retinal and CNS 
haemangioblastoma, 
phaeochromocytoma, 
pancreatic tumour, visceral 
cysts 
VHL  3p25 
Birt-Hogg-Dube 
syndrome 
135150 variable Fibrofolliculomas, lung cysts and 
pneumothorax and colorectal 
polyps 
FLCN  17p11.2 
Familial non-
syndromic clear cell 
RCC 
144700 Clear cell - ? 
Hereditary papillary 
renal cancer 
605074 Papillary 
type 1 
- MET  7q31 
Hereditary 
leiomyomatosis and 
renal cancer 
605839 Papillary 
type 2 
Cutaneous and uterine 
leiomyomas, leomyosarcoma 
FH  1q25-32 
Succinate 
dehydrogenase 
subunit mutations 
 variable Extra-adrenal and adrenal 
phaeochromocytoma, head and 
neck paraganglioma 
SDHB  1p36-p35 
SDHD  11q23 
Hyperparthyroidism-
jaw tumour 
145001 Papillary 
RCC, renal 
hamartoma, 
Wilms 
tumour 
Parathyroid tumours, fibro-
osseus mandibular and 
maxillary tumours , renal cysts 
CDC73/HRPT2  
1q25 
Chromosome 3 
translocation 
 Clear cell - Various 
Lynch syndrome  Transitional 
Cell 
carcinomas 
of the renal 
pelvis and 
ureter 
Colorectal cancer, endometrial 
cancer 
MSH2  2p22-p21 
MLH1  3p21.3 
PMS22  7p22.2 
PMS1  2q31.1 
MSH6  2p16 
Reproduced from (Maher, 2010) with permission from Karger AG, Basel. 
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1.3 WILMS TUMOUR 
1.3.1 EPIDEMIOLOGY OF WILMS TUMOUR 
Wilms tumour or nephroblastoma is the most common renal tumour of childhood and 
accounts for 6.3% of malignancies in children. Wilms tumour affects approximately 1 in 
8000-10000 children. It is named eponymously after Dr. Max Wilms who first described it.  
Around 5-10% of children who develop Wilms tumor develop bilateral or multifocal 
tumours. Although the prevalence of bilateral Wilms tumour is higher in children with a 
Wilms tumour genetic predisposition syndrome, around 85% of children with Beckwith-
Wiedemann syndrome (BWS) or Wilms tumour-Aniridia-Genital anomalies-Retardation 
(WAGR) syndrome have only unilateral tumours (Huff, 1998; Porteus et al., 2000). 
The average age of presentation in children with unilateral tumour is 42-47 months and for 
bilateral tumours, the average age is 30-33 months (Breslow et al., 1993). The male to 
female ratio is 0.92 to 1.0 with a slightly increased risk in girls. Occasionally, Wilms tumour 
can also occur in adulthood.  
1.3.2 AETIOLOGY OF WILMS TUMOUR 
Wilms tumour is an embryonal malignancy that consists of blastermal, epithelial or stromal 
cells. Wilms tumour is thought to develop due to genetic mutations that predispose to 
nephrogenic rests. Nephrogenic rests are benign foci of embryonal renal cells that persist 
abnormally into postnatal life. They are found in around 1% of newborn kidneys and should 
regress or differentiate by early childhood (Beckwith et al., 1990). The rests are considered 
to be precursors to Wilms tumours and those that accumulate additional mutations 
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transform into a Wilms tumour (Dome et al., 2002; Gylys-Morin et al., 1993). The presence 
of multiple nephrogenic rests in the kidneys is termed nephroblastomatosis. It may present 
as a diffuse overgrowth of rests, forming a rim that enlarges the size of the kidney, or as 
multiple distinct rests (Perlman et al., 2006). 
Nephrogenic rests can be classified into intralobar or perilobar rests. Intralobar rests are 
usually solitary and randomly distributed throughout the kidney. However, they are usually 
located centrally in the renal lobe. Perilobar rests are located at the periphery of the kidney 
and are often multiple. WAGR and Denys-Drash syndrome are usually associated with 
intralobar rests, and Beckwith-Wiedemann syndrome is usually associated with perilobar 
rests (Breslow et al., 2006). However, this association is not absolute. 
1.3.3 FAMILIAL WILMS TUMOUR 
A hereditary cause for Wilms tumour is thought to account for 10-15% of individuals who 
develop Wilms tumour. This hereditary cause can be syndromic or non-syndromic. 
1.3.3.1  Syndromic predisposition to Wilms Tumour 
Syndromic predisposition to Wilms tumour can generally be subdivided according to 
syndromes that involve the Wilms tumour gene WT1 or involve the chromosome 11p15.5 
imprinted locus. Table 2 summarises the features of the common syndromic causes of 
Wilms tumour. 
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Table 2. Syndromic causes of Wilms tumour 
Syndrome MIM Associated features Gene/Chromosome 
locus 
WAGR 194072 Aniridia, Genital anomalies, mental 
retardation 
11p13 deletion 
involving WT1 & 
PAX6 
Denys-Drash 
syndrome (DDS) 
194080 Male genital anomalies, microscopic  
renal anomalies 
WT1 mutations 
Frasier syndrome 136680 Male genital anomalies, microscopic 
renal anomalies, gonadoblastoma 
WT1 intron 9 splice 
site mutation 
Beckwith-Wiedemann 
syndrome (BWS) 
130650 Overgrowth, macroglossia, anterior 
abdominal wall defects 
hemihypertrophy, embryonal tumours 
Chromosome 
11p15.5 
abnormalities due 
to copy number 
changes, mutations 
or loss of imprinting 
 
1.3.3.2  Familial Non-syndromic Wilms Tumour 
1-2% of individuals who develop Wilms tumour have a family history of another affected 
relative, usually a sibling, parent, aunt, uncle or close cousin (Breslow et al., 1996).  
1.3.4 SPORADIC WILMS TUMOUR 
Somatic mutations can also be found in sporadic cases of Wilms tumour. WT1 mutations 
have been identified in 10-20% (of which >70% are somatic) of individuals who develop 
Wilms tumour without genitourinary anomalies or DDS (Dome et al., 1993).  
Somatic mutations involving WTX1 (20-30% of tumours), CTNNB1 (15%), TP53 (5%) and 
FBXW7 (4%) have been reported (Dome et al., 1993). 
10 
 
Somatic defects affecting the BWS critical region at 11p15.5 have been discovered in Wilms 
tumour tissue and in some cases in the surrounding normal renal tissue (Ogawa et al., 1993; 
Okamoto et al., 1997). Subsequently, Scott and colleagues studied the genomic DNA from 
lymphoctyes of 437 cases of non-syndromic Wilms tumour patients and detected 
constitutional 11p15.5 defects in 3% of cases (and 12% of bilateral cases) (Scott et al., 
2008a).  
1.4 AIMS OF THE THESIS 
The aim of this thesis is to explain the range of phenotypic variation in the kidney cancer 
predisposition disorders and to define potential candidates of this variability.  
Beckwith-Wiedemann syndrome is a disorder of genomic imprinting resulting in 
overgrowth, malformations and an increased risk of embryonal tumours including Wilms 
tumour. Birt-Hogg-Dube syndrome is an autosomal dominant disorder which results in a 
predisposition to benign skin tumours, lung cysts with or without spontaneous 
pneumothorax and an increased lifetime risk of renal cell carcinoma. Both conditions show 
variability in their clinical manifestations. 
Therefore these two familial kidney cancer predisposition syndromes will serve as ideal 
models to explore the genetic and epigenetic factors that might influence phenotypic 
expression. 
The phenotypic variability studied in this thesis is not just limited to kidney cancer but 
covered the whole spectrum of clinical features associated with BWS and BHD. Although the 
particular subgroup of BWS caused by imprinting centre 2 (IC2) epimutations have a 
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relatively lower risk of Wilms tumour than some other subgroups, renal tumours can occur 
and it was of interest to investigate whether there were relationships between both this and 
other aspects of BWS phenotypic variability with factors such as assisted reproductive 
technologies (ART) and the emerging entity of Muti-locus imprinting disturbance (MLID) in 
BWS. 
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CHAPTER 2. THE CLINICAL, MOLECULAR AND EPIGENETIC 
INVESTIGATION OF BECKWITH-WIEDEMANN SYNDROME 
DECLARATION: 
The results of this BWS study have been published in the journal Human Reproduction (Lim 
et al., 2009a). Sections of the introduction to this chapter have been published as review 
articles in Epigenomics (Lim et al., 2009b) and The Obstetrician & Gynaecologist (Lim et al., 
2010b). 
2.1 INTRODUCTION 
2.1.1 GENOMIC IMPRINTING 
Genomic imprinting is a form of epigenetic regulation of gene expression resulting in 
preferential expression of one allele of a gene according to the parent-of-origin of the allele. 
Imprinting can be incomplete and/or tissue or stage-specific, but when imprinting is 
complete, only one allele is expressed. Some imprinted genes are expressed from the 
paternally inherited allele and others from the maternally inherited allele (Reik et al., 2001). 
2.1.1.1 The Importance of Biparental Contribution To the Mammalian Genome 
The maternal and paternal contribution to the mammalian embryonic genomes are not 
equivalent. This was first demonstrated in experimental nuclear transfer in mouse embryos, 
which indicated that both a paternal and maternal contribution is required for complete 
embryogenesis. Diploid gynogenetic (only maternal contribution) and androgenetic (only 
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paternal contribution) embryos cannot develop normally. (McGrath et al., 1984; Surani et 
al., 1984) 
The importance of this biparental contribution to the human genome was demonstrated by 
abnormal pregnancies resulting in hydatidiform moles and ovarian teratomas. Hydatidiform 
moles can result from a conception lacking maternal contribution to the genome 
(androgenetic conceptus) (Kajii et al., 1977; Ohama et al., 1981). On the other hand, ovarian 
teratomas can occur as a result of a spontaneous activation of an ovarian oocyte, resulting 
in a duplication of the maternal genome (gynogenetic conceptus)(Ohama et al., 1985). 
Subsequently, it was demonstrated that the requirement for biparental inheritance was 
restricted to specific regions of the genomes. This was done by experiments with mice 
carrying balanced translocations that generated mouse embryos containing small genomic 
regions that were derived only from the mother or father (uniparental disomies)(Cattanach 
et al., 1985). These specific regions of the genomes were then found to harbour imprinted 
genes and the first imprinted genes were reported in 1991 (Barlow et al., 1991). 
There are currently approximately 100 imprinted genes identified in the human and/or 
mouse genomes (www.mgh.har.mrc.ac.uk/imprinting.impstables.html). Most imprinted 
genes reside in clusters and this clustering enables co-ordinated regulation of their 
expression by imprinting control elements or imprinting centres (IC) (Reik et al., 2001). 
These clusters are rich in cytosine-phosphoguanine dinucleotide sequences (CpG) islands 
(Neumann et al., 1995). 
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Genomic imprinting in mammals has also been shown to prevent parthenogenetic 
development in mice. Parthenogenesis refers to a form of asexual reproduction where 
growth and development of the embryo occurs without fertilisation by a male. 
Parthenogenetic mice embryos usually die by 10 days of gestation. The successful survival to 
adulthood in parthenogenetic mice from two maternal genomes following the deletion of 
an imprinted cluster in mice oocyte resulting in expression of paternally expressed genes 
provides further proof of the importance of biparental contribution in normal development 
(Kono et al., 2004). 
2.1.2 MECHANISMS INVOLVED IN GENOMIC IMPRINTING 
The establishment and maintenance of genomic imprinting are regulated by a number of 
mechanisms including DNA methylation, chromatin modification and expression of large 
noncoding RNAs. DNA methylation plays a crucial role in the establishment and 
maintenance of genomic imprinting (Jaenisch et al., 2003). The covalent addition of a 
methyl group to the cytosine in the unmethylated CpG dinulceotide (methylation of CpG 
dinucleotides) can affect the expression of genes in a number of ways. 
1.) Methylated CpGs in the promoter region of a gene can result in gene silencing by 
preventing the binding of transcription factors (Figure 2-1). 
2.) Methylation of CpGs can also prevent the binding of insulator proteins such as CTCF to 
methylated differentially methylated regions (DMRs) (see later). 
3.) DNA methylation can also induce changes in chromatin structure by attracting methyl-
CpG-binding proteins (MBPs) that bind to methylated CpGs and attract proteins such as 
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chromatin remodelling proteins and histone deacetylases (HDACs) resulting in modification 
of histones to produce a more compact structure (heterochromatin), which prevents gene 
transcription (Dennis, 2003). 
 
Figure 2-1 DNA methylation regulates gene expression. 
(A) The CpG island promoter is unmethylated and allows binding of transcription factors, which is 
required for transcription initiation. (B) The CpG Island promoter methylation prevents binding of 
transcription factors and results in gene silencing. (Lim et al., 2010b) by permission of John Wiley 
and Sons 
 
The epigenetic marking of the human genome by DNA methylation is heritable (from one 
cell to another during cell division), stable and allows a form of “cellular memory”. The 
process of DNA methylation is catalysed by the DNA methyltransferases. DNMT3a and 
DNMT3b are involved in the establishment of methlyation and DNMT1 is involved in the 
maintenance of methylation. This allows control of expression of developmental genes at 
specific times of embryonic development in specific tissues and also ensures maintenance of 
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the correct methylation marking of imprinted genes (Bestor et al., 1983; Okano et al., 1999; 
Pradhan et al., 1999). 
CpG islands are a common occurrence in imprinted gene domains. At imprinting centre 
associated differentially methylated regions (DMRs), the methylation status of the CpG 
islands differs according to the parent of origin (i.e., one parental allele is methylated and 
the opposite parental allele is unmethylated) (Reik et al., 2001). A key feature of parent-
specific imprinting marks in DMRs is that they are erased and then reset (established) in the 
primordial germ cells during gametogenesis to reflect the sex of the parent for the next 
generation (Lee et al., 2002; Szabo et al., 2002).  
DMRs mark imprinting control centres which can act as insulator elements regulating the 
expression of imprinted genes. One example of this is at the 11p15.5 imprinted region 
involving the IGF2/H19 locus. The H19 DMR maps between H19 and IGF2 and contains 
binding sites for a zinc finger protein, CCCTC-binding factor (CTCF). On the maternal allele 
the CTCF protein binds to the unmethylated H19 DMR and insulates the IGF2 promoter 
region from an enhancer downstream of H19. This causes the enhancer to preferentially 
interact with the H19 promoter and the untranslated H19 RNA is expressed from the 
maternal allele whereas IGF2 expression is silenced. In contrast the H19 DMR is methylated 
on the paternal allele and CTCF is unable to bind. This allows the downstream enhancer to 
preferentially interact with the IGF2 promoter and IGF2, but not H19, is expressed from the 
paternal allele (Bell et al., 2000).  
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Imprinted noncoding RNAs (e.g. H19, KCNQ1OT1) are also a frequent feature of imprinted 
gene clusters and are often in close proximity to oppositely imprinted protein coding genes. 
For examples, H19 and IGF2, KCNQ1O1T and CDKN1C, and Igf2r and Airn. The mechanisms 
by which how these noncoding RNAs affect imprinting establishment and maintenance is 
currently an area of active research. In addition, the role of chromatin modifications in the 
establishment and maintenance of imprinting is another area of active research (Kacem et 
al., 2009). 
2.1.3 MECHANISMS LEADING TO DISORDERS OF IMPRINTING 
Mutations or epimutations (pathogenic alterations in DNA methylation or chromatin 
structure without a change in DNA sequence) affecting the function of the expressed 
imprinted gene allele (but not the silenced allele) can result in an imprinting disorder. In 
addition, loss of imprinting (i.e. both alleles are expressed) can also cause disease. Common 
mechanisms that give rise to an imprinting disorder include (a) uniparental disomy (upd), (b) 
intragenic mutations or copy number alterations that directly alter the function of an 
imprinted gene and (c) mutations or epimutations in imprinting control centres that result in 
altered imprinting/expression of imprinted gene(s) (Table 3). In imprinting disorders such as 
Beckwith-Wiedemann syndrome and Silver-Russell syndrome (Abu-Amero et al., 2008; 
Cooper et al., 2005) altered gene expression from aberrant loss or gain of methylation at an 
imprinting centre DMR is the most frequent cause of disease. These epimutations result 
from a primary alteration in a DMR (in cis), but in rare cases may be secondary to alterations 
in remote (in trans) factors (Reik et al., 2001).  
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Table 3. Examples of mechanisms leading to imprinting disorders 
(Lim et al., 2010b) by permission of John Wiley and Sons 
 
Mechanism Definition/explanation 
Uniparental disomy  Both chromosomes in a cell are derived from a single parent (and 
there is no chromosomal material from the other parent). 
Uniparental disomy may affect the whole chromosome (complete) or 
part of a chromosome. If the chromosomal region contains an 
imprinted gene then uniparental disomy will be associated with 
alterations in imprinted gene expression.  
Deletion/duplication Deletions involving imprinted regions can affect imprinting by either: 
 deletion of an expressed gene on that allele (so abolishing gene 
expression); or  
 deletion of the imprinting control centre, which results in loss of 
regulatory control of imprinting.  
Duplications involving the imprinted regions can double the 
expression of imprinted genes expressed from that allele. 
Mutation Loss of function mutations in a gene on the expressed allele will 
impair gene function whereas a mutation in the silenced allele will 
have no apparent effect. Hence mutations in imprinted genes are 
associated with parent-of-origin effects on clinical phenotype.  
Epimutation An epimutation is a specific loss of methylation (hypomethylation) or 
gain of methylation (hypermethylation) at an imprinting control 
centre without any change in DNA sequence. This alters expression 
of imprinted genes on the same allele. 
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As an inherited mutation in an imprinted gene will only be of functional significance if it is in 
the expressed allele, imprinting disorders are notable for unusual inheritance patterns with 
parent-of-origin effects on penetrance and expression (Figure 2-2). In some cases, members 
of the same family may have divergent phenotypes that result from a similar genomic 
abnormality. For example, Prader Willi Syndrome and Angelman Syndrome may both result 
from deletions of chromosome 15q11-q13 and the phenotype depends on which parent the 
deletion is inherited from. 
 
Healthy carriers
Affected individuals
 
Figure 2-2 Example of parent-of-origin effects in Beckwith-Wiedemann syndrome (BWS) 
Pedigree demonstrating the manifestation of BWS in this family only when the familial CDKN1C 
mutation is inherited from the mother. 
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2.1.4 HUMAN IMPRINTING SYNDROMES 
Imprinting disorders are often associated with abnormalities of growth and development 
and there may be an increased risk of malignancy, most notably in Beckwith-Wiedemann 
Syndrome, a disease that is associated with the 11p15.5 imprinted gene cluster. The human 
imprinting syndromes are summarised in Table 4 below. The imprinted loci involved in the 
imprinting syndromes summarised are presented in Figure 2-3 and the reported 
mechanisms involved at each loci are summarised in Table 5. For this thesis, I will 
concentrate on Beckwith-Wiedemann syndrome.  
Table 4. Summary of Human Imprinting syndromes 
Human Imprinting Syndromes 
The 11p15.5 imprinted region: Beckwith-Wiedemann Syndrome (BWS) & Silver-Russell Syndrome 
(SRS): 
Beckwith-Wiedemann Syndrome (BWS) 
 Congenital overgrowth disorder associated with developmental anomalies and 
susceptibility to embryonal tumours 
 Results from alteration in expression (or function) of 11p15.5 genes IGF2/H19 and/or 
CDKN1C/KCNQ1OT1 
 Genotype-phenotype correlations exist in BWS 
 There is an increased risk of BWS in children born following assisted reproductive 
technologies (ART) 
 In IC2 epimutation cases, loss of methylation at other imprinted loci have been reported 
Silver-Russell Syndrome (SRS) 
 Congenital growth disorder characterised by growth retardation and facial 
dysmorphology. 
 Most cases are associated with an epimutation at IC1 causing loss of expression of IGF2 
(opposite to that seen in BWS) 
 5-10% of cases are due to upd(7)mat 
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The 15q11-q13 imprinted region: Angelman syndrome & Prader-Willi syndrome  
Angelman syndrome (AS) 
 Neurodevelopmental disorder characterised with severe learning disability, 
microcephaly, characteristic seizure patterns, speech difficulties, ataxia and generally 
happy demeanour 
 Caused by inactivation of maternally expressed genes on 15q11-q13 with UBE3A being the 
key gene involved 
 Reported increased risk of AS following ART 
Prader-Willi syndrome (PWS) 
 Neurodevelopmental disorder characterised by hypotonia and poor feeding in early life 
followed by excessive eating and obesity together with hypogonadotrophic hypogonadism 
and typical physical characteristics 
 Caused by inactivation of paternally expressed genes on 15q11.q13 (opposite to that seen 
in AS) 
6q24 imprinted region: Transient Neonatal Diabetes Mellitus 
 Diabetes occurs in the first 6 weeks of life which resolves by 18months of age but affected 
individuals are at risk of developing diabetes in later life 
 Associated with intrauterine growth retardation 
 Caused by biallelic expression of PLAGL1 and HYMA1 either by upd(6)pat, paternal 
duplications or epimutation at the maternal allele at the TND DMR 
 In some epimutation cases, hypomethylation of multiple imprinted loci (HIL now known 
as multilocus imprinting disturbance (MLID)) are reported 
 Homozygous mutations in ZFP57 identified in some affected individuals with HIL/MLID 
The 14q32 imprinted region: Temple syndrome and Kagami-Ogata syndrome 
Temple syndrome 
 Phenotype of initial growth retardation and hypotonia followed by precocious puberty, 
short stature and facial dysmorphisms 
 Physical characteristics overlap with PWS but mental capacity is usually normal in 70% 
and severe mental retardation is rare 
 Caused by loss of functional paternally expressed genes DLK1 and RTL1 due to 
upd(14)mat, paternal deletions or epimutation (loss of methylation) at the IG-DMR 
Kagami-Ogata syndrome 
 More severe phenotype with severe growth retardation, skeletal abnormalities, facial 
dysmorphism and abdominal muscular defects 
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 Characteristic “coat hanger rib” appearance on x-ray 
 Caused by overexpression of the paternally expressed genes especially RTL1 as a result of 
upd(14)pat, maternal deletions, and epimutation (gain of methylation) of the IG-DMR 
The GNAS imprinting cluster at 20q13: Pseudohypoparathyrodism: 
 The 20q13 imprinting cluster is complex with GNAS coding for multiple gene products via 
alternative first exons 
 The main transcript Gsα is required for hormone stimulated cyclic AMP formation 
involved with calcium homeostasis in the renal tubules 
 Pseudohypoparathyrodism refers to end organ resistance to parathyroid hormone (PTH) 
with a biochemical features of hypocalcaemia, hyperphosphataemia and elevated PTH 
levels 
 Pseudohypoprathyroidism type 1A (PHP-1A) is due to maternally transmitted heterozygous 
inactivating mutations in GNAS coding sequences and is associated with the end organ 
resistance to PTH, TSH and gonadotrophins with typical biochemical features of 
pseudohypoparathyroidism and physical features of Albright Hereditary Osteodystrophy 
(AHO) 
 Paternally transmitted heterozygous mutations in GNAS coding sequences result in 
pseudopseudohypoparathyroidism (PHPP) with AHO without the hormone resistance and 
biochemical features of pseudohypoparathyroidism 
 Pseudohypoparathyrodism type 1B (PHP-1B) have the biochemical features of 
pseudohypoprathyroidism without AHO features  
 Familial cases of PHP-1B are due to maternally inherited heterozygous STX16 deletions 
leading to isolated exon 1A DMR loss of methylation and sporadic cases are due to 
epimutations at the exon 1A DMR with or without methylation changes at the other 3 
DMRs in the cluster 
NLRP7 mutations and familial biparental complete hydatidiform moles: 
 Biparental complete hydatidiform moles are due to conceptions with both paternal and 
maternal chromosomes but there is loss of maternal methylation marks at imprinted loci 
across the genome 
 Familial cases can result from homozygous NLRP7 mutations in the mother 
 Homozygote females have normal methylation patterns in somatic cells but imprinting of 
their germ cells is defective leading to molar pregnancies and reproductive wastage 
 Homozygote males have normal methylation levels and normal fertility 
 
Republished with permission of Future Medicine Ltd, from (Lim et al., 2009b); permission conveyed through 
Copyright Clearance Centre, Inc 
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Figure 2-3 The imprinted gene clusters involved in human imprinting syndromes. 
(a) 11p15.5 in Beckwith-Wiedemann syndrome and Russell-Silver syndrome (b) 15q11-q13 in Angelman 
syndrome and Prader-Willi syndrome (c)6q24 in Transient Neonatal Diabetes Mellitus (d) 14q32 in Temple 
syndrome and Kagami Ogata syndrome (e) 20q13 in Pseudohypoparathyroidism. Arrows represent direction of 
transcription of active genes. Diagonal lines represent alternate splicing of the alternative 1st exons to 
downstream exons in the GNAS cluster. Only relevant genes at each imprinted cluster are shown. Figure is not 
to scale. Republished with permission of Future Medicine Ltd, from (Lim et al., 2009b); permission conveyed 
through Copyright Clearance Centre, Inc 
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Table 5. Human Imprinting syndromes and their reported mechanisms 
Domain Disease Cytogenetic 
abnormality 
Uniparental 
Disomy 
Gene Mutation Imprinting centre 
epimutation 
Deletions/duplicat
ions involving 
imprinting centre 
11p15.5 BWS Chromosomal 
rearrangement 
(1-2%) 
upd(11)pat 
(20%) 
CDKN1C on 
maternal allele 
(5% sporadic, 50% 
in familial cases) 
IC1 epimutation 
(H19 DMR 
hypermethylation 
(5%) 
IC2 epimutation 
(KvDMR1 
hypomethylation) 
(50%) 
IC1 deletion on 
maternal allele 
(<5%) 
IC2 deletion on 
maternal allele 
(<2%) 
 
11p15.5 SRS Maternal 
duplication of 
11p15 (<2%) 
 
upd(11)mat 
(1 case) 
IGF2 mutation on 
paternal allele (1 
family) 
CDKN1C gain of 
function mutation 
on maternal allele 
(1 family) 
IC1 epimutation 
(H19 DMR 
hypomethylation) 
(up to 70%) 
IC2 duplication on 
maternal allele (1 
case) 
7p12.2, 
7q32.2 
SRS Chromosomal 
rearrangement 
(<2%) 
Maternal 
duplication of 
7p  
upd(7)mat 
(5-10%%) 
- - - 
6q24 TNDM Visible paternal 
duplication of 
6q24 (2%) 
upd(6)mat 
(35-40%) 
- Hypomethylation 
of the TNDM 
(PLAGL1) DMR 
(20%) 
Submicroscopic 
duplication of the 
6q24 region on the 
paternal allele (35-
40%) 
14q32.2 Temple Chromosomal upd(14)mat - Hypomethylation Deletion involving 
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Syndrome rearrangement 
(rare) 
(72-80%) of the IG-DMR on 
the paternal allele 
(12-19%) 
the 14q32 
imprinted region 
on the paternal 
allele (9%) 
14q32.2 Kagami 
Ogata 
syndrome 
Chromosomal 
rearrangement  
(22%) 
upd(14)pat 
(67%) 
- Hypermethylation 
of the IG DMR on 
the maternal 
allele (19%) 
Deletion involving 
the 14q32 
imprinted region 
on the maternal 
allele (17%) 
15q11-q13 AS 5-7mb visible 
deletion on  
maternal allele 
at 15q11-q13 
(65-75%) 
Chromosomal 
rearrangement 
(<1%) 
upd(15)pat 
(7%) 
UBE3A on 
maternal allele 
(11%) 
Hypomethylation 
of the SNRPN 
DMR on the 
maternal allele 
(80-90% of 
imprinting defect 
cases) 
*2-5% of AS have 
imprinting defects 
Deletion involving 
the AS-SRO on the 
maternal allele (10-
20% of imprinting 
defect cases) 
*2-5% of AS have 
imprinting defects 
15q11-q13 PWS 5-7mb visible 
deletion on 
paternal allele 
at 15q11-q13 
(65-75%) 
Chromosomal 
rearrangement 
(<1%) 
upd(15)mat 
(25-30%) 
- Hypermethlyation 
of the SNRPN 
DMR on the 
paternal allele 
(75-80% of 
imprinting defects 
cases) 
*1% of PWS are 
due to imprinting 
defects 
Deletion involving 
the PWS-SRO on 
the paternal allele 
(15% of imprinting 
defect cases) 
*1% of PWS are 
due to imprinting 
defects 
20q13 PHP1b - upd(20)pat 
(1 report in a 
sporadic 
case) 
Familial cases: 
STX16 mutation 
on maternal allele 
leads to isolated 
Sporadic cases: 
Hypomethylation 
of the Exon1A 
DMR on the 
Deletion involving 
the GNAS 
imprinting cluster 
on the maternal 
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exon 1A DMR 
hypomethylation 
(Most familial 
cases) 
 
maternal allele 
+/- epimutation 
involving NESPAS. 
XLαS & NESP55 
DMRS (Most 
sporadic cases) 
allele (Rare – 2 
familial cases 
reported without 
STX16 mutation) 
20q13 PHP1a  Deletion 
involving 20q13 
on the maternal 
allele (1 case 
reported) 
- GNAS mutation 
(coding for Gsα) 
on maternal allele 
(Most cases) 
- - 
20q13 PPHP  Deletion 
involving 20q13 
on the paternal 
allele (1 case 
reported) 
- GNAS mutation 
(coding for Gsα) 
on paternal allele 
(Most cases) 
- - 
AS: Angelman syndrome; BWS: Beckwith-Wiedemann syndrome; DMR: Differentially methylated region; IC: 
Imprinting centre; IG-DMR: Intergenic differentially methylated region; PHP1a: Pseudohypoparathyroidism 
type 1A; PHP1b: Pseudohypoparathyroidism type 1B; PPHP: Pseudo-pseudohypoparathyroidism; PWS: Prader-
Willi Syndrome; SRO: Shortest region of overlap – region identified by deletion mapping  in AS/PWS that is 
required for correct methylation pattern and gene expression of the imprinted region; SRS: Silver-Russell 
syndrome; TNDM: Transient Neonatal Diabetes Mellitus; UPD: Uniparental Disomy. Adapted with permission 
of Future Medicine Ltd, from (Lim et al., 2009b); permission conveyed through Copyright Clearance Centre, Inc 
2.1.5 THE 11P15.5 IMPRINTED REGION 
The 11p15.5 imprinted region contains a cluster of imprinted genes including IGF2, H19, 
CDKN1C and KCNQ1OT1 (Figure 2-3(a)). The cluster can be subdivided into two domains 
containing imprinting centres which regulate the expression of these genes in cis. Imprinting 
centre 1 (IC1) located more telomerically controls the imprinting/expression of IGF2 and 
H19. Imprinting centre 2 (IC2) is located more centromerically and controls the imprinting of 
a number of genes including CDKN1C, KCNQ1 and KCNQ1OT1.  
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2.1.5.1  Normal Imprinting at 11p15.5 
IC1 is epigenetically marked by the H19 DMR which is located between H19 and IGF2 and is 
normally methylated on the paternal allele (Bell et al., 2000). As described earlier, the 
insulator protein CTCF binds to the unmethylated H19 DMR on the maternal allele resulting 
in silencing of IGF2 and preferential expression of H19 from the maternal allele. On the 
other hand, the H19 DMR is methylated on the paternal allele and hence CTCF is unable to 
bind and there is expression of IGF2 and silencing of H19 from the paternal allele (Hark et 
al., 2000)(Figure 2-4). 
IC1: H19 DMR
 
Figure 2-4 Normal imprinting at IC1 at 11p15.5. 
On the maternal allele, the H19DMR is unmethylated allowing CTCF to bind to the CTCF sites at the 
H19DMR. This acts as a boundary element preventing downstream enhancers access to the IGF2 
promoter resulting in preferential expression of H19 and silencing of IGF2 on the paternal allele. On 
the maternal allele, the H19DMR is methylated preventing CTCF from binding to the DMR allowing 
the downstream enhancers access to the IGF2 promoter. This results in preferential expression of 
IGF2 from the paternal allele. 
28 
 
IC2: KvDMR1
 
Figure 2-5 Normal imprinting at IC2. 
KvDMR1 is methylated on the maternal allele resulting in expression of CDKN1C and KCNQ1 from the 
maternal allele. On the paternal allele, KvDMR1 is unmethylated resulting in preferential expression 
of KCNQ1OT1 (the antisense transcript RNA of KCNQ1) resulting in silencing of CDKN1C and KCNQ1 
 
IC2 regulates a number of imprinted genes including the candidate tumour suppressor gene 
CDKN1C, KCNQ1 and an antisense transcript KCNQ1OT1 (a noncoding RNA previously known 
as LIT1). The DMR at IC2 is called the KvDMR1 which is located within intron 10 of KCNQ1, 
coincident with the transcriptional start site for KCNQ1OT1 (Weksberg et al., 2005). KvDMR1 
is normally methylated on the maternal allele. This results in preferential expression of both 
KCNQ1 and CDKN1C from the maternal allele. On the paternal allele, KvDMR1 is 
unmethylated and this allows preferential expression of KCNQ1OT1 and silencing of CDKN1C 
and KCNQ1 from the paternal allele (Figure 2-5)(Diaz-Meyer et al., 2003; Lam et al., 1999; 
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Smilinich et al., 1999). The mechanism by which this noncoding RNA causes silencing is still 
not understood. It remains unclear whether it causes silencing directly or as a secondary 
effect from its transcription. 
The paternally expressed IGF2 is a fetal growth promoter whereas the maternally expressed 
gene CDKN1C is a growth suppressor. As a result of genomic imprinting, there is “balance” 
between the expression of these two genes resulting in normal growth. This reflects Hague’s 
parental conflict theory of imprinting whereby it is in the interest of the father to derive 
more maternal resources to his offspring which will lead to a greater survival fitness hence 
promoting the propagation of his genes to successive generations. In contrast, the mother’s 
interest is to produce the maximum number of viable embryos in addition to ensuring her 
own nutritive needs for survival and future reproduction. Therefore embryo growth will be 
influenced by the expression of paternally derived growth promoters and maternally 
derived growth suppressors (Moore et al., 1991). 
2.1.5.2  Disordered imprinting at 11p15.5 
Disruption of imprinting at the 11p15.5 imprinted region can be caused by a number of 
mechanisms and is associated with abnormal growth, developmental defects and tumour 
susceptibility but neurological development is mostly unaffected. The two human imprinting 
syndromes, Beckwith-Wiedemann syndrome (an overgrowth disorder) and Silver-Russell 
syndrome (a disorder of growth restriction) are associated with abnormal imprinting at 
11p15.5. 
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2.1.6 BECKWITH-WIEDEMANN SYNDROME 
Beckwith-Wiedemann syndrome (BWS) is a congenital overgrowth disorder and model 
human imprinting syndrome with an estimated incidence of 1/13700 (Weksberg et al., 
2009). BWS is characterised by features of prenatal or postnatal overgrowth, macroglossia 
(enlarged tongue) and anterior abdominal wall defects. The abdominal wall defects range 
from mild divarification of the abdominal recti muscles to more severe exomphalos 
requiring surgical correction. Additionally, other clinical features that are often variable in 
presentation include facial naevus flammeus, ear lobe creases, neonatal hypoglycaemia, 
organomegaly, hemihypertrophy, genitourinary anomalies and most significantly embryonal 
tumours (Cooper et al., 2005; Elliott et al., 1994; Reik et al., 1997). 
Complications can occur due to the various features associated with BWS. Polyhydramnios 
may complicate the pregnancy and an overgrown baby may pose difficulties in delivery at 
birth. Neonatal hypoglycaemia can be severe and require treatment with intravenous 
glucose. Untreated severe hypoglycaemia may present as seizures and if prolonged may 
affect neurodevelopment. An enlarged tongue may cause feeding difficulties and surgical 
correction is needed in some cases. Learning difficulties can occur as a result of untreated 
hypoglycaemia or if associated with a chromosomal abnormality. Overall, the overgrowth 
tends to become less prominent with increasing age and the prognosis is good if 
exomphalos is treated successfully and embryonal tumours do not occur (Elliott et al., 
1994). 
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2.1.6.1  Risk of tumours in BWS 
Around 5-10% of BWS patients develop tumours which include Wilms tumour (WT; most 
common), hepatoblastoma, rhabdomyosarcoma, adrenocortical carcinomas and 
neuroblastomas. Most of the tumours occur in childhood, in the first 8 years of life with only 
a few cases being reported after this. Children with BWS are usually offered surveillance due 
to the increased risk of childhood tumours by serial abdominal ultrasound scans and 
monitoring of serum alpha-fetoprotein (Beckwith, 1998; Everman et al., 2000). Certain 
clinical features in BWS that are associated with a higher risk of developing tumours include 
hemihypertrophy, nephromegaly and nephrogenic rests (Coppes et al., 1999; DeBaun et al., 
1998).  
2.1.6.2  Molecular mechanisms affecting imprinting in BWS 
Most cases of BWS are sporadic. Familial cases of BWS account for around 15%. BWS is a 
heterogenous disorder and a wide variety of molecular mechanisms can cause disordered 
imprinting/function of IGF2 and/or CDKN1C and result in BWS. In essence, BWS results from 
the over expression of IGF2 and/or underexpression of CDKN1C (Cooper et al., 2005). The 
molecular mechanisms disrupting genomic imprinting at 11p15.5 resulting in BWS reported 
to date include: 
1. upd(11)pat (paternal uniparental disomy of chromosome 11) 
2. IC1 epimutation 
3. IC2 epimutation 
4. Intragenic CDKN1C mutation 
5. IC1 or IC2 deletion/mutation 
6. Cytogenetic abnormalities affecting 11p15.5 
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20% of BWS cases are caused by upd(11)pat (mosaic isodisomy resulting from mitotic 
recombination). upd(11)pat result in two paternal alleles producing biallelic expression of 
IGF2 and reduced expression of CDKN1C (Figure 2-6). 
IC1 epimutations with gain of methylation of the maternal allele of the H19DMR result in 
biallelic expression of IGF2 and silencing of H19 (Figure 2-7). This epimutation accounts for 
5% of BWS cases. 
IC2 epimutations with loss of methylation (LOM) at KvDMR1 on the maternal allele cause 
biallelic KCNQ1OT1 expression and loss of CDKN1C expression from the maternal allele 
(Figure 2-8). This is the commonest molecular mechanism which accounts for 50% of 
sporadic cases of BWS. 
Germline mutations in CDKN1C on the maternally inherited allele occur (Figure 2-9) in 5% of 
sporadic cases of BWS cases but account for around 50% of familial cases (Hatada et al., 
1996; Lam et al., 1999). Familial cases of BWS with CDKN1C mutations show autosomal 
dominant inheritance with parent-of-origin effects such that BWS is only seen with 
maternally transmitted mutations (see Figure 2-2 above). 
Although IC1 and IC2 epimutations usually occur sporadically, IC1 and IC2 deletions can also 
occur and lead to familial disease. IC1 deletions on the maternal allele affecting the CTCF 
binding sites are associated with apparent H19 DMR hypermethylation and biallelic 
expression of IGF2. An IC2 deletion is associated with silencing of CDKN1C. IC1 deletions 
occur more commonly than IC2 deletions (Niemitz et al., 2004; Sparago et al., 2004; Sparago 
et al., 2007).  
33 
 
Finally, cytogenetic abnormalities (chromosomal rearrangements/ translocations) leading to 
copy number changes at 11p15.5 account for under 2% of BWS cases. 
Molecular testing for BWS using methylation-specific multiplex ligation-dependant probe 
amplification (MS-MLPA) is widely used to both determine IC1 and IC2 methylation status 
and copy number (Scott et al., 2008a; Scott et al., 2008b). 
 
 
Figure 2-6 upd(11)pat causing BWS 
(a) Normal imprinting at IC1. (b) upd(11)pat in BWS. 2 copies of the paternal allele result in biallelic 
expression of IGF2 
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Figure 2-7 IC1 epimutation causing BWS 
(a) Normal imprinting at IC1. (b) IC1 epimutation in BWS. There is gain of methylation at the 
H19DMR on the maternal allele. This results in biallelic expression of IGF2. 
 
Figure 2-8 IC2 epimutation causing BWS 
(a) Normal imprinting at IC2. (b) IC2 epimutation in BWS. There is loss of methylation of KvDMR1 on 
the maternal allele resulting in biallelic expression of KCNQ1OT1 and silencing of CDKN1C and 
KCNQ1 on both alleles. 
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Figure 2-9 CDKN1C mutation on maternal allele causing BWS 
(a) Normal imprinting at IC2. (b) CDKN1C mutation in maternal allele in BWS. There is biallelic 
silencing of CDKN1C due to an intragenic mutation on the maternal copy of CDKN1C. 
 
2.1.7 GENOTYPE (& EPIGENOTYPE)-PHENOTYPE CORRELATIONS IN BWS 
Analysis of genotype-phenotype correlations in BWS have revealed key associations that 
provide important insights into the pathogenesis of specific developmental abnormalities 
which can aid clinical management (Cooper et al., 2005).  
Although various non-tumour related clinical features associated with BWS can be seen 
across all BWS molecular subtypes, genotype (& epigenotype) phenotype- correlations have 
been identified in various studies. Hemihypertrophy is seen more commonly in upd(11)pat 
(Cooper et al., 2005; Ibrahim et al., 2014; Mussa et al., 2015). Exomphalos is more common 
in IC2 epimutation and CDKN1C mutations (Brioude et al., 2013; Cooper et al., 2005; Ibrahim 
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et al., 2014; Mussa et al., 2015). Cleft palate is reported more commonly in mutations in 
CDKN1C (Mussa et al., 2015). Organomegaly is found more commonly in the IC1 
epimutation group compared to other molecular subgroups (Mussa et al., 2015). 
The overall risk of tumours in BWS as a whole is between 5-10% (Brioude et al., 2013; 
Ibrahim et al., 2014; Mussa et al., 2015). However looking at the specific subgroups of 
molecular causes in BWS reveal differences in the incidence of tumours. IC1 epimutation 
have an overall tumour risk of 28%, upd(11)pat was 16%, CDKN1C mutation was 6.7% and 
IC2 epimutation was 2.6% (Maas et al., 2016). 
Together, upd(11)pat and IC1 epimutation are associated with the highest risk of WT and 
hepatoblastoma. IC1 epimutation cases have the highest risk of WT (24%) and accounts for 
95% of malignancies in this subgroup (Mussa et al., 2016). The incidence of WT in the 
CDKN1C mutation and IC2 epimutation cases is very rare but not zero (Ibrahim et al., 2014; 
Maas et al., 2016). Increased expression of IGF2 has been shown to be linked to an 
increased WT risk in both BWS and in sporadic nonsyndromic WT cases. In BWS this is 
reflected in the increased incidence of WT in the upd(11)pat and IC1 epimutation subgroups 
as these both result in loss of imprinting of IGF2 leading to biallelic expression of IGF2. IC1 
epimutations also occur as a somatic event in many sporadic WTs (Scott et al., 2008a; Scott 
et al., 2008b).  
Hepatoblastoma is the commonest tumour in the upd(11)pat patients occurring in 5% of 
upd(11)pat patients and accounts for 25% of all tumours in this molecular subgroup (Mussa 
et al., 2016). Hepatoblastoma occurred rarely in other molecular subgroups (0.6% overall). 
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Neuroblastoma was most frequent in the CDKN1C mutation subgroup with an incidence of 
4.3% representing more than 50% of tumours reported in this molecular subgroup (Maas et 
al., 2016; Mussa et al., 2016). 
2.1.7.1 Tumour surveillance recommendation in BWS 
In the United Kingdom WT screening/surveillance has been recommended in individuals 
with a >5% risk of developing WT (Scott et al., 2006).  In BWS this can be targeted to BWS 
cases resulting from increased expression of IGF2 (upd(11)pat, IC1 epimutation, paternal 
duplication) and in cases of clinically diagnosed BWS without a known molecular cause. 
Surveillance is offered by 3-4 monthly abdominal ultrasound scans until the age of 7 years as 
the risk of developing WT following this age decreased to general population figures (Scott 
et al., 2006). 
The use of serial serum alpha-fetoprotein (aFP) measurement every 3 months until the age 
of 4 years as surveillance for hepatoblastoma have been recommended in BWS. However, 
the use of aFP as a surveillance method is currently debated due to the poor evidence on 
effectiveness, the invasiveness of regular phlebotomy in early childhood, low incidence of 
hepatoblastoma and the complexity of interpretation of aFP levels in childhood (Mussa et 
al., 2015). As a result, some centres do not currently recommend routine aFP 
measurements for hepatoblastoma. 
There is no current international consensus for tumour surveillance in BWS and practice 
may vary from not only country to county but between different clinical centres within a 
country. In the UK, the Clinical Genetics Society (CGS), a component society of the British 
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Society of Genetic Medicine, agreed WT screening should be recommended for BWS 
patients due to upd(11)pat, IC1 epimutations and those with an unknown molecular 
aetiology and not recommended in IC2 epimutation patients. However, no current guidance 
has been provided for hepatoblastoma. Therefore there is a need for an international 
consensus working group to discuss evidence based and best practice recommendations for 
surveillance and management in BWS. 
 
2.1.8 ASSISTED REPRODUCTIVE TECHNOLOGIES AND BWS AND OTHER IMPRINTING 
DISORDERS 
Assisted reproductive technologies (ART) such as in vitro fertilisation (IVF) and intra-
cytoplasmic sperm injection (ICSI) are associated with  an increased risk of prematurity, low 
birth weight, imprinting disorders and congenital malformations (mainly male urogenital 
tract anomalies) (Hyrapetian et al., 2014). ART is associated with a ninefold increased risk of 
BWS (Halliday et al., 2004). However, the absolute risk is low, in the region of less than 
0.1%. The risk of BWS following ART appears to be associated with IC2 epimutations 
(DeBaun et al., 2003; Gicquel et al., 2003; Halliday et al., 2004; Maher et al., 2003).  
Around a similar time when these observations in BWS were made, there were 2 reports 
suggesting a link between Angelman syndrome and ICSI (Cox et al., 2002; Orstavik et al., 
2003). Following these, a number of cases of Silver-Russell syndrome (SRS) were reported in 
the medical literature following the use of ART (Bliek et al., 2006; Douzgou et al., 2008; 
Kallen et al., 2005; Svensson et al., 2005).  
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Several papers have since reported correlation of ART with Angelman syndrome and Silver-
Russell syndrome(Doornbos et al., 2007; Hiura et al., 2012; Lammers et al., 2012; Sutcliffe et 
al., 2006; Vermeiden et al., 2013). Although, no correlation was found between ART and 
Prader-Willi syndrome, two studies found an increased incidence of fertility problems in 
parents of affected PWS children (Doornbos et al., 2007; Sutcliffe et al., 2006). The highest 
risks appear to be associated with BWS and SRS where a Japanese nationwide study found 
that the frequency of ART in BWS and SRS was almost 10-fold higher than anticipated 
compared to AS and PWS (Hiura et al., 2012). 
A number of studies have investigated whether ART-associated variables such as ovarian 
hyperstimulation, the timing of embryo transfer, culture, and other factors might influence 
the risk of imprinting disorders (Amor et al., 2008; Manipalviratn et al., 2009). However, 
currently, the relative importance of infertility (or treatment of infertility) and epigenetic 
changes during in vitro embryo culture is still disputed. 
 
2.1.9 BWS AND LOSS OF METHYLATION AT MULTIPLE IMPRINTED LOCI 
A subgroup of BWS patients have been discovered to have MLID i.e. altered methylation at 
DMRs in other imprinted regions in addition to 11p15.5 (Bliek et al., 2009; Rossignol et al., 
2006). 
In addition, patients with another imprinting disorder Transient Neonatal Diabetes Mellitus 
(TNDM) which are due to imprinting defects at 6q24 (See Figure 2-3, Table 4 and Table 5) 
have also been discovered to have loss of methylation at multiple imprinted loci including 
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11p15.5 (Mackay et al., 2006a; Mackay et al., 2006b). In addition to the typical clinical 
features of TNDM, these patients can have overlapping clinical features of other imprinting 
syndromes including BWS (Mackay et al., 2006b). Mutations in a zinc finger protein gene 
ZFP57 was identified as a cause of TNDM with MLID (Mackay et al., 2008). Autosomal 
recessive mutations in ZFP57 predispose these individuals to develop imprinting defects in 
6q24 and other imprinted loci. Therefore ZFP57 is a gene that affect imprinting in trans. 
ZFP57 is implicated in the maintenance of maternal and paternal DNA methylation at DMRs 
(Li et al., 2008). 
Homozygous mutations in the gene NLRP2 were identified in a mother of 2 children with 
BWS due to IC2 epimutations (Meyer et al., 2009). In contrast to ZFP57, mutations in NLRP2 
did not predispose the homozygous/compound heterozygous mutation carrier to develop 
imprinting defects. The mother with the NLRP2 mutations had normal methylation at 
imprinted loci but it was the offspring that had imprinting defects. One of her BWS child also 
had loss of methylation at a non-11p15.5 loci. This is similar to females with recessive NLRP7 
mutations (a paralogous gene to NLRP2) who have normal methylation levels themselves, 
but their conceptions are at risk of severe loss of methylation at imprinted loci across the 
genome resulting in familial hydatidiform molar pregnancies (Murdoch et al., 2006). More 
recently autosomal recessive mutations in NLRP5 have also been reported to cause affected 
women to have pregnancies at risk of methylation abnormalities resulting in imprinting 
syndromes with MLID (Docherty et al., 2015). 
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2.1.10 SUMMARY 
I have given an overview of genomic imprinting and how disruption of imprinting by a 
number of mechanisms can result in human imprinting syndromes. BWS is a model 
imprinting disorder and studies into BWS have provided novel insights into the mechanisms 
of genomic imprinting in human and pathways in growth and development. The 
identification of genotype-phenotype correlations in BWS have provided an important 
framework for diagnostic testing and surveillance in children with BWS in view of the 
increased embryonal tumour risk in childhood. The link between ART use and BWS provides 
further avenues for studying the aetiology of imprinting disorders. The identification of a 
subgroup of BWS patients with loss of imprinting at other imprinted loci (MLID) is an 
important finding which may explain phenotypic variability in BWS patients and overlapping 
phenotypes with other imprinting disorders.  
 
2.1.11 AIMS OF PROJECT 
The aim of the BWS project is to investigate the possible causes of phenotypic variability in 
BWS by elucidating the aetiology and the clinical and molecular characterisation of 
epigenetic changes in BWS. 
1. To detect the prevalence of epigenetic changes at non-11p15.5 loci in BWS patients  
It will be important to calculate the prevalence of additional epigenetic changes in a large 
cohort of BWS patients. I investigated BWS patients with IC2 epimutations for two reasons: 
1) IC2 epimutation is the predominant molecular subgroup in BWS who develop loss of 
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methylation at other imprinted loci. 2) The epigenetic alterations in non-11p15.5 in BWS 
have all affected loss of methylation at normally methylated maternal imprinted loci thus 
far. 
2. To clinically characterise the cohort of patients with additional epigenetic changes 
identified in our study and compare their phenotype with BWS IC2 epimutation cases 
without additional epigenetic changes. 
It will be important to further study the clinical features/phenotype in this subgroup of 
patients to identify further epigenotype-phenotype correlations which may aid diagnostic 
testing, surveillance and prognosis. 
3. To determine the molecular genetic defect in ART conceived BWS cases. 
Studies to date have detected that the majority of ART conceived BWS cases have IC2 
epimutations. I investigated the cause of BWS in the ART conceived BWS cases in our cohort 
to confirm this observation. 
4. To study the prevalence of additional epigenetic changes in BWS patients who were 
conceived with ART 
As ART causes an increased risk of BWS, it will be important to clarify if ART conceived BWS 
patients have additional epigenetic changes affecting other imprinted loci. As the exact 
cause of how ART causes an increased risk of BWS is still not understood, the study of BWS 
patients conceived with ART may provide novel insights into the understanding of the 
aetiology and may have implications to other children conceived by ART. 
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5. To compare the clinical features of BWS patients naturally conceived with ART 
conceived BWS patients 
I compared the clinical features of ART conceived BWS cases with a control group of 
naturally conceived BWS patients with the same molecular aetiology of BWS to generate 
comparisons between the two groups of patients.  
6. To study the phenotype of BWS patients with epigenetic changes at multiple imprinted 
loci 
I studied the clinical features/phenotype of the BWS cases (naturally conceived and ART 
conceived) with additional epigenetic changes to determine the phenotypic differences.  
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2.2 METHODS 
2.2.1 ACQUISITION AND PATIENT RECRUITMENT 
Molecular diagnostic testing for Beckwith-Wiedemann syndrome was performed in the 
West Midlands Regional Genetics Laboratory in Birmingham Women’s Hospital. 
Recruitment letters, patient information leaflets, consent forms and a clinical questionnaire 
for the study were sent to the referring clinicians of the patients tested positive for BWS. 
The clinicians would then consent the families for the research study and complete a 
standard clinical questionnaire. 
2.2.2 PATIENT ASSESSMENT 
Clinical information was obtained from the returned standard clinical questionnaire (see 
Appendix A), hospital medical notes or direct examination. 
2.2.3 CONSENT AND ETHICS APPROVAL 
Informed consent was obtained from all participants. All clinical research adhered to 
principles outlined by the Declaration of Helsinki. The BWS study is a sub-study of the 
Molecular Pathology of Human Genetic Disease study which has received ethical approval 
by the South Birmingham Research Ethics Committee (REC) (REC reference 5175) prior to 
my involvement in the project. However upon completion of my project, I have been 
involved in revising the information leaflet and consent form to an updated version that was 
submitted for an amendment in 2011 which received a favourable ethical opinion of the 
amendment by the South Birmingham REC. These are included in Appendix F. 
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2.2.4 ACQUISITION OF BLOOD OR DNA SAMPLES 
After consent was obtained, DNA samples were obtained from the stored DNA samples 
used for molecular diagnostic testing. If further DNA samples were needed, letters were 
sent to the patient’s clinicians for a repeat blood sample or an aliquot of DNA to be sent to 
the research team. 
2.2.5 MATERIALS 
2.2.5.1 Chemical reagents 
Agarose Bioline 
dNTPS (diluted from 100mM to a working stock of 2mM) Bioline 
EDTA (ethylenediaminetetraacetic avid) Sigma 
Ethanol Fisher Scientific 
Ethidium bromide Sigma 
Genescan-500 LIZ Size Standard Applied Biosystems 
Hi-Di Formamide Applied Biosystems 
Hyperladder TM I (Separation range 200- 10000bp) Bioline 
Loading buffer  
Primers Sigma 
10X TBE Electrophoresis Buffer (diluted to 1X) Geneflow 
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Water (distilled-RNase/DNase free, dH20) Invitrogen 
Big Dye Applied Biosystems 
Streptavidin -coated Sepharose beads (Biotage) 
Denaturation Solution 0.2M NaOH 
Washing buffer (1x) Biotage 
2.2.5.2 Kits 
EZ DNA Methylation Gold Kit – Zymo Research 
Pyro Gold Reagents – Qiagen/Biotage 
PyroMark Prader-Willi/Angelman Kit Biotage 
 
2.2.6 MOLECULAR GENETIC INVESTIGATION 
2.2.6.1 DNA extraction 
DNA extraction was performed by the West Midlands Regional Genetics Laboratory or by 
other NHS diagnostic laboratories in the UK. In the West Midlands Regional Genetics 
laboratory, DNA was extracted from peripheral lymphocytes in blood using the Pregene 
Genomic DNA Purification kit according to the manufacturer’s instructions. Extracted 
genomic samples were then quantified by using nanodrop (ND-1000) by measuring 
absorbance at 260nM. 
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2.2.6.2 Bisulphite modification of DNA for methylation analysis 
The analysis of DNA methylation status at CpG sites can be performed by various techniques 
using bisulphite modified DNA. Following the process of bisulphite modification, 
unmethylated Cytosines are converted to Uracil. Methylated Cytosines on the other hand 
remained unchanged by the process of bisulphite modification. This principle can then be 
used for analysis for DNA methylation changes (Figure 2-10).  
Genomic DNA derived from peripheral blood lymphocytes was bisulphite modified using the 
EZ DNA Methylation Gold kit (Zymo Research) according to the manufacturer’s protocol. 
2.2.6.2.1 EZ DNA Methylation Gold Kit Protocol 
Preparation of CT Converstion Reagent:  
900μl water, 50ul of M-Dissolving Buffer and 300μl of M-Dilution Buffer was added to one 
tube of CT Conversion Reagent and mixed for 10 minutes 
Preparation of M-Wash Buffer: 
24ml of 100% ethanol was added to the 6ml M-Wash Buffer concentrate before use. 
Protocol: 
1. 130μl of the prepared CT Conversion Reagent was added to 20μl of DNA Sample (500 
nanogram of DNA in 1ul added to 19μl of dH20) and mixed. 
2. The following temperature steps was performed: 98°C for 10 minutes, 64°C for 2.5 hours, 
then held at 4°C. 
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3. 600μl of M-Binding Buffer was added to a Zymo-Spin IC Column, followed by the addition 
of the sample. The cap was then closed and mixed by inverting several times. 
4. The column was then centrifuged at full speed (≥10,000 x g) for 30 seconds. The follow 
through was then discarded. 
5. 100μl of M-Wash Buffer was added to the column and spun 30 seconds. 
6. 200μl of M-Desulphonation Buffer was added to the column and left to stand for 15-
20minutes. 
7. The column was then spun at full speed for 30 seconds. 
8. 200μl of M-Wash Buffer was then added to the column. This wash step was repeated. 
9. 10μl of M-Elution Buffer was added directly to the column matrix and placed into a 1.5ml 
tube. The tube was then spun briefly to elute the DNA. 
10. The DNA is then ready for immediate analysis or stored at or below -20°C for later use. 
2.2.6.3 Bisulphite Sequencing of PEG1 DMR at 7q32 
Bisulphite sequencing refers to the process of conventional DNA sequencing following 
bisulphite modification of genomic DNA (Figure 2-10). Bisulphite sequencing was 
undertaken for analysis of the methylation status at the CpG sites at the PEG1 DMR at 7q32. 
Primers were designed using the Methyl Primer Express software supplied by Applied 
Biosystems ( sense primer 5’- AGTTGGGGTTGTTTTTGG-3’) and 3’ anti-sense primer 5’-
TACCAAAATCTAAAAATCCCATT-3’). This amplified a 264bp fragment which contains 15 CpGs.  
49 
 
Bisulphite Modification
CCGGCAAGCACGCGACCCCGGCGGGCAC
CH3 CH3 CH3
Unmethylated Cytosines
converted to Uracil
Bisulphite modification of DNA for methylation analysis: 
Bisulphite Seqencing
Following PCR & 
sequencing, Uracil
detected as Thymine. 
Methylated Cytosines are 
unchanged
 
Figure 2-10 Bisulphite modification of DNA 
Bisulphite modification of DNA for methylation analysis (e.g. bisulphite sequencing) 
 
In normal controls, due to genomic imprinting, the bisulphite sequencing of the PEG1 DMR 
will reveal cytosine and thymine peaks at CpG sites representing methylated and 
unmethylated alleles respectively, with taller cytosine peaks. In patients with loss of 
methylation or hypomethylation of this DMR, there will be a reversal of the peaks with taller 
thymine peaks at these CpG sites representing loss of methylation.  
Protocol: 
2.2.6.3.1 PCR amplification for sequencing 
Standard conditions for PCR amplification were used. PCR amplification was performed in 
20μl reactions as follows: 
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 2μl of Bisulphite Modified DNA 
 2μl dNTP (0.2mM) 
 1.6μl MgCl2 (2mM) 
 0.2μl Hot Star Taq 
 2μl Buffer (qiagen) 
 0.2μl Forward Primer (0.2uM) 
 0.2μl Reverse Primer (0.2uM) 
 11.8μl dH20 
PCR conditions were an initial denaturation of 95°C for 15 minutes followed by 35 cycles of 
20 seconds denaturation at 95°C, 10 seconds annealing at 56°C and 10 seconds extension at 
72°C. This was followed by a final extension step at 72°C for 5 minutes. Each set of PCR 
reactions included a negative control (in which dH20 was added instead of DNA) to check 
for contamination. 
2.2.6.3.2 Agarose gel electrophoresis 
PCR products were checked on 1.5% horizontal agarose gels to separate the PCR products 
and to ensure that the PCR reaction had worked without contamination. The agarose gels 
were made by melting agarose with 1X TBE in a domestic 600W microwave oven, then 
cooling the mixture before adding ethidium bromide (0.5g/ml final concentration) and 
casting the gel in a gel casting tray. 5ul of PCR products was mixed with loading buffer. A 
DNA sizing ladder (Hyperladder I) was added to lane 1 to check for correct PCR product size. 
Separation of DNA was achieved by electrophoresis at 60-140V for 30-120 minutes. The 
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bands were visualised using Ethidium Bromide and a UV transillumination 254nm 
wavelength). 
2.2.6.3.3 PCR product clean up 
The PCR product was cleaned up (to remove unwanted dNTPs and primer) by using Exosap 
with 9μl reaction comprising 2μl of Exosap, 2μl of dH20 and 5μl of PCR products with the 
following cycling conditions: 37°C for 30 min followed by 80°C for 15 min. 
2.2.6.3.4 Sequencing reaction 
The Exosaped PCR product was then sequenced in both forward and reverse direction using 
relevant primers. Each 10μl reaction was set up as follows: 
 4.5μl exosaped PCR products 
 0.5μl BigDye Reaction Mix 
 2.0μl 5X Sequencing buffer 
 1.0μL dH20 
 2.0μl forward or reverse primer (2μM) 
The cycling conditions were 96°C for 3 minutes followed by 30 cycles of 96°C (30s), 50°C 
(15s) and 60°C (4 min). 
2.2.6.3.5 Sequencing reaction clean-up preparation 
Sequencing reactions were cleaned up to remove any unincorporated dye terminators. The 
EDTA method of precipitation was used. To the 10μl of sequencing reaction, 1μl EDTA 
(250nM) was added and mixed before adding 30μl of absolute ethanol. This was incubated 
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for 5-10min at room temperature and then centrifuged for 20min at 2000rpm at 20°C. The 
supernatant was removed by briefly spinning the plate upside down to a maximum of 
400rpm. 90μl of 70% ethanol was then added, mixed and the plate centrifuged again for a 
further 10min at 2000rpm at 20°C. The supernatant was discarded by inverting the plate 
and spinning to 500rpm. The pellet was then left to air dry or place on heated plate for 2 
minutes. 
2.2.6.3.6 Preparation and analysis of sequencing reactions 
Pellets were resuspended in 10μl Hi-Di Formamide and then denatured for 5 minutes before 
snap-cooling on ice. Sequencing reactions were run on the ABI 3730 DNA Analyzer. Analysed 
sequences were then analysed using Chromas software, printed and relative peak heights 
ratios at CpG sites were assessed manually. 
 
2.2.6.4 Pyrosequencing of the SNRPN DMR at 15q13 
The methylation status of the SNRPN DMR at 15q13 was performed by pyrosequencing the 
using the commercially available PyroMark Prader-Willi/Angelman kit by Biotage according 
to the manufacturer’s protocol and using the Pyromark ID system. 
Pyrosequencing is a method of sequencing DNA based on the “sequencing by synthesis” 
principle. It uses the detection of pyrophosphate release on nucleotide incorporation, rather 
than traditional Sanger sequencing which uses chain termination with dideoxynucleotides. It 
offers reliable quantification of allele representation and CpG methylation status with 
inbuilt control for bisulphite modification. 
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A. Steps 1 and 2 B. Steps 3 and 4
C.  Step 5
 
Figure 2-11 Principles of Pyrosequencing 
A. Steps 1& 2     B. Steps 3 & 4      C. Step 5 
 
The Pyrosequencing reaction involves five steps (www.qiagen.com): 
Step 1 
A sequencing primer is hybridized to a single-stranded PCR amplicon that serves as a 
template, and incubated with the enzymes, DNA polymerase, ATP sulfurylase, luciferase, 
and apyrase as well as the substrates, adenosine 5' phosphosulfate (APS), and luciferin 
(Figure 2-11. A). 
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Step 2 
The first deoxribonucleotide triphosphate (dNTP) is added to the reaction. DNA polymerase 
catalyzes the incorporation of the deoxyribo-nucleotide triphosphate into the DNA strand, if 
it is complementary to the base in the template strand. Each incorporation event is 
accompanied by release of pyrophosphate (PPi) in a quantity equimolar to the amount of 
incorporated nucleotide (Figure 2-11. A). 
Step 3 
ATP sulfurylase converts PPi to ATP in the presence of adenosine 5' phosphosulfate (APS). 
This ATP drives the luciferase-mediated conversion of luciferin to oxyluciferin that generates 
visible light in amounts that are proportional to the amount of ATP. The light produced in 
the luciferase-catalyzed reaction is detected by a charge coupled device (CCD) chip and seen 
as a peak in the raw data output (Pyrogram). The height of each peak (light signal) is 
proportional to the number of nucleotides incorporated (Figure 2-11. B). 
Step 4 
Apyrase, a nucleotide-degrading enzyme, continuously degrades unincorporated 
nucleotides and ATP. When degradation is complete, another nucleotide is added (Figure 
2-11. B). 
Step 5 
Addition of dNTPs is performed sequentially. It should be noted that deoxyadenosine alfa-
thio triphosphate (dATP·S) is used as a substitute for the natural deoxyadenosine 
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triphosphate (dATP) since it is efficiently used by the DNA polymerase, but not recognized 
by the luciferase. As the process continues, the complementary DNA strand is built up and 
the nucleotide sequence is determined from the signal peaks in the Pyrogram trace (Figure 
2-11. C). 
2.2.6.4.1 Preparation of reagents 
Each PCR primer was dissolved in 120μl high purity water to give a concentration of 10uM. 
The sequencing primer was dissolved in 180μl Annealing Buffer to give a concentration of 
10μM.  
PCR amplification for pyrosequencing protocol 
50μl PCR reactions were set up using Hot Star Taq DNA polymerase (Qiagen) with the 
following: 
 1μl of bisulphite modified DNA 
 1μl Forward primer (10uM) 
 1μl Reverse primer (10uM) 
 dNTPs 5ul (2uM) 
 5μl 10X Buffer 
 0.4μl Hot Star Taq DNA polymerase 
 36.6μl dH20 
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PCR conditions were an initial denaturation of 95°C for 5 minutes followed by 50 cycles of 
20 seconds denaturation at 95°C, 20 seconds annealing at 55°C and 20 seconds extension at 
72°C. This was followed by a final extension step at 72°C for 5 minutes. Each set of PCR 
reactions included a negative control (in which dH20 was added instead of DNA) to check 
for contamination. PCR products were checked on 1.5% horizontal agarose gels to separate 
the PCR products and to ensure that the PCR reaction had worked without contamination 
(as described above). 
 
2.2.6.4.2 Sample preparation 
40μl of the biotinylated PCR product was immobilised on streptavidin-coated Sepharose 
beads (Streptavidin SepharoseTM High Performance, GE healthcare): 
1. 40μl of PCR products was added onto a normal 96 well plate. 3μl of Sepharose beads 
and 37μl of Binding buffer were added to each well with the PCR products and the 
plate was sealed. The plate was incubated at room temperature on a mixer/shaker 
for 5 mintues to keep the beads dispersed. 
2. 1.6μl of sequencing buffer (10μM) and 38.4μl of Annealing buffer were added to 
each well on a separate PSQ flat plate (PSQ96 Plate Low).  
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2.2.6.4.3 Pyrosequencer protocol 
The pyrosequencer was switched on 1 hour before use. The Pyromark ID software system 
was launched on the attached computer and the following sequence to analyse was entered 
into Pyromark ID:  
G/ACTCCATCG/ACG/ATCACG/AACCG/ACT 
Boxed nucleotides indicate control for completion of bisulphite treatment. 
The following nucleotide dispensation order was used:  
TGAGCTCATCGATCGAGTCACTGATCGAGC 
This setting was saved as a SNP run (Saved as PWS/AS).  
 
 
Figure 2-12: Vacuum Prep Worktable layout.  
Parking Position 
Water 
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2.2.6.4.4 Vacuum machine stand preparation protocol 
1. Five of the plastic troughs were placed onto the Vacuum Prep Worktable (Figure 
2-12).  
2. The troughs were filled with approximately 180ml of their respective solution (High 
purity H20, 70% Ethanol, 1X Washing Buffer), except for the trough for Denaturation 
solution (0.2mMNaOH) which was filled with approximately 120ml.  
3. The flat well PSQ plate with sequencing primer and buffer was placed in its position 
on the vacuum prep worktable (labelled in Figure 2-12) with well A1 to the front left 
at the designated position on the machine. 
4. The 96 well plate with PCR products and beads was placed onto the designated slot 
on the Vacuum Prep Woktable with well A1 to the front and left. 
5. The vacuum switch was closed (Off) and the vacuum pump was started.  
6. The vacuum was applied to the Vacuum Prep Tool by operating the vacuum switch 
(On). 
7. The probes on the Vacuum Prep Tool were washed by lowering the tool into high 
purity water (Parking position) for approximately 20 seconds ensuring that proper 
vacuum has been attained by checking that the arm of the vacuum gauge has moved 
beyond the red zone.  
8. The beads containing immobilised templates were captured on the filter probes by 
slowly lowering the Vacuum Prep toll into the PCR plate. (Capturing of the beads 
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must take place within three minutes of the agitation being terminated as sepharose 
beads sediment quickly) 
9. I ensured that the liquid has been aspirated evenly from all wells and that all beads 
have been captured onto the probe tips. The surface of the remaining solution 
should be level with or lower than the filter probe tips, when they are resting on the 
bottom of the well. 
10. The Vacuum Prep Tool was moved to the trough containing 70% ethanol (trough1) 
and the solution was allowed to flush through the filters for 5 seconds. 
11. The tool was then moved to Denaturation solution (trough2) and allowed to flush 
through the filters for 5 seconds. 
12. The tool was then moved to Washing buffer (trough 3) and allowed to flush through 
the filters for 5 seconds. 
13. The tool was picked up and moved beyond 90° vertical and held for a few seconds 
before returning to the horizontal position to allow the liquid to completely drain 
from the probe. 
14. The vacuum was closed (Off) to release the vacuum when the tool is above the flat 
well PSQ96 plate. 
15. The beads were released into the flat well PSQ96 plate. The Vacuum Prep tool was 
shaken while allowing the filter probed to rest on the bottom of the wells. 
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16. The Vacuum Prep tool was removed from the plate and the pump switched on again 
and placed into High Purity Water (trough 4) for 5 seconds then lifted to beyond 90° 
degree vertical then replaced into the parking position and the both the vacuum  and 
pump switched off. 
The steps above are summarized in Figure 2-13 below 
 
 
 
Figure 2-13 Sample preparation time line using the Vacuum Prep Tool 
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2.2.6.4.5 Primer Annealing 
1. The plate with the samples was heated at 80°C for 2 minutes using the PSQ 96 
Sample Prep Thermoplate Low. 
2. The plate was removed from the heating block and then left to cool to room 
temperature. 
2.2.6.4.6 Pyrosequencing Reaction 
1. SNP runs was selected from the General Tab. In the Setup menu, the wells used on 
the 96well plate were selected for analysis. The selection Entry was selected and the 
saved PWS/AS assay was chosen followed by Sample ID (which will print the well 
number of the report) followed by Save. 
2. The Pyromark Q96 Cartridge was loaded with Enzyme, Substrate, A, C, G, T (dNTPs) 
(Figure 2-14) from the Pyromark Gold Reagents Kit with volumes indicated on the 
computer during run Setup (Click View on General Tab). 
3. The PSQ96 Plate with the samples and the filled Pyromark Q96 Cartridge was loaded 
for analysis in the PSQ 96 instrument. 
4. The run was started by clicking Run. 
 
Figure 2-14 Illustration of the Pyromark Q96 Cartridge seen from above 
Add enzyme mixture (E), substrate mixture (S), and nucleotides (A,T,C,G) according to the volume 
information provided by the Pyromark ID software during run setup 
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Figure 2-15 Illustration of PyroMark Prader-Willi/Angelman Syndroms assay results 
Orange columns indicate quantified CpG sites. Blue columns indicate QC for completion of bisulfite 
treatment (a C followed by an A in the original sequence). The pyogram shows the reverse assay of 
the top strand (adapted from www.biotage.com) 
 
2.2.6.4.7 Pyrosequencing results 
Once run is complete, results were viewed using the Pyromark ID software according to the 
manufactures instructions. An example of analysis from the manufacturer for the 15q region 
(PWS and AS) is shown in Figure 2-15. 
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2.2.6.5  Methylation Specific Polymerase Chain Reaction (MS-PCR) of PLAGL1 DMR at 
6q24 and DLK1 IG-DMR at 14q32 
Methylation status at the PLAGL1 CpG island at 6q24 and DLK1 IG-DMR at 14q32 were 
analyzed using methylation-specific PCR (MS-PCR) using published primers (Mackay et al., 
2005; Temple et al., 2007) 
MS-PCR utilises the divergent sequence changes as a result of bisulphite modification of 
differentially methylated DNA, yielding different size product with a ratio that reflects that 
of the initial starting material. The reaction contained a forward primer and divergent 
reverse primers. 
2.2.6.5.1 PLAGL1 DMR 
Forward PLAGL1–fam CACRACATCTACCATTTATCATTCAACC     [R=A/G] 
Reverse PLAGL1 –unmeth GGTTATGATGGTGATTTGGGGAAGTGTTTTG 
Reverse PLAGL1-meth TTCGGGGAAGCGTTTCGCGCGTTAAGGTT 
The amplification reaction with a final volume of 10μl with Hot Star Taq was set up using: 
 0.2μl Forward primer (20μM PLAGL1-fam) 
 0.2μl Reverse Methylated primer (20μM PLAGL1-meth) 
 0.2μl Reverse Unmethylated primer (25μM PLAGL1-unmeth) 
 1μl dNTPs (2μM) 
 0.8μl MgCL2 
 1μl 10X buffer 
 0.2ul Hot Star Taq 
 5.4ul dH20 
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 1ul Bisulphite modified DNA 
The following cycling conditions were used: Initial denaturation 95°C for 15min followed by 
29 cycles of denaturation at 95°C for 30s, annealing at 60°C for 30s, extension at 72°C for 
30s. This was then followed by a final extension at 72°C for 5min. 
 
2.2.6.5.2 DLK1 IG DMR    
GTL2- fam CTCCAACAACAAAACCCAAAATCAAACAAACTCTC. 
GTL2b-unmeth GTGTAGATGGTGGAGAGTAGAGAGGGAGTGT 
GTL2b-meth CGCGTTTTGGTTCGTTGGTTTTGGCGGCG. 
The amplification reaction with a final volume of 10μl with Hot Star Taq were set up using: 
 0.2μl Forward primer (25uM GTL2-fam) 
 0.2μl Reverse Methylated primer (25uM GTL2b-meth) 
 0.2μl Reverse Unmethylated primer (25uM GTL2b-unmeth) 
 1μl dNTPs (2uM) 
 0.8μl MgCL2 
 1μl 10X buffer 
 0.2μl Hot Star Taq 
 5.4μl dH20 
 1μl Bisulphite modified DNA 
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The following cycling conditions were used: Initial denaturation 95°C for 15min followed by 
28 cycles of denaturation at 95°C for 20s, annealing at 60°C for 20s, extension at72°C for 
20s. This was then followed by a final extension at 72°C for 5min. 
2.2.6.5.3 Genescan of both PLAGL1 and DLK1 
The following steps were used 
1. 2.5μl of Genescan LIZ was added to 500μl of Hi-Di followed by a quick mix. 
2. 140μl of dH20 is added to the PCR products. 
3. Using a new plate, 10μl of Hi-Di/LIZ was added to each well. 
4. 1μl of diluted PCR products was added to the wells in the plate. 
5. The plate and samples was then denatured at 90°C for 5 minutes then snap cooled in 
ice. 
Methylated and unmethylated product sizes were visualised on a ABI PRISM GeneMapper 
software version 3.0 according to the manufacturer’s instruction using size standard 
GS500LIZ. Peaks were inspected and peak heights <100 or >8000 pixels were discarded. 
 
2.2.7 CALCULATION OF METHYLATION INDICES 
All experiments (bisulphite sequencing, MS-PCR, Pyrosequencing) were run in triplicate on 
at least 2 different bisulphite modified DNA for each sample. Each experiment included a 
normal control (to validate results) and a negative control (to rule out contamination). 
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Quantitative measurement of methylation levels was not possible for the PEG1 DMR due to 
the technique of bisulphite sequencing which only generates qualitative data. Quantitative 
measurement of methylation levels using MS-PCR and Pyrosequencing was possible. For 
each DMR analysed, samples from 20 normal controls were used to determine the normal 
distribution of methylation indices (methylated:unmethylated).  
For MS-PCR of PLAGL1 DMR and DLK1 IG-DMR, the methylation index is defined as the ratio 
of the area under the curve of the methylated peak to the area under the curve of the 
unmethylated peak. 
For Pyrosequencing of the SNRPN DMR, the methylation index is defined as the ratio of 
quantified G:A alleles at each CpG on the reverse strand.  
For both techniques, hypomethylation (or loss of methylation) is defined as a ratio of more 
than two standard deviations below the mean value. 
 
2.2.8 STATISTICAL ANALYSIS 
Fisher Exact testing, Wilcoxon-Rank sum, t-testing and Kaplan-Meier analysis were used as 
appropriate. Statistical significance was taken at the 5% level. 
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2.3 RESULTS 
2.3.1 PATIENT DEMOGRAPHICS 
2.3.1.1 Naturally conceived BWS IC2 epimutation patients 
87 BWS children without a history of ART with an IC2 epimutation (KvDMR1 LOM of the 
maternal allele) tested at the West Midlands Regional Genetics laboratory were identified. 
The mean age of this cohort is 6.0 years.  There were 42 males and 45 females in this group. 
The 87 children were from 87 pregnancies. There were 2 twin and 1 triplet pregnancies (all 
co-twins and co-triplets were unaffected). 
2.3.1.2 ART conceived BWS patients 
There were 25 affected BWS patients that were conceived with ART (12 IVF and 13 ICSI). The 
mean age of the group was 3.4 years. There were a total of 14 males and 11 females BWS 
patients in this group. The 25 patients were from 23 pregnancies with 10 twins (two 
affected twin pairs and six twins with no clinical evidence of BWS in their co-twins). 
2.3.2 MOLECULAR ANALYSIS OF ART CONCEIVED BWS PATIENTS  
IC2 epimutation is the predominant molecular cause of BWS in post-ART BWS patients 
24/25 (96%) post-ART patients were found to have a molecular genetic diagnosis of BWS 
with IC2 epimutation (LOM of maternal KVDMR1) found in all these 24 patients. In addition 
they had at least 2 or more clinical features. The one patient without a molecular diagnosis 
had clinical features of macroglossia, macrosomia, umbilical hernia, ear lobe creases and 
mild speech and language delay, thus fitting the clinical diagnosis of BWS. 
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2.3.3 COMPARISON OF POST-ART AND NATURALLY CONCEIVED BWS WITH IC2 
EPIMUTATIONS 
The phenotype of the 24 post ART BWS cases with IC2 epimutations was compared with the 
87 naturally conceived BWS IC2 epimutation cases. 
 
2.3.3.1 Methylation Index 
The calculated mean methylation index for KvDMR1 in the post-ART group and naturally 
conceived group were 4.6% (range 0-18) and 7.6% (range 0-13) respectively. There was no 
statistically significant difference (P=0.6) between the two groups. The operational 
diagnostic threshold for KvDMR1 LOM in the West Midlands Regional Genetics Laboratory is 
a methylation index of <20% following robust validation comparing normal controls and 
known positive controls. 
 
2.3.3.2 Clinical Features: Differences in the frequencies of exomphalos and facial 
naevus flammeus 
Table 6 summarises the frequencies of clinical features in the 2 groups.  
There was no statistically significant difference in the frequencies of the occurrence of 
neonatal hypoglycaemia, macroglossia, ear lobe creases, intellectual disability and 
hemihypertrophy in both groups.  
Facial naevus flammeus occurred more frequently in the ART conceived BWS cases. By 
contrast, exomphalos occurred less frequently in the ART conceived BWS cases. 
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Table 6. Frequency of clinical features in ART conceived BWS patients (ART Group) and naturally 
conceived BWS patients (Non-ART group) 
 ART Group Non-ART Group  
Clinical Feature Frequency (%) Frequency (%) P Value 
Neonatal 
Hypoglycaemia 
50 50 NS 
Macroglossia 89 87 NS 
Ear Creases 56 65 NS 
Hemihypertrophy 15 16 NS 
Intellectual Disability 4 4 NS 
Facial Naevus 
Flammeus 
88 46 P=0.002 
Exomphalos 39 69 P=0.015 
Exomphalos occurred less frequently in the ART group. Facial naevus flammeus occurred more 
commonly in the ART group. Statistical significance was taken at the 5% level. 
 
2.3.3.3 Embryonal Tumours: Increased risk in ART conceived BWS 
2/24 (8.3%) of the ART conceived BWS patients developed tumours whereas no tumours 
occurred in the naturally conceived BWS group. One post IVF child developed a 
hepatoblastoma at the age of 8 months and one post ICSI child developed a 
rhabdomyosarcoma at the age of 9 months. No Wilms tumour developed in both groups.  
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Figure 2-16 Kaplan-Meier curve comparing risk of embryonal tumours in IC2 epimutation BWS 
cases 
A statistically significant increased risk of embryonal tumours was demonstrated in the ART group 
(Log rank X2 = 10.18, P=0.0014) 
 
Kaplan-Meier analysis (Figure 2-16) of tumour risk in the 24 ART conceived BWS cases 
(mean age 3.4 years) and the 87 naturally conceived BWS cases (mean age 6.0 years) 
demonstrated a significantly increased risk in the ART cases (log rank X2 = 10.18, P=0.0014).  
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2.3.4 METHYLATION PROFILING OF BWS IC2 EPIMUTATION CASES 
2.3.4.1 Analysis of maternally methylated DMRs 
A cohort of 55 BWS IC2 epimutation cases (8 ART conceived and 47 naturally conceived 
BWS) in whom sufficient DNA was available, were analyzed to look at the methylation status 
at the following imprinted DMRs: 
1. PEG1 at 7q32 
2. PLAGL1 at 6q24 
3. SNRPN at 15q13 
Unfortunately, DNA from the two children with tumours was not available for analysis. 
A total of 6 BWS IC2 epimutation patients were found to have LOM at additional DMRs. 3 
were from the post-ART group and 3 from the naturally conceived group. Figure 2-17, Figure 
2-18, and Figure 2-19, show examples of the results of the methylation analysis at the 3 
DMRs affected. Figure 2-20 is a diagrammatic representation of the methylation analysis 
results. 
In the ART group the prevalence of additional LOM is 37.5% (3/8). One post ICSI child 
demonstrated additional LOM at 2 DMRs; the PEG1 and SNRPN DMRs. Another ICSI child 
had additional LOM at the PLAGL1 DMR. An IVF child had additional LOM at PEG1 DMR. In 
the naturally conceived group the prevalence of additional LOM is 6.4% (3/47). Two children 
had additional LOM at the PEG1 DMR and one child had additional LOM at the PLAGL1 DMR. 
The frequency of additional LOM was found to be significantly higher in the ART conceived 
cases compared to naturally conceived cases (37.5% vs 6.4% P=0.034). 
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Figure 2-17 Loss of methylation at PEG1 DMR in a patient with Beckwith-Wiedemann syndrome 
Bisulphite genomic sequencing trace at the PEG1 DMR. (A) Normal control. DNA sequencing shows 
both a cytosine and a thymine peak at CpG sites 11, 12 and 13, representing methylated and 
unmethlated alleles respectively, with taller cytosine peaks. (B) Patient with LOM at PEG1. DNA 
sequencing shows reversal of the expected peaks with taller thymine peaks at CpG sites 11, 12 and 
13, indicating a loss of methylation. [(Lim et al., 2009a) by permission of Oxford University Press]  
 
 
Figure 2-18 Loss of methylation at SNRPN DMR in a patient with BWS 
Reverse strand pyrosequencing trace. Percentage of methylated cytosines is represented as the 
percentage of guanine (G) and the percentage of unmethylated cytosines which normally will be 
represented by thymine is represented by alanine (A) on the reverse strand. (A) Normal control, (B) 
patient with LOM at SNRPN [(Lim et al., 2009a) by permission of Oxford University Press] 
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Figure 2-19 Loss of methylation at PLAGL1 DMR in a patient with BWS 
Electropherogram of amplification products of MS-PCR. The X axis represents the calculated product size (in bp 
and also represented as the top number in the box). The Y axis represents the peak height (bottom number in 
the box). The methylated to unmethylated ratio was calculated as the area under the curve (middle number in 
the box) of methylated versus unmethylated amplified products. (A) Normal Control (ratio 1.04) (B) Patient 
with LOM at PLAGL1 DMR (ratio 0.61) [(Lim et al., 2009a) by permission of Oxford University Press] 
Methylation Analysis
 
Figure 2-20 Diagrammatic representation of methylation analysis results in BWS IC2 epimutation 
cases 
The frequency of loss of methylation at additional DMRs was significantly higher in the assisted reproductive 
technologies group. ART: Assisted reproductive technologies. LOM+ : loss of methylation at additional DMRs.  
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2.3.4.2 Analysis of paternally methylated DMR  
The methylation status at the DLK1 DMR at 14q32 were analysed in the 6 cases found to 
have multiple maternal DMR hypomethylation above. None of these 6 cases had 
methylation abnormalities at this DMR. 
 
2.3.4.3 Analysis of clinical features of additional LOM cases 
No major phenotypic differences were evident between the children with LOM at additional 
loci and those without this epigenotype. Table 7 summarises the clinical and molecular 
characteristics of the 6 cases with additional LOM. 
In two of the three naturally conceived BWS cases with LOM at additional loci, there were 
no reports of fertility problems in the parents or the use of ovarian stimulation. 
Unfortunately, there was no information on the use of ovarian stimulation in the 3rd couple 
apart from the child was naturally conceived. 
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Table 7. Clinical and molecular characteristics of Imprinting Centre 2 epimutation Beckwith-
Wiedemann syndrome patients with additional loss of methylation at other imprinted loci 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 
Sex M F M F M M 
ART IVF ICSI ICSI No No No 
Pregnancy Singleton Singleton Twin Singleton Singleton Singleton 
Macrosomia No NR No No Yes Yes 
Exomphalos Yes No No Yes Yes No 
Umbilical Hernia No Yes Yes No No Yes 
Macroglossia No Yes Yes Yes Yes Yes 
Hemihypertrophy Yes No No No No Yes 
Embryonal 
Tumour 
No No No No No No 
Ear creases Yes No Yes NR Yes Yes 
Neonatal 
Hypoglycaemia 
No Yes Yes Yes Yes Yes 
Facial Naevus 
Flammeus 
Yes Yes Yes No Yes Yes 
Intellectual 
Disability 
No No No No No No 
6q24 (PLAGL1) 
methylation 
Normal Normal LOM Normal Normal LOM 
MI N= (0.65-1.78) 1.25 1.23 0.55 1.22 0.93 0.61 
7q32 (PEG1) 
methylation 
LOM LOM Normal LOM LOM Normal 
15q13 (SNRPN) 
methylation 
Normal LOM Normal Normal Normal Normal 
MI N= (0.55-1.1) 0.84 0.05 0.98 0.82 0.77 0.89 
14q32 (DLK1) 
methylation 
Normal Normal Normal Normal Normal Normal 
MI N= (0.5-1.4) 0.91 0.82 0.83 0.85 0.76 0.88 
11p15.5 
(KvDMR1) 
methylation 
LOM LOM LOM LOM LOM LOM 
MI 0.04 0 0 0.12 0 0.02 
 
M, male; F, female; IVF, in vitro fertilisation; ICSI, intra-cytoplasmic sperm injection; LOM, loss of 
methylation; MI, methylation index; NR, not recorded; N, normal range [(Lim et al., 2009a) by 
permission of Oxford University Press] 
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2.4 DISCUSSION 
Our BWS research group in Birmingham previously reported that six out of 149 UK children 
with BWS had a history of conception using ART (4% of BWS cases versus 1.2% of the 
general population, P=0.009)(Maher et al., 2003). Groups in USA and France also reported 
similar findings in their BWS cohorts (DeBaun et al., 2003; Gicquel et al., 2003).  Subsequent 
studies has shown a 9 to 10 fold increased risk of BWS following ART compared to natural 
conceptions (Halliday et al., 2004; Hiura et al., 2012). This project identified IC2 
epimutations in 24 of 25 post ART BWS patients. Previously IC2 epimutations was described 
in 11 of 12 ART conceived BWS patients by 2 groups (DeBaun et al., 2003; Gicquel et al., 
2003). Therefore, IC2 epimutations appear to occur more commonly in ART conceived BWS 
cases then expected when compared to the 50% expected in unselected BWS cases (Cooper 
et al., 2005). This provides further evidence for a causal link between ART and IC2 
epimutations. However, the cause for this association remains unclear.  
The process of ART with IVF requires oocyte collection and in vitro culture before the 
embryos are implanted in the womb. ICSI requires an additional step of direct injection of 
the sperm into the ovum. Many parts of the ART process could potentially affect the 
developing epigenome. These include artificial hyperstimulation of ovulation, the culture 
conditions of the embryos, effect of embryo cryopreservation and timing of embryo 
transfer. The pattern of mosaicism of the imprinting defects suggests they occurred post-
fertilisation by some mechanism that impairs the maintenance of imprints. The underlying 
mechanism allowing failure to protect imprinted loci against demethylation is unclear but 
suggests that it may fail in ART causing tissue-specific loss of imprints (Chiba et al., 2013).  
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ART is associated with an increased relative risk of imprinting disorders although the 
absolute risk is small. Experiments with animals suggest that in vitro embryo culture may be 
associated with epigenetic alterations (Dean et al., 1998; Khosla et al., 2001; Reik et al., 
1993). In particular, the Large Offspring syndrome in cattle and sheep undergoing ART has 
similar phenotypic similarities with BWS and have been associated with loss of maternal 
allele methylation at the IGF2R DMR (Young et al., 2001) and more recently IC2 
epimutations (Chen et al., 2015). However, it has been argued that either the initial 
infertility or even the use of ovarian stimulation may predispose to epigenetic errors 
(Ludwig et al., 2005). 
The underlying cause of infertility in the couple should also be considered as a potential 
cause of the methylation disturbance. Couples requesting ART have reduced fertility, 
increased reproductive loss rate and are usually of advanced parental age. These can all be 
associated with various congenital and developmental anomalies. There are reports that 
some infertile men with oligozoospermia have pre-existing imprinting errors in their sperm 
(Kobayashi et al., 2007; Marques et al., 2004). Therefore there are many confounding 
factors that make it difficult to be certain of the role of ART from the underlying fertility 
problems. Unfortunately in my study, insufficient data and difficulty obtaining further 
information on the rates of miscarriage or years trying to conceive in both cohorts made it 
difficult to study this hypothesis.  
Some insights into the association into infertility as a cause of perturbation in genomic 
imprinting come from studies into familial biparental complete hydatidiform molar 
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pregnancies where biallelic mutations in a maternal effect gene NLRP7  in the female 
predisposes to their conceptions being at high risk of reproductive wastage and biparental 
hydatidiform moles (Murdoch et al., 2006). Together with my colleague Dr Esther Meyer, 
we reported that in a consanguineous family with a recurrence of BWS in a pair of siblings 
due to IC2 epimutation, homozygous mutations in the maternal effect gene NLRP2  in the 
mother was found to be the underlying cause (Meyer et al., 2009).  MLID was present in one 
of the affected BWS siblings and the mother also had a hydatidiform molar pregnancy. More 
recently, mutations in the NLRP5 gene in females have been described as another maternal 
effect gene that can cause MLID and infertility and reproductive wastage in their 
conceptions (Docherty et al., 2015). The MLID cases reported by Docherty include clinical 
phenotypes of BWS (IC2 epimutation), SRS (H19 hypomethylation) as well as clinically non-
specific –MLID.  The NLRP5 protein is known to be a component of the subcortical maternal 
complex (SCMC) of proteins which also includes KHDC3L, TLE6 and OOEP (Zhu et al., 2015). 
The SCMC proteins have been shown to be important for progression of development 
beyond the first zygotic cell divisions.  Interestingly KHDC3L (previously known as C6orf221), 
is also a maternal effect gene which causes females with biallelic mutations to develop high 
rates of pregnancy loss and biparental complete hydatidiform moles (Parry et al., 2011). 
Therefore these observations in NLRP5 and KHDC3L suggest a role of the SCMC in 
postzygotic maintenance of DNA methylation at imprinted genes. It will be interesting to see 
if NLRP2 and/or NLRP7 turn out to be either further components of the SCMC or influences 
function of the SCMC. NLRP2 and NLRP7 have similar NACHT nucleotide binding domain and 
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Leucine-rich repeat (LRR) domains as NLRP5 and other proteins in the NLRP family (Meyer et 
al., 2009).  
These maternal effect genes NLRP2, NLRP5 and NLRP7 are examples of trans-acting genes 
that appear to regulate genomic imprinting in their offspring. This is different to the trans-
acting gene ZFP57 in which mutations predisposes to TNDM with MLID in the affected 
probands themselves (Mackay et al., 2008). The emerging role of the SCMC in human 
developing embryos may also provide insights into the role of ART in imprinting disorders 
looking in particular at the various processes of ART and their effects on the SCMC 
increasing the risk of certain imprinting disorders or MLID. 
Genotype-phenotype correlations with regards to Wilms tumour and exomphalos in BWS 
have been described previously by a number of groups (Bliek et al., 2001; Cooper et al., 
2005; DeBaun et al., 2002; Engel et al., 2000; Gaston et al., 2001; Ibrahim et al., 2014; Lam 
et al., 1999; Maas et al., 2016; Mussa et al., 2015; Sparago et al., 2007; Weksberg et al., 
2001). BWS patients due to UPD or IC1 epimutation (H19 DMR gain of methylation) are at 
significantly increased risk of Wilms tumour. To date, Wilms tumour has very rarely been 
reported in BWS patients with IC2 epimutations or with mutations in CDKN1C. By contrast, 
exomphalos occurs more commonly in IC2 epimutation and CDKN1C mutation cases but is 
rarely seen in UPD or IC1 epimutation cases.  
Chang and colleagues previously reported no phenotypic differences between post-ART and 
naturally conceived BWS cases (Chang et al., 2005). However, they did not compare like 
with like in terms of looking at the molecular causes in the naturally conceived group. As 
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described above, because the predominant molecular subtype involved in ART conceived 
BWS cases is an IC2 epimutation, in this project I compared this group with a control cohort 
of naturally conceived BWS cases with IC2 epimutations. Therefore a more direct 
comparison can be made to draw conclusions from. My data suggest that the ART conceived 
cases had a significantly lower risk of exomphalos compared to naturally conceived cases. In 
addition, there is a significantly increased risk of non-Wilms tumour neoplasia risk in the ART 
conceived group. The increased neoplasia risk, although statistically significant, should be 
considered a preliminary finding as it is based on only two cases. Caution should be 
exercised before recommending any surveillance in the ART cohort for these as the 
numbers are small. In addition, the effectiveness of surveillance for such tumours has to be 
considered. 
No Wilms tumour has been identified in both naturally conceived and ART-conceived BWS 
cases in this study. This provides further evidence that Wilms tumour surveillance is not 
indicated in BWS IC2 epimutation cases. 
It is interesting to note that a childhood tumour was present in two of the 19 post-ART 
conceived BWS children reported by Chang and colleagues (Chang et al., 2005). Rossignol 
and colleagues reported 2 of 11 BWS children with LOM at multiple loci developed an 
embryonal tumour (a rhabdomysarcoma and a hepatoblastoma) but neither of these 2 
cases were conceived using ART (Rossignol et al., 2006). Due to lack of DNA, I was unable to 
test the 2 ART conceived BWS cases who develop non-Wilms tumours in my project, to 
determine if they had LOM at multiple loci. However, it is hoped that our finding will prompt 
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other groups to examine their data to better define the relationship between ART and MLID 
in BWS children with non-Wilms tumour neoplasia. 
With regards to the lower incidence of exomphalos in the ART group, although it might be 
suggested that less severe KvDMR1 hypomethylation in the ART conceived cases might lead 
to a milder phenotype, comparison of KvDMR1 methylation indices from DNA extracted 
from peripheral leucocytes in the two groups did not show any statistically significant 
difference. However, methylation patterns may differ in different tissues. Nevertheless, this 
explanation would not account for the possible higher risk of neoplasia in the ART conceived 
cases in this study. 
The finding that BWS children with IC2 epimutations might also display loss of methylation 
at multiple imprinted loci was reported initially by Rossignol and colleagues, Bliek and 
colleagues and subsequently by Azzi and colleagues (Azzi et al., 2009; Bliek et al., 2009; 
Rossignol et al., 2006). In this study, I found significantly higher frequencies of loss of 
methylation at non-11p15.5 DMRS in the ART conceived cases compared to naturally 
conceived cases. This is in contrast with the Rossignol study and Azzi study which found 
similar rates in both groups. The Bliek study did report among the 16 BWS IC2 epimutations 
patients they detected with MLID, one child born following IVF. However, the overall 
number of BWS cases which were conceived with ART tested in their cohort was not 
reported to make comparisons.  
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Table 8. Studies reporting Multi-Locus Imprinting Disturbance (MLID) in BWS 
 Rossignol 
et al 2006 
Bliek et al 
2009 
Azzi et al 
2009 
Tee et al 
2013 
Poole et 
al 2013 
Court et 
al 2013 
Maeda 
et al 
2014 
Lim et al 
2009 
(this 
thesis) 
No of 
BWS 
cases 
40 IC2 81 IC2 68 IC2 187 IC2 21 IC2 42 IC2 44 IC2 55 IC2 
No of 
imprinted 
DMRs 
tested 
4 9 7 3 12 27 29 3 
Number 
of MLID 
cases 
10/40 
(25%) 
17/81 
(21%) 
16/68 
(24%) 
33/187 
(18%) 
8/21 
(38%) 
14/42 
(33%) 
15/44 
(34%) 
6/55 
(11%) 
ART with 
MLID 
3/11 
(27%) 
1 ART 
case (total 
unknown) 
4/12 
(25%) 
7/14 
(50%) 
0/2 (0%) Not 
specified 
2/5 (40%) 3/8 
(37.5%) 
Non-ART 
with MLID 
7/24 
(29%) 
16 non-
ART (total 
not clear) 
12/56 
(21%) 
26/173 
(15%) 
8/12 
(42%) 
Not 
specified 
13/39 
(33.3%) 
3/47 
(6.4%) 
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Subsequently, more studies have been published with increasing number of imprinted 
DMRs tested in BWS patients (Court et al., 2013; Maeda et al., 2014; Poole et al., 2013; Tee 
et al., 2013). Comparison of the results of this thesis with the other published studies 
looking at incidence of MLID in BWS including ART and number of imprinted DMRs tested 
are summarised in Table 8. There continues to be variability in the incidence of MLID 
comparing ART and naturally conceived BWS IC2 cases. The reasons for this variability may 
be due to ascertainment bias and size of cohort studied, number of imprinted DMRs studied 
and the technique used to detect the methylation changes with certain techniques having 
better sensitivity at detecting mosaic methylation changes. 
The hypothesis remains consistent that differences in the phenotype between ART 
conceived and naturally conceived BWS patients might be caused by epigenetic differences 
at these additional imprinted DMRs. Further analysis of a larger number of DMRs in more 
extensive cohorts of patients should provide further information on the relative frequency 
of hypomethylation at different loci in ART conceived and naturally conceived BWS patients.  
The additional DMR loss of methylation found in this study has been at DMRs which are 
normally methylated in the maternal allele. Due to limited amount of DNA available, the 
methylation status at the DLK-IG DMR on 14q32 was only tested in the 6 patients found to 
have additional loci LOM and there was no abnormal methylation levels detected. This DMR 
is normally methylated on the paternal allele. Our finding agrees with the finding in the Bliek 
study which also did not find any additional LOM affecting this DMR in their BWS cohort. In 
addition, a study of another imprinting disorder, transient neonatal diabetes mellitus 
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(TNDM) due to abnormal imprinting at PLAGL1 revealed that loss of methylation at 
additional loci also occurred in this group of patients but also restricted to normally 
maternally methylated DMRs (Mackay et al., 2008). They studied the DLK-IG DMR and did 
not find any abnormalities as well. Our results provide further evidence that the maternal 
allele methylated DMRs are more susceptible to epigenetic alterations. Subsequent to 
completion of this BWS project, it has now been reported that both loss and gain of 
methylation in both paternal and maternal allele methylated DMRs have been identified in 
BWS patients with MLID. ZBFDF2, NESP and ZNF597/NAA60 are paternally methylated 
DMRs that have been reported to gain methylation (Court et al., 2013; Maeda et al., 2014). 
These gains of methylation have been reported to be due to a concomitant loss of 
methylation of the GPR1-AS, GNAS and ZNF597 DMRs (all maternally methylated) nearby 
which have been shown to regulate methylation of these somatic DMRs in a hierarchical 
fashion (Court et al., 2014; Kobayashi et al., 2013; Liu et al., 2005). To date the most 
frequent DMRs affected in BWS patients with MLID are the PLAGL1, GRB10, PEG1/MEST, 
GNAS, IGF2R and ZNF331 (Court et al., 2013; Docherty et al., 2014; Tee et al., 2013).  
Analysing the phenotypes of naturally conceived cases with and without MLID did not 
identify any differences. However, the numbers were small. It will be interesting to compare 
the phenotypes of BWS cases with MLID with other imprinting disorders including a 
subgroup of TNDM patients with MLID in whom overlapping phenotypes have been 
described (Mackay et al., 2006b). 
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Recently, Poole and colleagues found that mild to moderate developmental 
delay/intellectual disability was found to occur in 8/8 of BWS patients with MLID compared 
to 3/11 non-MLID BWS patients (Poole et al., 2013). This reached statistical significance. This 
is in contrast to my study where the frequency of intellectual disability/developmental delay 
(4%) was similar in both the ART and naturally conceived BWS IC2 epimutations groups. 
There were no occurrences of intellectual disability in the MLID patients in my study. 
Previously developmental delay and intellectual disability was found to be mainly found in 
BWS cases due to duplications involving the paternal copy of 11p15.5 (Slavotinek et al., 
1997). Therefore more studies are required to clarify the risk of developmental 
delay/intellectual disability in BWS and in MLID.  
The finding that MLID was more frequently seen in ART conceived BWS cases could have 
implications for other ART conceived children. This raises the possibility of developmental 
defects, abnormal growth or childhood cancers in ART conceived children might be due to 
variable combinations of epigenetic alterations at imprinted DMRs. Williams carried out a 
large UK population-based cohort study over 17 years (1992-2008) looking at overall risk of 
cancer in ART conceived children under the age of 15 years and found no increase in the 
overall risk compared to the expected risk (Williams et al., 2013). Interestingly, they did 
however find an increased risk of two rare specific cancers rhabdomyosarcoma and 
hepatoblastoma, both of which were identified in our cohort of ART conceived BWS cases. 
In the children that were identified by the Williams study with both these tumours, none 
were reported to have an imprinting disorder. Despite the increased risk identified for these 
two tumours, the absolute excess risks remain small. Though this might be due to chance, 
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the finding of these two tumours in our ART conceived BWS patient cohort raise the 
possibility of an epigenetic cause (an imprinting disorder or MLID) being a risk factor. 
In summary, this study provides further evidence that locus heterogeneity at 11p15.5 
affects phenotype in BWS. Disruption of IC1 or overexpression of IGF2 remains the main 
cause of Wilms tumour in BWS and Wilms tumour rarely occurs in BWS cases due to IC2 
epimutations/deletions or mutations in CDKN1C.  Trans acting and environmental factors 
can influence the variability in phenotype in BWS as evidenced in the difference in the 
clinical phenotype in ART conceived cases of BWS when compared to the naturally 
conceived BWS cases with the same underlying molecular defect.  
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CHAPTER 3. THE CLINICAL AND MOLECULAR GENETIC 
INVESTIGATION OF BIRT-HOGG-DUBE SYNDROME 
DECLARATION: 
My work setting up the FLCN locus specific mutation database (LSDB) as part of the BHD 
project in collaboration with the European BHD Consortium and curation of variants into the 
database have been published in the journal Human Mutation (Lim et al., 2010a). In this 
thesis analysis of variants in the database was performed following a cut off date of 
11/08/2011. 
3.1 INTRODUCTION 
3.1.1 BIRT-HOGG-DUBE SYNDROME 
Birt-Hogg-Dube syndrome (BHD) was first described in 1975 by Drs. Arthur Birt, Georgina 
Hogg and James Dube in Canada. They described a large family segregating cutaneous 
manifestations of fibrofolliculomas, acrochordons and skin tags with an autosomal 
dominant inheritance pattern (Birt et al., 1977). As more “BHD families” were reported, an 
association was then made with the cutaneous manifestations of BHD with the occurrence 
of spontaneous pneumothorax due to the presence of lung cysts (Binet et al., 1986; Toro et 
al., 1999; Zbar et al., 2002). Subsequently, an increased risk of renal cancer in BHD was 
established following an increasing number of reports of renal tumours in patients with BHD 
syndrome (Pavlovich et al., 2005; Roth et al., 1993; Toro et al., 1999; Zbar et al., 2002). 
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3.1.1.1 Skin manifestations 
The principal skin manifestations of BHD syndrome are fibrofolliculomas. These are benign 
tumours of the hair follicles. They appear as white or flesh coloured papules and increase in 
number and size with age. Studies on a cohort of BHD patients in North America report that 
the fibrofolliculomas usually occur after the age of 20 years. The typical areas that develop 
fibrofolliculomas include the face, neck, chest and upper back. They can vary in number and 
size between affected members in a particular family and therefore are highly variable. They 
typically do not cause any symptoms. The numbers can range from very few in mild cases to 
many hundreds in severe cases (Menko et al., 2009; Schmidt et al., 2005; Toro et al., 2008).  
The initial description of the cutaneous features of BHD syndrome in addition to 
fibrofolliculomas also includes trichodiscomas and acrochordons (Birt et al., 1977). 
Trichodiscomas were initially defined as benign tumours of the hair discs and was not 
clinical discernible from fibrofolliculomas by clinical examination alone (Pinkus et al., 1974). 
However, they are now thought to represent the same morphological spectrum of 
fibrofolliculomas upon closer histological examination and better sectioning techniques 
(Schulz et al., 1999; Vincent et al., 2003).  Acrochordons or skin-tags seen in BHD can also 
occur in the general population. As they are often easier to identify just by direct clinical 
examination due to their pedunculated appearance, they are rarely biopsied for histological 
analysis in BHD. However, a few papers that studied the histological appearance of some of 
these lesions showed that they are actually pedunculated fibrofolliculomas that can give the 
same macroscopic appearance of an acrochordon (Balus et al., 1983; De la Torre et al., 
1999). Therefore, it is likely that fibrofolliculomas, trichodiscomas and some of the 
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acrochordons in BHD may represent the same cutaneous lesion (De la Torre et al., 1999; 
Vincent et al., 2003).  
3.1.1.2 Lung manifestations 
Lung cysts which predisposes to spontaneous pneumothorax was found to occur in around 
80% of BHD patients. The cysts are often bilateral and typically occur in the basal regions of 
the lungs (Toro et al., 2007; Toro et al., 2008). This is in contrast to sporadic primary 
pneumothorax where cysts occur typically in the apical regions of the lungs (Sahn et al., 
2000). These cysts are usually detectable by CT scanning of the thorax which is more 
sensitive than plain chest radiographs (Grant et al., 2009). Respiratory function is usually 
unaffected despite the presence of multiple lung cysts (Toro et al., 2007). 
Spontaneous pneumothorax may present symptomatically as chest pain or breathlessness. 
The risk of pneumothorax in BHD patients is increased by 50 fold compared to the general 
population and is attributed to the presence of the lung cysts (Zbar et al., 2002). Despite the 
high number of BHD patients who have lung cysts, the prevalence of pneumothorax has 
been reported as 24% with a median age of first occurrence of 38 years (Toro et al., 2007). 
The youngest reported pneumothorax in BHD occurred in a 7 year old child (Bessis et al., 
2006). BHD patients may develop a single pneumothorax but recurrent episodes are 
common (Toro et al., 2007). Recurrent exposure to changes in atmospheric pressures such 
as flying and deep sea diving is the major risk factor for spontaneous pneumothorax.  
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3.1.1.3 Renal manifestations 
The risk of renal cancer is the most threatening manifestation of BHD. The histological types 
that occur in BHD renal tumours are chromophobe tumours, oncocytomas, clear cell, 
although the most characteristic is a mixed hybrid of chromophobe and oncocytomas. 
Papillary renal cancer and other mixed histology have also been reported in BHD (Fahmy et 
al., 2007; Janitzky et al., 2008; Kluijt et al., 2009; Pavlovich et al., 2005; Pavlovich et al., 
2002).  
The estimated lifetime risk of renal cancer in BHD was estimated at 27% with a mean age of 
diagnosis of 50.4 years (range 31-74 years) in a series of BHD patients reported by Pavlovich 
and colleagues (Pavlovich et al., 2005; Pavlovich et al., 2002). The youngest age of onset of 
renal cancer in a BHD patient has been reported at the age of 20 years (Khoo et al., 2002). 
The difficulty with assessing the true risk of renal cancer in BHD arises from the clinical 
variability of the phenotype in BHD, and the low number of patients identified with the 
condition. There have not been many large studies in BHD to further define the risk. In 
addition, there may be ascertainment bias in the recruitment of patients where more 
severely affected patients are identified and subsequently recruited for studies. 
The renal tumours that occur in BHD show similarities in features with other renal tumour 
predisposing genetic conditions such as von Hippel-Lindau disease (VHL). Bilateral and 
multifocal tumours can be seen as well as a younger age of onset of renal tumours 
compared to sporadic renal cancers. However, relatively few patients with metastatic renal 
cancer have been described in the literature (Pavlovich et al., 2005).  
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In addition to renal cancer, cysts in the kidneys can also be found in BHD patients when 
undergoing renal imaging surveillance (Kluijt et al., 2009; Toro et al., 1999). However, it is 
difficult to be certain if the incidence of renal cysts in BHD is different from renal cysts in the 
general population, as the latter is currently unknown. 
3.1.1.4  Other tumours 
Apart from renal cell carcinoma, other tumours that have been reported in individuals with 
BHD include colorectal cancer and polyps (Khoo et al., 2002; Toro et al., 2008), malignant 
melanoma (Houweling et al., 2011; Toro et al., 1999; Toro et al., 2008), parotid gland 
tumours (Schmidt et al., 2005; Toro et al., 2008), basal cell carcinoma (Leter et al., 2008; 
Toro et al., 1999; Toro et al., 2008), breast cancer (Leter et al., 2008; Toro et al., 2008), 
prostate cancer (Houweling et al., 2011; Toro et al., 1999; Toro et al., 2008), bladder cancer, 
sarcoma, pituitary adenoma, phaeochromocytoma, astrocytoma, gastric carcinoma 
(Houweling et al., 2011), cutaneous leiomyosarcoma, uterine cancer, dermatofibrosarcoma 
protuberans,  Thyroid cancer, Hodgkin disease, squamous cell carcinoma of cervix (Toro et 
al., 2008) and skin squamous cell carcinoma (Leter et al., 2008). 
 
3.1.2 MOLECULAR GENETICS OF BHD SYNDROME 
3.1.2.1 Identification of the gene responsible for BHD 
The chromosomal locus for the gene responsible for BHD was located at chromosome 
17p11.2 by linkage analysis on BHD families (Khoo et al., 2001; Schmidt et al., 2001). 
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Subsequently, truncating mutations in a novel gene at that locus, FLCN coding for a 
unknown protein called Folliculin, was identified in BHD patients (Nickerson et al., 2002). 
3.1.2.2 The Folliculin (FLCN) gene 
The FLCN gene has 14 exons with a transcriptional start site in exon 4. FLCN encodes a 579 
amino acid protein folliculin which is expressed in most tissues including the skin, lung, 
kidney and in fetal lung, kidney liver and brain tissue (Nickerson et al., 2002). The function 
of folliculin is yet to be fully understood. Folliculin and its interacting proteins Folliculin 
interacting protein 1 (FNIP1) and Follculin interacting protein 2 (FNIP2), are thought to be 
involved in the energy and nutrient sensing pathways via the AMPK (5’AMP-activated 
protein kinase) and mTOR (mammalian target of rapamycin) signalling pathways (Baba et 
al., 2006; Hasumi et al., 2008; Takagi et al., 2008). 
There is a mutation hotspot in a hypermutable polycytosine (C8) track in exon 11 of FLCN 
where around 50% of BHD patients have a germline duplication (formerly insertion) or 
deletion of a cytosine in the tract (Schmidt et al., 2005). Detection of a mutation by gene 
sequencing is estimated to be in the region of 88% of BHD families which fulfil a clinical 
diagnosis of BHD (Toro et al., 2008). Recently, there have been several reports of large 
intragenic deletions and duplication detected in BHD patients by techniques such as 
Multiple Ligation-Dependent Probe Amplification assay (MLPA) which can detect copy 
number changes within a gene that is not detectable by normal gene sequencing 
(Benhammou et al., 2011; Kunogi et al., 2010). Using techniques such as MLPA will increase 
the diagnostic yield of FLCN mutation testing by a further 5% in BHD. However, there 
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remains around 5% of clinically diagnosed BHD patients in which current sequencing and 
copy number detection techniques will not identify a causative mutation (Benhammou et 
al., 2011).  
3.1.2.3 Diagnostic criteria for BHD  
Prior to the identification of FLCN as the causative gene in BHD, the diagnosis of BHD was 
made clinically by the presence of at least 5-10 cutaneous fibrofolliculomas, of which at 
least one must be histologically confirmed on biopsy (Khoo et al., 2002; Toro et al., 1999). 
Recently, the European Birt-Hogg-Dube consortium has suggested major and minor 
diagnostic criteria for the diagnosis of BHD syndrome in the light of DNA testing for BHD 
(Menko et al., 2009). BHD patients should fulfil one major or two minor criteria below:  
Major Criteria:  
 At least 5 fibrofolliculomas or trichodiscomas, at least one histologically confirmed, 
of adult onset 
 Pathogenic FLCN germline mutation 
Minor Criteria: 
 Multiple lung cysts: bilateral basally located lung cysts with no other apparent cause 
with or without spontaneous primary pneumothorax 
 Renal cancer: early onset (<50 years) or multifocal or bilateral renal cancer, or renal 
cancer of mixed chromophobe and oncocytic histology 
 A first degree relative with BHD 
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These diagnostic criteria take into account FLCN mutation analysis, penetrance and clinical 
variability.  
 
3.1.2.4 Folliculin is a tumour suppressor gene 
The functions of folliculin are largely unknown. Studying the renal tumours that occur in 
BHD patients by DNA sequencing to detect somatic mutations detected loss of 
heterozygosity of FLCN as well as acquired mutations in the wild type allele (Vocke et al., 
2005). This is in keeping with a tumour suppressor gene and follows Knudson’s two hit 
hypothesis. A first “hit” in a tumour suppressor gene is not sufficient for the development of 
a tumour. However the acquisition of a second “hit” in the remaining wild type allele due to 
loss of heterozygosity or mutation will result in the loss expression of that tumour 
suppressor gene and can drive tumour proliferation. In patients with cancer predisposition 
syndromes due to a germline mutation in a tumour suppressor gene (e.g. RB1 in 
retinoblastoma), a mutation is already present in one allele of the tumour suppressor gene 
in every cell of the body. Therefore the acquired second “hit” occurs at a younger age 
compared to sporadic cancers, and can also result in bilateral and multifocal tumours 
(Knudson, 1971). Several tumour predisposing genetic syndromes including BHD show these 
hallmarks with younger age onset tumours, bilateral and multifocal tumours. 
In addition loss of FLCN mRNA expression was also detected in renal tumours from BHD 
patients (Warren et al., 2004). However, studies on the fibrofolliculomas of the skin showed 
no loss of mRNA expression (Warren et al., 2004). In addition, loss of heterozygosity was not 
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detected in fibrofolliculomas, therefore suggesting that the mechanism of tumourigenesis in 
the skin is different from the kidneys (van Steensel et al., 2007). 
3.1.2.5 The mTOR signalling pathway and Folliculin  
The energy-sensing mammalian target of Rapamycin (mTOR) signalling pathway plays an 
important role in cell growth regulation and receives input from multiple signalling 
pathways such as nutrients and growth factors resulting in protein synthesis. Dysregulation 
of the mTOR pathway has been implicated in a number of hamartoma tumour 
predisposition syndromes such as Tuberous Sclerosis (due to mutations in TSC1/TSC2)(Inoki 
et al., 2005), PTEN hamartoma tumour syndrome (due to mutations in PTEN)(Eng, 2003) and 
Peutz-Jegher syndrome (due to mutations in LKB1)(Shaw et al., 2004). These disorders are 
all caused by mutations in tumour suppressor genes which normally negatively regulates the 
mTOR signalling pathway .  
Recent studies have shown that folliculin interacts with proteins that affect the mTOR 
pathway. Folliculin was shown to form a complex with its interacting proteins FNIP1 and 
FNIP2 that binds to AMPK via its gamma subunit. AMPK is involved in energy and nutrient 
sensing and is one of the negative regulators of the mTOR signalling pathway. The C- 
terminus of folliculin is involved with binding to FNIP and FNIP2 (Hasumi et al., 2008). 
The precise role of folliculin in the mTOR pathway remains to be fully elucidated. Folliculin 
appear to have several functions and it will be important to clarify these functions with 
respects to renal cancer development. These will help researchers into developing effective 
targeted therapies for renal cancer. 
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Figure 3-1 The FLCN pathway. 
A. The FLCN/FNIP1/FNIP2 complex binds AMPK and FLCN is phosphorylated by a rapamycin-sensitive 
kinase (mTORC1). B. When FLCN is deficient, AKT, mTORC1 and mTORC2 are activated. Adapted by 
permission from Macmillan Publishers Ltd: Nature reviews. Urology (Linehan et al., 2010), copyright 
2010 
 
 
97 
 
3.1.2.6 Naturally occurring animal models 
Two naturally occurring animal models of BHD exist.  
3.1.2.6.1 Hereditary multifocal cystadenocarcinoma and nodular dermatofibrosis  
An exon 7 missense substitution H255R (which is also reported in human) in the canine BHD 
gene is seen in German Shepherd dogs who develop a condition called hereditary multifocal 
renal cystadenocarcinoma and nodular dematofibrosis (Lingaas et al., 2003).  
These dogs develop bilateral, multifocal tumours in the kidneys, cutaneous nodules 
consisting of dense collagen fibres and uterine leiomyomas.  The kidney tumours that 
develop in these dogs show evidence of a second hit in the canine FLCN gene with loss of 
heterozygosity of the second wild type allele in most of the kidney tumours and also in 
around 30%, of early cystic renal lesions (Bonsdorff et al., 2008; Bonsdorff et al., 2009). Loss 
of heterozygosity was not found in the cutaneous tumours in these dogs, therefore showing 
similar results as humans. 
3.1.2.6.2 The Nihon Rat 
The Nihon rat has a germline single nucleotide insertion leading to a frameshift mutation in 
the rat FLCN orthologue (Okimoto et al., 2004). The heterozygotes develop renal cancer 
from preneoplastic lesions appearing from 3 weeks to adenocarcinoma by 6 months of age. 
The histological features of the renal tumours resemble human chromophobe renal cancer 
(Kouchi et al., 2006). Loss of heterozygosity was demonstrated in the kidney tumours. 
Introduction of wild type Flcn (Bhd) suppressed the renal carcinogenesis (Togashi et al., 
2006). Homozygote rats are embryonically lethal. 
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3.1.2.7 Experimental animal models 
Homozygous BHD knockout mouse have been shown by Hasumi and colleagues to be 
embryonically lethal (Hasumi et al., 2009). In their knockout mouse model, heterozygotes 
develop renal tumours including chromophobe, hybrid oncocytomas and clear cell histology 
with concomitant loss of heterozygosity of wildtype Flcn. The kidney tumours that develop 
from the heterozygotes showed evidence of mTOR pathway activation (both mTORC1 & 
mTORC2). 
Chen and colleagues generated conditional knockdown mice in which Flcn was only 
inactivated in the kidneys (Chen et al., 2008). These mice developed renal hyperplasia, 
multiple cysts and died with renal dysfunction by 3 weeks of age. Treatment with the mTOR 
inhibitor Rapamycin prolonged survival of these mice and inhibited the development of 
renal cysts. However, the cysts recurred and they died within 10 days of stopping treatment. 
Working on a xenograft model, Hong and colleagues introduced UOK257 cancer cell line into 
immunodeficient nude mice (Hong et al., 2010). UOK257 cell line is a renal cell carcinoma 
cell line from a BHD patient. These cells are FLCN null with the exon 11 common mutation 
c.1285dupC and deletion of the second wild type allele. Following the xenografting of the 
cell line, the mice developed tumours. Upon reintroduction of wild type FLCN into UOK257, 
these suppressed the growth of the tumours, thus providing further evidence for the role of 
folliculin as a tumour suppressor.  
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3.1.3 FAMILIAL PRIMARY SPONTANEOUS PNEUMOTHORAX AND FLCN MUTATIONS 
FLCN mutations have also been identified in patients presenting with familial primary 
spontaneous pneumothorax (PSP) (MIM#173600) (Frohlich et al., 2008; Graham et al., 2005; 
Gunji et al., 2007; Ishii et al., 2009; Painter et al., 2005; Ren et al., 2008). These patients 
have lung manifestations of BHD but without any cutaneous manifestations or renal 
tumours. However, since the diagnostic criteria proposed by the European BHD consortium, 
these patients with FLCN mutations would be diagnosed as having BHD. For the purpose of 
genotype-phenotype correlation analysis, I will analyse PSP patients and FLCN mutations as 
having PSP to aid analysis. 
3.1.4 FAMILIAL NON-SYNDROMIC CLEAR CELL RENAL CELL CARCINOMA AND FLCN MUTATIONS 
Woodward et al (2008) detected germline FLCN mutations were detected in 4.3% of 
probands with  features of inherited non-syndromic clear cell renal cell carcinoma (FcRCC) 
(Woodward et al., 2008). These patients are reported (at the time of ascertainment) to not 
have any other manifestations of BHD. In view of their findings, they recommended adding 
FLCN testing to the panel of investigations for potential cases of inherited RCC together with 
VHL gene mutation analysis and constitutional cytogenetics.  
However, as for PSP, the diagnostic criteria for BHD proposed by the European BHD 
consortium will also result in FLCN mutation positive inherited RCC cases being diagnosed 
with BHD syndrome. 
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3.1.5 SUMMARY 
I have provided an overview on BHD and the current understanding about the 
manifestations of the condition, the gene responsible for BHD, the pathways that are 
thought to be involved in tumourigenesis in BHD, along with experimental model results. 
The association of BHD with the three main manifestations affecting the skin, lung and 
kidney are well established. However, other tumours have been described in BHD such as 
colorectal cancers and malignant melanomas, and the risks of these are still yet to be 
clarified. Further studies on large cohorts of BHD patients and possible genotype-phenotype 
correlations are needed to help understand further the many aspects of the condition and 
identify causes of phenotypic variability. 
 
3.1.6 AIMS OF PROJECT 
The aims of the BHD project are to study a large cohort of BHD families in the UK to collect 
and analyse phenotypic and natural history data and study the genetic factors that may 
affect clinical variability in BHD. 
1. To define the natural history and lifetime risk of the various manifestations in BHD 
To date there are less than 150 families with BHD reported in the medical literature. Due to 
phenotypic variability, it is important to try and further define the natural history of BHD 
with regards to the lifetime risks of the various manifestations. This will help advice patients 
and define a surveillance programme for the tumours that develop in BHD patients. 
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2. To collect detailed phenotypic information on a large cohort of BHD patients  
Detailed phenotypic examination of patients will help identify previously unrecognised or 
rarer manifestations in BHD. Analysis of phenotype may also provide novel insights into the 
aetiology and possible pathways that may be affected in BHD, and thus help inform 
experimental studies. 
3. To collate published and unpublished novel FLCN sequence variants and establish a 
mutation database/locus specific-database for FLCN 
The establishment of an online database for FLCN variants/mutations will provide a useful 
resource for clinicians/researchers/scientists working on BHD. Analysis of the database with 
regards to the variants will help in genotype-phenotype analysis. 
4. To study the factors that affect phenotypic variability in BHD  
Genotype-phenotype studies can be done in a large cohort of BHD patients to help identify 
those most at risk of kidney cancers or the other tumours that may develop in BHD. In 
addition, analysis can be performed to look for other factors such as genetic/environmental 
modifiers which may affect phenotype. 
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3.2 METHODS 
3.2.1 PATIENT RECRUITMENT AND ASCERTAINMENT 
The West Midlands Regional Genetics Laboratory is the only laboratory in the UK offering a 
diagnostic service for FLCN gene testing by sequencing and MLPA. Since the service was set 
up in 2007, a list of FLCN mutation positive patients was recorded. Patient information 
leaflets and consent forms were sent to the patient’s referring clinician to disseminate to 
their patients.  
3.2.2 CONSENT AND ETHICS APPROVAL 
Informed consent was obtained from all participants. All clinical research adhered to 
principles outlined by the Declaration of Helsinki. The BHD study is a sub-study of the 
Molecular Pathology of Human Genetic Disease study which has received ethical approval 
by the South Birmingham Research Ethics Committee (REC) (REC reference 5175) prior to 
my involvement in the project. However upon completion of my project, I have been 
involved in revising the information leaflet and consent form to an updated version that was 
submitted for an amendment in 2011 which received a favourable ethical opinion of the 
amendment by the South Birmingham REC. These are included in Appendix F. 
3.2.3 PATIENT ASSESSMENT 
I carried out clinical examination on patients who consented to take part in the study at 
clinics and from home visits to characterise the phenotype of each affected individual 
(clinical data collection proforma in Appendix B). Portable dermoscopy was used to look for 
characteristic dermoscopic findings of fibrofolliculomas on affected patients to confirm 
clinical appearance of fibrofolliculomas in individuals who have not required histological 
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diagnosis (Jarrett et al, 2009). Further clinical information was also obtained from medical 
records. Confirmation of cancer diagnosis was obtained from cancer registries. 
3.2.4 CALCULATION OF LIFETIME RISKS 
The lifetime risk (up to the age of 70) for the various manifestations in BHD were calculated 
using statistic software GraphPad PRISM and MedCalc by generating Kaplan-Meier survival 
curves. 
3.2.5 STATISTICAL SIGNIFICANCE IN GENOTYPE-PHENOTYPE CORRELATION ANALYSIS 
Statistical significance when comparing Kaplan-Meier survival statistics between different 
genotypes were taken at the 5% level. 
3.2.6 EVIDENCE OF GENETIC MODIFIERS:   
A similar approach was taken to that used to identify genetic modifier effects in 
neurofibromatosis type 1 and von Hippel-Lindau disease (Easton et al., 1993; Webster et al., 
1998) such that the similarity of disease was compared in close and more distant relatives 
and between families in kindreds with identical FLCN mutations. To quantify disease 
similarity we assigned values for age at onset of fibrofolliculomas and then compared the 
age of onset of fibrofolliculomas index in FLCN mutation positive patients with variable 
degrees of relatedness. Correlation between age of onset and degree of relationship 
between the two individuals was analysed by generating sequential paired data and 
correlation analysis was performed by the Spearman correlation co-efficient analysis. The 
degree of relationship was classified as first degree relationship (Parent-child or sibling 
relationships), second degree relationships, third or more distant relationships. The age of 
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onset was classified into groups of 10 years.  For mutation carriers who have not manifested 
cutaneous signs, the age at examination/censure was used. 
3.2.7 SOFTWARE/PLATFORM FOR THE LOCUS SPECIFIC DATABASE FOR FOLLICULIN 
I used the Leiden Open Variation Database (LOVD) software as a repository for all published 
sequence variants in FLCN in the medical literature as well as unpublished novel sequence 
variants submitted by collaborating diagnostic laboratories in Europe. The database is 
available publically at www.lovd.nl/flcn and is hosted by the University of Leiden who 
maintain the technical aspects of webhosting and maintenance of servers.  
3.2.8 ASCERTAINMENT AND CURATION OF SEQUENCE VARIANTS FOR THE FLCN LSDB 
A literature search was performed using PubMed with the keywords “Birt-Hogg-Dube”, 
“BHD”, “Folliculin”, “FLCN”, “Primary Spontaneous Pneumothorax”, “Hereditary Kidney 
Cancer” and “Familial Kidney Cancer”. All reported FLCN sequence variants and their 
reported pathogenicity was listed and uploaded using the LOVD software. I also checked the 
references section of each paper to further widen the literature to ensure maximal data 
capture. 
Through collaboration with the European BHD consortium, an email was sent to research 
and diagnostic laboratories in member countries to publicise the setting up and ongoing 
plan of the LSDB. Subsequently, a list of novel variants was added to the online database. 
Mutation/Variant names are given according to the Human Genome Variation Society 
(HGVS) nomenclature. The numbering of the cDNA sequence of FLCN (+1 = A of the 
initiation codon ATG) was obtained from the National Centre for Biotechnology Information 
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(NCBI) database (accession number NM_144997.5) (Appendix C). Previously reported 
mutations are renumbered based on the HGVS nomenclature and numbering system before 
curating onto the database. However, the original nomenclature used in the report is also 
included in the corresponding entry in the database to allow cross-reference. 
For each variation, information is provided at the molecular level. This includes the DNA 
change, exon, protein change (predicted), type of mutation, the reported and concluded 
pathogenicity of the variant, source of DNA, and technique used, brief clinical information 
(reported disease phenotype, patient unique identifier and hyperlink to published reference 
or submitter contact information for unpublished variants) and also the submitter ID. 
Clinical context and molecular findings were used to guide assignment of pathogenicity. All 
putative novel mutations were identified in affected individuals, segregated with disease 
status and were not detected/reported in control individuals.  The putative mutations were 
graded according to type of mutation. Frameshift and nonsense mutations were considered 
pathogenic; splice site variants were considered pathogenic if predicted to disrupt the 
consensus donor or acceptor splice sites; missense variants were classified as “probably 
pathogenic” unless proven by experimental evidence or detected in multiple families. 
Contributors can easily submit their variants to the online database. Upon registering on the 
homepage with a username and password, instant access is granted to submit data. Data is 
provided in two parts: 1) Variant details (details of the variants at the molecular level) and 2) 
Patient details (details of anonymous clinical information) linked to the variant. Upon 
submission of data, an email is generated to the curator (me) informing of the data 
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submission. An email is also sent to the submitters to confirm submission of the data. I can 
then log in to the database and check the details of the data submitted and verify the 
nomenclature and conclude the pathogenicity before curating onto the database and 
making the entry publically available.  
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3.3 RESULTS 
 
3.3.1 PATIENT RECRUITMENT AND ASSESSMENT 
A total of 118 FLCN mutation positive individuals from 39 families in the UK were recruited 
and assessed (Table 9). The male to female ratio is 1:1.1 (56 males, 62 females). The mean 
age of the cohort is 50.7 years (range 22-85). 
3.3.2 ASCERTAINMENT OF PROBANDS FROM EACH FAMILY 
The most common manifestation that led to the diagnosis of BHD in the 39 probands was 
cutaneous fibrofolliculomas (Table 9) (Figure 3-2). 31/39 (80%) probands were diagnosed 
with BHD following investigation for their skin manifestations. Interestingly, in those 31 
probands, 10 had a previous medical history of recurrent spontaneous pneumothorax with 
hospital admissions. 2/39 (5%) probands were diagnosed with BHD following presentation 
with recurrent pneumothorax and 7/39 (15%) probands were diagnosed following diagnosis 
of renal cancer. There was 1 proband (BHD2) who was only diagnosed with BHD following 
presentation with renal cancer despite earlier manifestations of fibrofolliculomas and 
recurrent pneumothoraces. 
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Table 9. Features of the 39 recruited families with 118 FLCN mutation positive individuals  
No Family 
ID 
Mutation 
 
  
No of 
FLCN +ve 
individuals 
[Total: 
(M/F)] 
No of 
mutation 
carriers with 
FF 
No of 
mutation 
carriers 
with PTX 
No of 
mutation 
carriers 
with 
Renal Ca 
No of 
mutation 
carriers 
with 
Colorectal 
cancer 
Manifestation 
leading to 
diagnosis in 
proband 
Earlier 
manifestation 
in proband (if 
applicable) 
Other tumours  
1 BHD1 c.1285dupC 20 (8/12) 16 3 7 3 Renal Ca  Malignant 
melanoma 
Calcified 
tumour 
heart 
ventricle 
2 BHD2 c.1389C>G 1 (1/0) 1 1 1 0 Renal Ca FF, PTX -  
3 BHD3 c.-227-
?_c.1432+?dup 
5 (3/2) 5 0 1 1 FF  -  
4 BHD4 c.1285dupC 8 (5/3) 8 4 1 0 FF PTX Eccrine spiroma 
of scalp 
 
5 BHD5 c.890_893delAAAG 1 (0/1) 1 0 0 0 FF  Thyroid folicullar 
adenoma 
 
6 BHD6 c.890_893delAAAG 2 (1/1) 2 1 1 0 Renal Ca  -  
7 BHD7 c.1285dupC 7 (5/2) 7 1 0 0 FF  -  
8 BHD8 c.1318_1334dup17 5 (1/4) 5 1 1 0 PTX FF -  
9 BHD9 c.1285dupC 1 (0/1) 1 1 0 0 FF PTX -  
10 BHD10 c.1657T>C 1 (1/0) 1 1 0 0 FF  -  
11 BHD12 c.1597_1598del 2 (0/2) 1 1 1 0 FF  -  
12 BHD13 c.-227-
?_c.1432+?dup 
2 (2/0) 2 0 0 0 FF  -  
13 BHD14 c.1285dupC 3 (1/2) 3 1 0 0 FF  -  
14 BHD15 c.1076delC 2 (0/2) 2 1 0 0 PTX  -  
15 BHD16 c.1318_1334dup17 1(0/1) 1 0 0 0 FF  -  
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16 BHD17 c.890_893delAAAG 4 (1/3) 4 1 1 0 FF  Breast Cancer  
17 BHD20 c.1285dupC 2 (1/1) 2 1 0 0 FF PTX -  
18 BHD24 c.836_839delCCGA 1 (0/1) 1 0 0 0 FF  -  
19 BHD25 c.1285dupC 2 (0/2) 2 1 0 0 FF PTX Adrenal tumour  
20 BHD27 c.1318_1334dup17 4 (1/3) 3 0 3 0 PTX  Lung cancer  
21 BHD29 c.1285dupC 3 (1/2) 3 0 1 0 FF  Malignant 
melanoma 
 
22 BHD31 c.1285dupC 4 (3/1) 4 1 0 1 FF PTX -  
23 BHD35 c.1429C>T 1 (1/0) 1 0 0 0 FF  Multiple Basal 
cell carcinomas 
 
24 BHD36 c.469_471delTTC 1 (1/0) 1 0 0 0 FF  -  
25 BHD40 c.890_893delAAAG 2 (1/1) 1 2 0 0 FF PTX -  
26 BHD50 c.1285dupC 1 (0/1) 1 0 0 0 FF  -  
27 BHD51 c.510C>A 1 (1/0) 1 0 0 0 FF  -  
28 BHD52 c.1318_1334dup17 4 (2/2) 1 0 2 0 Renal Ca  -  
29 BHD53 c.1285dupC 2 (2/0) 2 0 0 0 FF  -  
30 BHD54 c.240delC 1 (0/1) 1 0 0 0 FF  Angiomyolipoma  
31 BHD57 c.1389C>G 1 (1/0) 1 0 1 0 FF  -  
32 BHD59 c.1367_1398del32 1 (0/1) 1 0 0 0 FF  Angiomyolipoma  
33 BHD60 c.689dupT 8 (5/3) 7 2 0 0 FF PTX -  
34 BHD61 c.1318_1334dup17 3 (0/3) 3 2 2 0 FF PTX -  
35 BHD62* c.715C>T 1 (1/0) 1 0 1 1 Renal Ca  Oesophageal 
Cancer 
 
36 BHD64 c.1285dupC 2 (2/0) 1 0 0 0 FF  -  
37 BHD65 c.1285dupC 2 (0/2) 1 1 0 0 FF PTX Thyroid 
Follicular Cancer 
Adrenal 
tumour 
38 BHD70 c.1285delC 5 (4/1) 5 2 0 0 FF PTX -  
39 BHD71 c.1A>G 1 (0/1) 1 0 0 0 FF  -  
(FF=Fibrofolicullomas, PTX = Pneumothorax, Renal Ca = Renal cancer) *=patient subsequently shown to also harbour a germline TP53 variant
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Figure 3-2 Manifestation that led to the diagnosis of BHD in the probands of each family 
Majority of probands were diagnosed following seeking medical attention of their skin 
manifestations.  
3.3.3 INITIAL MANIFESTATIONS OF BHD SYNDROME 
At the time of study, 8 subjects were unaffected (mean age 26.9 years) and 110 had 
developed one or more manifestations of BHD syndrome.  Fibrofolliculomas were the most 
frequent initial manifestation (87.3%) followed by pneumothorax (7.3%), renal cancer 
(3.6%) and colorectal cancer (1.8%).  
At the time of study, 64 patients had just a single manifestation of BHD syndrome (mean 
age of first manifestation = 34.3 years): most commonly fibrofolliculomas (n=61) followed 
by renal carcinoma (n=2) and pneumothorax (n=1).  37 patients had developed two 
manifestations of BHD syndrome (mean age at diagnosis of second manifestation = 45.1 
years): most commonly fibrofolliculomas and pneumothorax (n=20, mean age at second 
diagnosis = 36.95 years) and fibrofolliculomas and renal cancer (n=14, mean age at second 
Skin 
80% 
Renal Ca 
15% 
Pneumothorax 
5% 
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diagnosis = 54.3 years) and 3 patients had developed a combination of fibrofolliculomas and 
colorectal cancer (mean age at second diagnosis = 57 years). 9 patients (mean age at third 
diagnosis = 47.9 years) had developed three features of BHD syndrome (FF+PTX+RCC = 6; 
PTX+RCC+CRC= 1; FF+RCC+CRC =1; FF+PTX+CRC = 1). Age related curves for developing one 
or more manifestations of BHD syndrome were constructed (Figure 3-3).  
There was no clear pattern of patients with multiple manifestations being clustered in 
particular families. 
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Figure 3-3 Kaplan-Meier curves for probability of 1st, 2nd and 3rd manifestations of BHD 
syndrome in FLCN mutation positive individuals 
112 
 
 
3.3.4 SKIN MANIFESTATIONS 
The mean age of onset of fibrofolliculomas in the cohort was 34.1 years with the youngest 
age of onset of 20 years and the oldest age of onset of 77 years. Figure 3-4 shows the 
Kaplan-Meier curve for the age related risk of developing fibrofolliculomas from our cohort. 
Fibrofolliculomas were highly penetrant but may not be present in some individuals with 
FLCN mutations. At the age of 40 years, around 88% of FLCN mutation carriers would have 
manifested fibrofolliculomas. However, 12% of mutation carriers will not have manifested 
the cutaneous manifestations. The lifetime risk (age 70 years) of developing 
fibrofolliculomas is 97%. 
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Figure 3-4 Kaplan-Meier curve (with 95% confidence intervals) for age related risk of developing 
cutaneous manifestations of BHD in patients with FLCN mutations 
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The fibrofolliculomas that develop increase in size and number with increasing age. The 
fibrofolliculomas show phenotypic variability where some patients are only mildly affected 
(Figure 3-5) where as other patients are more severely affected (Figure 3-6). They show both 
inter-familial and intra-familial variability. 
The fibrofolliculomas rarely cause any symptoms but may sometime interfere in shaving in 
males, especially if they are numerous around the face and neck region. They may 
sometime coalesce and give an appearance of a larger lump or tumour, but on closer 
inspection, distinct fibrofolliculomas are usually clearly visible (Figure 3-7). Although they do 
not cause any symptoms per se, over 75% of patients report that they are burdened by the 
cosmetic appearance of their skin. 
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Figure 3-5 Photograph of the skin of a mildly affected patient with fibrofolliculomas 
20 papules on the left cheek and nose (area circled) histologically confirmed as fibrofolliculomas 
seen on this 50 year old patient with the exon 11 common mutation c.1285dupC (p.His429ProfsX27). 
The cutaneous lesions were only restricted to the area shown and were not found anywhere else on 
the body. 
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Figure 3-6 Photograph of the skin of a severely affected patient with fibrofolliculomas 
This patient has hundreds of papules histologically confirmed as fibrofolliculomas over the face, 
chest, neck and back, Note the patient is the same age and has the same exon 11 common mutation 
as the patient in Figure 3-5 above.  
 
Figure 3-7  Photograph of a collection of fibrofolliculomas appearing as a larger tumour 
On closer inspection there are around 8 fibrofolliculomas adjacent to one another coalescing to give 
an appearance of a larger lump. 
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3.3.5 EVIDENCE OF GENETIC MODIFIERS: AGE OF ONSET OF FIBROFOLLICULOMAS 
Table 10 summarises the results of the pair wise analysis of age of onset of fibrofolliculomas 
and the different degree of relatedness. First degree related individuals are more closely 
correlated in terms of their age of onset of fibrofolliculomas with siblings more closely 
correlated compared to parent-child. The correlation coefficient drops by 50% in second 
degree relationships. In third degree or more distant relationships, the correlation does not 
reach statistical significance. These results provide evidence for the presence of genetic 
modifiers influencing the age of onset of fibrofolliculomas in FLCN mutation positive 
individuals. 
 
Table 10. Pairwise analysis of correlation between degree of relatedness and age of onset of 
fibrofolliculomas 
Pair group  Spearman Correlation coefficient  P value  
All First degree relatives   0.63  <0.000001  
 - Siblings  0.68  <0.000001  
 - Parent-child  0.53  0.0003  
Second degree relatives  0.34  0.021  
Third degree and more distant relatives  0.23  0.110  
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3.3.6 LUNG MANIFESTATIONS 
3.3.6.1 Pneumothorax 
29/118 (24%) patients (17 males, 15 females) had a history of pneumothorax. In 20 (69%) (9 
males, 11 females) of them the pneumothorax was recurrent. The median age of first 
pneumothorax in the cohort is 32 years (range 16-63). The lifetime risk of developing a 
pneumothorax (up to age 70 years) is 33% (Figure 3-8).  
Typical symptoms reported by BHD patients who have had a pneumothorax are identical to 
sporadic pneumothoraces with chest pain and breathlessness. All of the pneumothoraces 
that have occurred were spontaneous and not a secondary result of trauma. 
3.3.6.2 Lung cysts 
32 FLCN mutation positive individuals had a CT scan of the thorax. Lung cysts were detected 
in 22 (68%) of these patients. In all 22 cases, cysts were detected bilaterally and were 
present in the lung bases. 12 (55%) patients with lung cysts had a history of pneumothorax. 
Of the 29 patients in the overall BHD cohort with a history of pneumothorax, only 12 had CT 
scans of their thorax and all had detectable lung cysts. There were 10 patients (45%) who 
had detectable cysts on CT scan but not developed a pneumothorax (median age 46 years, 
range 35-69). Of the 20 patients that had recurrent pneumothoraces, only 9 (41%) had a CT 
scan of the thorax looking for lung cysts. 
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Figure 3-8 Kaplan-Meier curve (with 95% confidence intervals) for age related risk of developing 
pneumothorax in patients with FLCN mutations 
3.3.7 RENAL CANCER 
24 patients (16 females and 8 males) from 14 families were diagnosed with a renal tumour. 
Table 11 summarises the patients with renal tumours. The male to female ratio is 1:2. The 
median age of diagnosis of a renal tumour was 52 years (range 25-85). 11/24 (46%) tumours 
were diagnosed before the age of 45 years. 13/24 (54%) tumours were detected following 
routine surveillance renal imaging following a molecular diagnosis of BHD. The lifetime risk 
of developing a renal tumour in this cohort is 36.8% (95% CI 20-50%) (Figure 3-9). 
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Table 11. FLCN mutation +ve individuals with renal tumours 
No ID Sex Age 
(y) 
Unilateral/
Bilateral/ 
Multifocal 
(U/B/M) 
Histology Presentation FLCN mutation Exon 
1 BHD1-6 M 62 B - Symptoms c.1285dupC 11 
2 BHD1-4 F 67 B Clear cell & 
oncocytoma 
Surveillance c.1285dupC 11 
3 BHD1-10 F 79 B M N/A Surveillance c.1285dupC 11 
4 BHD1-11 F 59 U Clear cell Surveillance c.1285dupC 11 
5 BHD1-12 F 62 B Clear cell Symptoms c.1285dupC 11 
6 BHD1-13 F 57 U - Symptoms c.1285dupC 11 
7 BHD1-14 F 35 U Clear cell Surveillance c.1285dupC 11 
8 BHD2-1 M 44 B M Clear cell Symptoms c.1389C>G 12 
9 BHD3-1 F 36 U Sarcomatoid Symptoms c.-227-
?_c.1432+?dup  
2-11 
10 BHD4-1 M 31 U N/A Surveillance c.1285dupC 11 
11 BHD6-1 F 25 U Clearcell Symptoms c.890_893delAAAG 9 
12 BHD8-3 F 44 U N/A Surveillance c.1318_1334dup17 12 
13 BHD12-2 F 60 U Hybrid 
oncocytoma/ 
chromophobe 
Surveillance c.1597_1598del 14 
14 BHD17-4 F 44 U Clear cell Symptoms c.890_893delAAAG 9 
15 BHD27-2 F 28 U Clear cell Symptoms c.1318_1334dup17 12 
16 BHD27-3 F 65 B N/A Surveillance c.1318_1334dup17 12 
17 BHD27-4 M 42 U - Symptoms c.1318_1334dup17 12 
18 BHD29-2 F 84 U N/A Surveillance c.1285dupC 11 
19 BHD52-2 M 54 B M Chromophobe Symptoms c.1318_1334dup17 12 
20 BHD52-4 M 55 B M Chromophobe Surveillance c.1318_1334dup17 12 
22 BHD57-1 M 41 B N/A Surveillance c.1389C>G 12 
21 BHD61-2 F 65 U Oncocytoma Symptoms c.1318_1334dup17 12 
23 BHD61-3 F 55 U N/A Surveillance c.1318_1334dup17 12 
24 BHD62-1* M 32 U Chromophobe Surveillance c.715C>T 7 
*patient subsequently found to also harbour a germline TP53 variant 
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Figure 3-9 Kaplan-Meier curve (with 95% confidence intervals) for age related risk of developing 
renal cancer in patients with FLCN mutations 
15 patients had unilateral tumours, 5 with bilateral tumours and 4 with bilateral multifocal 
tumours. Tumour histopathology was available for 14 patients. There were 7 clear cell, 3 
chromophobe, 1 oncocytoma, 1 sarcomatoid and 1 hybrid oncocytoma/chromophobe. In 
addition one patient with bilateral tumours was found to have a histology of a clear cell 
tumour in one kidney and an oncocytoma in the contralateral kidney. There were no 
incidence of metastatic disease. 
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3.3.8 COLORECTAL NEOPLASIA 
Colonoscopies were carried out in 21/118 (17.8%) patients (mean age 52.5years range 41-
72) either as a result of a family history of colorectal cancer (n=10), symptoms (7) or 
surveillance following a diagnosis of BHD (4). A total of 6 patients from 4 different families 
were diagnosed with a colorectal cancer. A total of 3 patients from 3 families developed 
colorectal polyps.  Table 12 summarises the features of these patients. The median age of 
diagnosis for colorectal cancer was 55 years (range 27-64). The male to female ratio was 5:1.  
The lifetime risk of developing colorectal cancer (up to age 70 years) is 13% (Figure 3-10). 
Table 12. Features of FLCN mutation +ve individuals that developed colorectal neoplasia  
No Family ID Mutation Sex Type Age of 
diagnosis 
(years) 
Location 
1 BHD1-1 c.1285dupC Male CRC 51 Colon 
2 BHD1-4 c.1285dupC Female CRC 61 Colon 
3 BHD1-5 c.1285dupC Male CRC 48 Colon 
4 BHD1-2 c.1285dupC Male Single Polyp - 
hyperplastic 
56 Rectum 
5 BHD3-5 c.-227-?_c.1432+?dup Male CRC 64 Caecum 
6 BHD8-1 
c.1318_1334dup17 
 
Female Single Polyp- 
tubular 
adenoma 
69 Sigmoid 
7 BHD14-2 c.1285dupC Female Multiple polyps 
- metaplastic 
41 Colon 
8 BHD31-4 c.1285dupC Male CRC 59 Colon 
9 BHD62-1* c.715C>T Male CRC 27 Rectum 
*patient subsequently found to also harbour a germline TP53 variant, CRC=colorectal cancer 
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Figure 3-10 Kaplan-Meier curve (with 95% confidence intervals) for age related risk of developing a 
colorectal cancer 
3.3.9 OTHER TUMOURS 
9 different tumours in addition to colorectal cancer, not recognised as a cardinal tumour 
type in BHD have been identified in this cohort (Table 9). 3 patients from 2 families 
developed a malignant melanoma. One female patient from BHD1 was diagnosed at age 77 
years (see multiple primary tumours below), and her nephew was diagnosed with 2 
melanomas at ages 27 and 37 years. A female patient from BHD29 was diagnosed at age 55 
years.  
An adrenal cortical tumour was also diagnosed in 2 unrelated patients. Angiomyolipomas 
were also diagnosed in 2 unrelated patients. There were also single occurrences of breast 
cancer (age 45 years – see multiple primary tumours below), and a calcified tumour of the 
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heart ventricle. One patient had a thyroid follicular adenoma and another unrelated patient 
was diagnosed with a thyroid follicular cancer. One patient also had multiple basal cell 
carcinomas. He did not have any clinical evidence of Gorlin syndrome (naevoid basal cell 
carcinoma syndrome). One patient was diagnosed with an oesophageal adenocarcinoma at 
the age of 32 years. He was also diagnosed with a colorectal cancer at age 27 years and with 
a chromophobe renal tumour at age 32 years. He was subsequently found to have a 
germline variant in the TP53 gene (see case report below). 
 
3.3.10 MULTIPLE PRIMARY TUMOURS 
4 patients in the cohort developed multiple primary tumours (excluding fibrofolliculomas). 
These patients are summarised in Table 13.  
3.3.10.1 Case report:  
Patient BHD62-1 had a medical history of ulcerative colitis and required a pan-
proctocolectomy at the age of 27 years where an incidental rectal adenocarcinoma was 
detected during pathological examination of the resected specimen. He then went on to be 
diagnosed with a gastro-oesophageal junction adenocarcinoma on endoscopic evaluation at 
age 32 following symptoms of dysphagia. Upon this discovery, an incidental 6cm renal 
tumour was detected on staging imaging which required a nephrectomy and was 
histologically confirmed as a chromophobe tumour. FLCN testing identified a pathogenic 
missense variant c.715C>T (p.Arg239Cyst). Skin examination confirmed the presence of 10 
facial fibrofolliculomas.  
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In collaboration with my colleague Dr James Whitworth, who is studying genetic factors in 
patients with multiple primary tumours, genetic testing using next-generation sequencing of 
94 inherited cancer genes on the TruSight cancer panel identified, in addition to the FLCN 
missense variant, a likely pathogenic TP53 missense variant (c.526C>T, p. Cys176Arg).  
 
Table 13. FLCN mutation +ve individuals with multiple primary tumours 
No ID Sex Tumour 1 (Age 
of diagnosis) 
Tumour2 (Age 
of diagnosis) 
Tumour 3 (Age of 
diagnosis) 
Mutation 
1 BHD1-4 F Colorectal 
Cancer (61) 
RCC: Clear cell & 
oncocytoma 
(67) 
Malignant 
Melanoma (77) 
c.1285dupC 
2 BHD17-4 F RCC: clear cell 
(44) 
Breast Cancer 
(45) 
- c.890_893delAAG 
3 BHD27-4 M RCC (42) Lung cancer (46) - c.1318_1334dup17 
 
4 BHD62-1* M Rectal 
adenocarcinoma 
(27) 
Oesophageal 
adenocarcinoma 
(32) 
RCC:chromophobe 
(32) 
c.715C>T 
*patient subsequently found to also harbour a germline TP53 variant, RCC=renal cell carcinoma 
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3.3.11 GENOTYPE-PHENOTYPE CORRELATION 
No clear differences were detected between the ages at onset of fibrofolliculomas according 
to the germline FLCN mutation (c.1285dupC vs c.1318_1334dup17, c.1285dupC vs 
c.890_893delAAAG). However, the exon 12 frameshift mutation c.1318_1334dup17 (p. 
L449QfsX255) was associated with a statistically significant higher lifetime risk (74% at age 
70 years) of developing renal cancer than in BHD patients with the exon 11 common 
mutation c.1285dupC (p.H429Pfsx27) (29% at age 70 years) (p=0.0034) (Figure 3-11). 
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Figure 3-11 Kaplan-Meier curves for risk of renal cancer in FLCN mutation patients with 
c.1318_1334dup 17 vs c.1285dupC mutation 
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3.3.12 FLCN MUTATION DATABASE 
At a cut off date of 06/08/2011 for the purpose of this chapter, there were 140 unique 
germline FLCN variants curated onto the FLCN mutation database available at 
www.lovd.nl/flcn (Figure 3-12). These included published variants (Benhammou et al., 2011; 
Bessis et al., 2006; Cho et al., 2008; Frohlich et al., 2008; Fuertes et al., 2009; Gad et al., 
2007; Graham et al., 2005; Gunji et al., 2007; Imada et al., 2009; Ishii et al., 2009; Kawasaki 
et al., 2005; Khoo et al., 2002; Kim et al., 2008; Kluger et al., 2009; Kluijt et al., 2009; Koga et 
al., 2009; Kunogi et al., 2010; Lamberti et al., 2005; Leter et al., 2008; Maffe et al., 2011; 
Meyer et al., 2009; Murakami et al., 2007; Nahorski et al., 2011; Nickerson et al., 2002; 
Painter et al., 2005; Palmirotta et al., 2008; Ren et al., 2008; Schmidt et al., 2005; Sempau et 
al., 2010; So, 2009; Tomassetti et al.; Toro et al., 2008; van Steensel et al., 2007; Warwick et 
al., 2010; Woodward et al., 2008) and novel variants that are unpublished. The database is 
publically available with useful search functions, database statistics, and hyperlinks to 
genome browsers and other resources including PubMed references. 
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Figure 3-12 Screenshot of www.lovd.nl/flcn homepage. 
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Figure 3-13 FLCN point mutations in the database (www.lovd.nl/flcn) 
Distribution map of mutations in the FLCN gene and their associated phenotype. The blue boxes 
represent the exons. Mutation below the genogram represent intronic mutations affecting splice 
sites and displayed as the cDNA sequence change. Mutations above the exons represent mutations 
in the coding exons and are displayed as the protein change. The mutations in red represent the 
mutations that have been detected in the UK cohort of BHD patients in this thesis. BHD: Birt-Hogg-
Dube; PSP: Primary Spontaneous Pneumothorax; FcRCC: Familial/inherited non-syndromic renal cell 
carcinoma. Genogram not drawn to scale. 
 
 
 
 
 
129 
 
Table 14. Point mutations listed on the FLCN mutation database 
Exon Mutation Protein Change 
(Predicted) 
Type Concluded 
Pathogenicity 
Reported 
Phenotype 
4 c.1A>G p.M1?   Missense Probably pathogenic BHD 
4 c.3delG p.M1?   Missense Probably pathogenic BHD 
4 c.3G>A p.M1? Missense Probably pathogenic BHD 
4 c.59delT p.F20SfsX Frameshift Pathogenic BHD 
4 c.147delA p.G50VfsX Frameshift Pathogenic BHD 
4 c.235_238delTCGG    p.S79TfsX Frameshift Pathogenic PSP 
4 c.240delC    p.D80EfsX Frameshift Pathogenic BHD 
4i c.250-2A>G  Splicesite Pathogenic BHD 
4i c.250-1G>A  Splicesite Pathogenic BHD 
5 c.252delC p.C85AfsX Frameshift Pathogenic BHD 
5 c.296delA    p.D99VfsX Frameshift Pathogenic BHD 
5 c.319_320delGTinsCAC    p.V107HfsX Frameshift Pathogenic BHD 
5 c.323G>T p.S108I Missense Probably pathogenic BHD 
5 c.328C>T p.Q110X Nonsense Pathogenic BHD 
5 c.340dupC    p.H114PfsX  Frameshift Pathogenic BHD 
5 c.347dupA    p.L117AfsX Frameshift Pathogenic BHD 
5 c.394G>A p.E132K Missense Probably pathogenic PSP 
5i c.397-10_397-1del  Splicesite Pathogenic PSP 
5i c.397-7_399del  Splicesite Pathogenic PSP 
6 c.404delC    p.F135LfsX Frameshift Pathogenic BHD 
6 c.420delC    p.I141SfsX Frameshift Pathogenic BHD 
6 c.443_459del    p.H148PfsX Frameshift Pathogenic BHD 
6 c.469_471delTTC    p.F157del Inframe 
deletion 
Probably pathogenic BHD,PSP 
6 c.510C>A p.T170X Nonsense Pathogenic BHD 
6 c.566_577delTGCTGGGGAA
GGinsCC    
p.L189PfsX Frameshift Pathogenic BHD 
6 c.583G>T p.G195X Nonsense Pathogenic BHD 
6 c.584delG    p.G195EfsX Frameshift Pathogenic BHD 
6 c.610_611delGCinsTA p.A204X Nonsense Pathogenic BHD 
6i c.618+2C>T  Splicesite Pathogenic BHD 
6i c.619-1G>A  Splicesite Pathogenic BHD 
7 c.632_633delAGinsC p.E211AfsX Frameshift Pathogenic BHD 
7 c.637delT p.F213LfsX Frameshift Pathogenic BHD 
7 c.649C>T p.Q217X Nonsense Pathogenic BHD 
7 c.655dupG p.A219GfsX Frameshift Pathogenic BHD 
7 c.671_672delCA p.T224SfsX Frameshift Pathogenic BHD 
7 c.689dupT p.H231TfsX Frameshift Pathogenic BHD 
7 c.715C>T p.R239C Missense Pathogenic BHD,FcRCC 
7 c.769_771delTCC p.S257del Inframe 
deletion 
Probably pathogenic BHD 
7 c.779G>A p.W260X Nonsense Pathogenic PSP 
7i c.779+1G>T  Splicesite Pathogenic BHD 
8 c.836_839delCCGA p.T279RfsX Frameshift Pathogenic BHD 
8i c.871+3_871+4delGAinsTCC
AGAT 
 Splicesite Pathogenic BHD 
9 c.887C>A p.S296X Nonsense Pathogenic BHD 
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9 c.890_893delAAAG p.E297AfsX Frameshift Pathogenic BHD,FcRCC 
9 c.943G>T p.E315X Nonsense Pathogenic PSP 
9 c.923_950dup p.G319SfsX Frameshift Pathogenic BHD 
9 c.997_998dupTC p.G334QfsX Frameshift Pathogenic BHD 
9 c.1013delG p.W338CfsX Frameshift Pathogenic BHD 
9 c.1021delC p.R341GfsX Frameshift Pathogenic BHD 
9i c.1062+1G>A  Splicesite Pathogenic BHD 
9i c.1062+2T>G  Splicesite Pathogenic BHD 
9i c.1063-10_c.1065del  Splicesite Pathogenic BHD 
9i c.1063-2A>G  Splicesite Pathogenic BHD 
10 c.1076delC p.P359LfsX  Frameshift Pathogenic BHD 
10 c.1127G>A p.W376X  Nonsense Pathogenic BHD 
10 c.1156_1175del p.S386DfsX Frameshift Pathogenic PSP 
10i c.1177-5_1177-3del3   Splicesite Pathogenic BHD 
10i c.1177-2A>G  Splicesite Pathogenic BHD 
11 c.1215C>G p.Y405X Nonsense Pathogenic BHD 
11 c.1252delC p.L418WfsX Frameshift Pathogenic BHD 
11 c.1285dupC p.H429PfsX Frameshift Pathogenic BHD,PSP 
11 c.1285delC p.H429TfsX Frameshift Pathogenic BHD 
11 c.1286dupA p.H429QfsX Frameshift Pathogenic BHD 
11 c.1285C>T p.H429Y Missense Probably pathogenic PSP 
11 c.1300G>A p.E434K Splicesite Pathogenic BHD 
11 c.1300G>C p.E434Q Splicesite Pathogenic BHD 
11 c.1300G>T p.E434X  Nonsense Pathogenic BHD 
11i c.1301-7_1304del11  Splicesite Pathogenic BHD 
12 c.1305delT p.F435LfsX Frameshift Pathogenic BHD 
12 c.1323delCinsGA p.H442TfsX Frameshift Pathogenic BHD 
12 c.1318_1334dup17 p.L449QfsX  Frameshift Pathogenic BHD,FcRCC 
12 c.1340_1346dupCCACCCT p.V452PfsX Frameshift Pathogenic PSP 
12 c.1367_1398del32 p.D456GfsX Frameshift Pathogenic BHD 
12 c.1372dupC    p.Q458PfsX Frameshift Pathogenic BHD 
12 c.1379_1380delTC p.L460QfsX Frameshift Pathogenic BHD 
12 c.1389C>G p.Y463X Nonsense Pathogenic BHD 
12 c.1408_1418delGGGAGCCCT
GT 
p.G470SfsX Frameshift Pathogenic BHD 
12 c.1426dupG p.D476GfsX Frameshift Pathogenic BHD 
12 c.1429C>T p.R477X Nonsense Pathogenic BHD,PSP 
12i c.1432+1G>A  Splicesite Pathogenic BHD 
12i c.1433-1G>T  Splicesite Pathogenic BHD 
13 c.1487_1490dupCTGT p.D498CfsX Frameshift Pathogenic BHD 
13 c.1523A>G p.K508R Missense VUS BHD 
13 c.1522_1524del p.K508del Inframe 
deletion 
Pathogenic BHD 
13 c.1528_1530delGAG p.E510del Inframe 
deletion 
Pathogenic BHD 
13 c.1533G>A p.W511X Nonsense Pathogenic PSP 
14 c.1557delT p.F519LfsX Frameshift Pathogenic BHD 
14 c.1579C>T p.R527X Nonsense Pathogenic BHD 
14 c.1597_1598del    p.Q533EfsX Frameshift Pathogenic BHD 
14 c.1597C>T p.Q533X Nonsense Pathogenic BHD 
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14 c.1657T>C p.W553R Missense Probably pathogenic BHD 
Mutations in yellow denote the point mutations detected in the UK BHD cohort in this thesis. (i = intron, BHD = 
Birt-Hogg-Dube syndrome, PSP = Primary Spontaneous Pneumothorax, FcRCC = Familial/inherited non-
syndromic clear cell renal cell carcinoma) 
 
 
3.3.13 FLCN VARIANTS/MUTATIONS 
41/139 of the variants uploaded on to the database are classified as single nucleotide 
polymorphisms. In the remaining 98 putative mutations, 88 were concluded as pathogenic, 
9 probably pathogenic, and 1 variant of unknown significance. Figure 3-13 and Figure 3-14 
displays the putative mutations in relation to the FLCN gene. Table 14 summarises the point 
mutations. 
Mutations are found in all coding exons (4-14) and a mutation hotspot exists in the polyC(8) 
tract in exon 11 with the c.1285dupC (previously reported as c.1733insC, c.1740dupC and 
C.1277insC) being the commonest mutation. 
Leaving out SNPs and large intragenic copy number changes, at the nucleotide level, the 
majority of putative mutations are deletions (36/81, 44.4%) and single base substitutions 
36/81, 44.4%). In addition, duplications (11/81, 16%), and deletion/insertions (6/81, 7.4%) 
make up the rest of the mutations. 
The majority of mutations in FLCN are predicted (in the absence of nonsense-mediated 
mRNA decay) to lead to protein truncation and loss of function. The most frequent 
mutational consequences are frameshifts (43/88, 48.9%), which are predicted to result in a 
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premature stop codon. In addition there are 19 splicesite (19/88, 21.6%), 16 nonsense 
(16/88, 18.2%), 9 missense (9/88, 10.2%), 4 in-frame deletions (4/88, 4.5%) and 7 large 
intragenic copy number changes (7/88, 7.9%). 
A total of 13 mutations have been reported in PSP. 3 of these mutations, the exon 11 
common mutation c.1285dupC (p.His429ProfsX27), an exon 12 nonsense mutation 
c.1429C>T (p.Arg477X) and an exon 6 in-frame deletion c.469_471delTTC (p.Phe157del), are 
reported in both BHD and PSP. 
In FcRCC families, 3 mutations, 2 frameshift mutations in exon 9 (c.890_893del, 
p.Glu297AlafsX25) and exon 12 (c.1318_1334dup17, p Leu449GlnfsX25) and a missense 
substitution in exon 7 (c.715C>T, p.Arg23Cyst) were detected. These 3 mutations have 
subsequently been found in patients presenting with classic BHD syndrome phenotype. 
 
Figure 3-14 Large intragenic deletions and duplications in FLCN in the database 
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3.3.14 FLCN INTRAGENIC DELETIONS/DUPLICATIONS 
7 large intragenic copy number changes have been identified in FLCN (Figure 3-14 above). 5 
large intragenic deletions in FLCN have been reported in BHD. One of the deletions, the 
exon 14 deletion has been reported by 3 studies and in an unpublished UK family 
(Benhammou et al., 2011; Kunogi et al., 2010; Sempau et al., 2010). Isolated exon 1 
deletions have been reported by Benhammou and colleagues in 4 unrelated families 
(Benhammou et al., 2011). 
2 large intragenic duplications in FLCN have been identified to date. A duplication involving 
exons 10 and 11 was reported by Benhammou and colleagues in a North American BHD 
family. In the UK cohort, 2 unrelated families with BHD (BHD3 & BHD13) have been found to 
have a large duplication spanning exons 2 to 11. This duplication was found to be in tandem 
by analysis with long-range PCR by the diagnostic laboratory at the West Midlands Regional 
Genetics Laboratory. 
 
3.3.15 GENOTYPE-PHENOTYPE CORRELATIONS FROM THE MUTATION DATABASE 
Figure 3-13 above displays the point mutations that have been discovered in the FLCN gene 
and their corresponding disease of BHD, PSP or FcRCC. Point mutations have been identified 
in all the coding exons. There appear to be no strong correlation with a particular mutation 
in a particular exon with the development of just PSP or FcRCC nor clustering of mutations 
in particular exons for PSP or FcRCC. 
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3.4 DISCUSSION 
 
BHD syndrome is a rare disorder and information on the frequency, natural history and 
nature of the clinical features is limited. This represents the first large cohort of BHD 
syndrome patients reported from the UK and there are only two other large series of BHD 
patients (from the USA and the Netherlands). Schmidt and Toro reported a total of 196 
patients from 102 families from the National Cancer Institute (NCI) from the USA (Schmidt 
et al., 2005; Toro et al., 2008).  Houweling described 115 patients from 35 families in the 
Netherlands (Houweling et al., 2011). In contrast to these two studies we only included 
patients with a detectable FLCN mutation. In general the clinical features apparent in the UK 
cohort are similar to those in the other two large series.  
80% of probands from the 39 families in the UK BHD cohort were diagnosed following 
investigations for skin manifestations. In addition, 87.3% of the symptomatic FLCN mutation 
positive individuals presented with fibrofolliculomas as their initial manifestation of BHD. 
The finding that some of these skin papules can be very mild leads to the impression that 
BHD is likely to be both under-diagnosed and under-recognised. Some of the mildly affected 
patients may not present to a doctor for treatment or diagnosis as they usually do not cause 
any symptoms. Therefore it is likely that there are BHD patients in the population who have 
not sought medical attention especially if there is no personal or family history of recurrent 
pneumothorax or kidney cancers. In addition, despite the presence of fibrofolliculomas, the 
underlying diagnosis of BHD may be delayed or overlooked in patients presenting with 
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pneumothorax or kidney cancer. This is shown in our cohort from the 10 probands who had 
required hospital admissions for recurrent pneumothoraces who were not diagnosed with 
BHD despite the presence of the skin papules at the time of the episodes of 
pneumothoraces. Therefore an earlier diagnosis of BHD could have been made in these 
families if the skin features were recognised. This suggests that there is still under 
recognition of BHD among non-dermatology clinicians. 
There is wide variability in the severity of the fibrofolliculomas that develop in BHD patients. 
It shows both inter and intra familial variability. The fibrofolliculomas are the most 
penetrant of all the manifestations of BHD. 88% of patients will have manifested these skin 
papules by the time they reach the age of 40 years. Conversely, 12% of patients will not 
have manifested any of these skin papules by the age of 40 years. This has important 
considerations for clinicians who are assessing patients with a possible diagnosis of BHD.  In 
order to avoid morbidity and mortality associated with late diagnosis of RCC, it is paramount 
that clinicians who are assessing patients with possible features of BHD have access to 
molecular genetic testing and that once a molecular diagnosis is made, all at risk relatives 
are offered predictive (presymptomatic) testing and regular clinical follow up and 
surveillance for RCC.  
In the context of genetic counselling for pre-symptomatic testing for a known familial FLCN 
mutation, clinical geneticists offering testing to an apparently unaffected at risk family 
member should take into consideration the age of the patient and the likelihood of the age-
related penetrance and variability of the skin features during the counselling and 
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assessment. In particular, caution should be taken in offering reassurance in the absence of 
skin manifestations during the pre-symptomatic testing counselling. 
Looking at the initial manifestations in our cohort, fibrofolliculomas is the most common 
first manifestation followed by pneumothorax. 54% have only a single manifestation of BHD, 
with fibrofolliculomas the most likely. 31% of patients developed two manifestations, with 
the combination of fibrofolliculomas and pneumothorax the most common (54%) followed 
by fibrofolliculomas and renal cancer (38%).  The patients with fibrofolliculomas and 
pneumothorax tend to develop their second manifestation at an earlier mean age (36.95 
years) compared to patients who develop fibrofolliculomas and renal cancer (54.3years). 
Only 7.6% of patients developed 3 manifestations of BHD with a mean age of 47.9 years. 
There were no clear patterns of patients with multiple manifestations being clustered in 
particular families. The Kaplan-Meier curve generated (Figure 3-3) provides information on 
the age related probability of developing a first, second and third manifestation of BHD. This 
will be useful in the context of counselling of patients in the clinical genetics clinic. 
The lifetime risk of pneumothorax in our cohort is 33% and the prevalence of lung cysts 
(among those that had CT scans) was 68%. In keeping with previous reported cohorts, the 
presence of lung cysts is the major determinant factor for pneumothorax (Toro et al., 2007). 
Unfortunately, CT scanning of the thorax is not routinely offered to all all newly diagnosed 
patients but, if it were, it would improve knowledge of the natural history of the lung 
manifestations of BHD and inform individualised risk estimates of pneumothorax. CT scans 
of the thorax were only performed in 32 patients.  There is also a lack of recognition of a 
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possible diagnosis of BHD in patients presenting with recurrent spontaneous pneumothorax.  
20 patients had recurrent pneumothoraces in the cohort, but only less than half (41%) were 
referred for a CT scan of the thorax. Although we are not able to make a direct conclusion 
from this, this observation may suggest that there may be families presenting with recurrent 
pneumothoraces without a family history of BHD who may not be investigated by CT scans 
for the aetiology of their pneumothoraces and therefore not detecting the classical lung 
cysts that involve the lung bases. This could therefore miss a possible clinical diagnosis of 
BHD syndrome. As shown by the proband analysis earlier, there is also under recognition of 
the BHD skin lumps by clinicians managing patients with recurrent pneumothoraces.  
In view of the high prevalence of lung cysts in BHD patients in this cohort, looking for the 
presence of typical BHD lung cysts by CT scans can help establish a diagnosis in the small 
percentage of suspected or possible BHD patients with normal FLCN testing. 
The lifetime risk of renal cancer in this cohort is quite high at 36.8% compared to the Dutch 
cohort (16%) recently reported. One possibility for this difference may be due to 
ascertainment bias. However, analysis of the proband of each family in our cohort showed 
that the majority of BHD probands in our cohort were diagnosed following presentation of 
skin manifestations. The youngest age of diagnosis of a renal tumour in our cohort is at age 
25 years. Therefore annual screening in BHD patients from the age of 20 years by renal 
imaging should be offered as recommended by the European BHD Consortium (Menko et 
al., 2009). In our cohort renal surveillance has detected a number of asymptomatic renal 
tumours which provides further cause for the usefulness of surveillance. In keeping with 
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other renal cancer predisposition syndromes, renal tumours in our cohort of BHD patients 
include bilateral (37%) and multifocal tumours (17%). The management of renal tumours in 
BHD therefore is similar to von Hippel-Lindau disease. Nephron sparing surgery is 
appropriate once a solid tumour reaches 3cm in size. 
Looking at the histology of the tumours, in our cohort clear cell histology was most common 
followed by chromophobe tumours. In contrast to the literature whereby a mixed/hybrid 
oncocytoma-chromophobe histology was reported to be the most common tumour type in 
BHD, this histology was only found in one patient in our cohort. A possible explanation for 
the discrepancy may be the element of bias in that 4 out of the 7 clear cell tumours in our 
cohort involved patients from the same large family (BHD1). Another explanation for the 
discrepancy may be that there may be histological appearances that are similar between 
clear cell RCC and chromophobe RCC both with granular/floccular eosinophilic cytoplasm 
(Houweling et al., 2011). In the Dutch study this led to a classification of tumours being 
intermediate between clear cell and chromophobe carcinoma (CC/CPH). We did not go back 
to re-classify the tumour histology in the UK cohort. The other possibility for the discrepancy 
is that more than half (54%) of the patients with renal tumours were detected on 
surveillance scans and were asymptomatic. As the management of these tumours is to 
monitor the size until partial nephrectomy is required at 3cm, the histology of these 
tumours were not available. Looking at the tumour types that can occur in BHD, slow 
growing benign tumours such as oncocytomas can be present in patients for many years 
with slow growth and therefore never requiring surgical resection and this may cause an 
element of bias with regards to histology. Thus faster growing tumour types (such as clear 
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cell RCC) are more likely to be resected leading to available histology. In addition to the one 
case of a sarcomatoid transformation of RCC in the Dutch cohort, one patient in our UK 
cohort also developed a sarcomatoid renal carcinoma. We were unable to establish from 
the histology report what the possible original histology of the RCC was. 
The European BHD consortium proposed diagnostic criteria for the diagnosis of BHD 
syndrome based on the presence of Major and/or Minor criteria (Menko et al., 2009). Renal 
cancer of early onset (<50 years) or multifocal or bilateral renal cancer, or renal cancer of 
mixed chromophobe and oncocytic histology make up one of the minor criteria. Looking at 
the histological types of RCC that have been detected in our cohort, only one was found to 
have the mixed chromophobe and oncocytic histology. Therefore the diagnostic criteria may 
have to be revised as the Dutch cohort also found only 1 tumour of this mixed 
chromophobe-oncocytic histology. 
The association between possible colorectal neoplasia and BHD was postulated following 
the recognition that Hornstein’s report in 1976 of colonic polyps and generalised dermal 
perifollicular fibromas were in fact patients with what is now known as BHD syndrome 
(Hornstein, 1976). To date it is still debated whether BHD is associated with an increased 
risk of colorectal cancer. Zbar and colleagues did not identify any increased risk in their 
cohort from the NCI (Zbar et al., 2002). However, Khoo reported a large French family 
harbouring an exon 11 c.1285delC mutation where 6 out of 8 mutation positive family 
members developed colonic polyps (Khoo et al., 2002). They postulated that colorectal 
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neoplasia risk might apply to certain subgroups with possible environmental factors or 
genetic modifiers playing a role.  
In collaboration with my colleague Dr Michael Nahorski and the group from the Netherlands 
(Dr Fred Menko, VUMC Amsterdam), we looked at a total of 149 patients with a clinical 
diagnosis of BHD from 51 families (32 with confirmed germline FLCN pathogenic mutations) 
from the UK (including 19 reported in this cohort/thesis: BHD1, BHD2, BHD3, BHD5, BHD6, 
BHD7, HD8, BHD9, BHD10, BHD12, BHD13, BHD14, BHD15, BHD16, BHD17, BHD20, BHD24, 
BHD27 & BHD31) and the Netherlands and found a lifetime risk of colorectal cancer of 11% 
up to age 70 years (Nahorski et al., 2010). In the UK, the lifetime risk for developing 
colorectal cancer is 7.3% in men and 5.5% in women. 
(CRUK,http://www.cancerresearchuk.org/health-professional/cancer-statistics/risk/lifetime-
risk#heading-One, Accessed May 2016). In my study (this thesis), which concentrates  on 
families only with proven germline FLCN mutations, we identified colorectal neoplasia in 9 
patients from 6 families who developed colorectal neoplasia of which there were 6 patients 
with colorectal cancer and 3 patients with colonic polyps. The lifetime risk in our cohort of 
colorectal cancer up to the age of 70 years is 13%. The median age for the diagnosis of 
colorectal cancer in this cohort was 55 years. Of note the patient from BHD62-1 suffered 
from ulcerative colitis and as part of his treatment for this he had a panproctocolectomy at 
age 27 which showed an incidental rectal adenocarcinoma. He subsequently developed 
further cancers and was also subsequently found to also have a germline variant in the TP53 
gene (see later). 
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In this cohort, 3 out of the 6 families that developed colorectal neoplasia (cancer or polyps) 
carry the c.1285dupC common mutation. This mutation occurs in a hypermutable 
mononucleotide tract (also called C8 mononucletiode tract or poly C tract) in exon 11.  In 
collaboration with Nahorski et al, we also looked at possible genotype-phenotype 
correlations for colorectal neoplasia in BHD. Looking at a combined total of 15 families from 
the UK (including BHD1, BHD9, BHD14, BHD20, BHD26 and BHD31) and the Netherlands 
with two recurrent mutations in FLCN showed a statistically significant increased lifetime 
risk of colorectal neoplasm in the c.1285dupC mutation carriers compared to the 
c.610_611delGinsTA mutation (Nahorski et al., 2010).  Therefore the risk of colorectal 
neoplasia in FLCN mutation positive individuals may be dependent on the genotype and 
suggest allelic heterogeneity. However other genetic modifiers and or environmental factors 
may be involved as only 3 out of 13 families (23%) with the c.1285dupC mutation reported 
individuals who developed colorectal neoplasia in this study/thesis. Another limitation of 
generating conclusions from this study is that only a small percentage (21/118, 17.8%) of 
FLCN mutation positive carriers in this cohort had a colonoscopy. 53 patients above the age 
of 45 years have not had a colonoscopy. 
Interestingly, the family reported by Khoo with colorectal neoplasia harbour a mutation in 
the C8 monucleotide tract (c.1285delC) (Khoo et al., 2002). Both the c.1285dupC and 
c.1285delC frameshift mutations would result in truncation of the FLCN protein 
(p.His429ProfsX27 –lacking 126 aminoacids and p.His429THrfsX39 –lacking 114 
respectively), in the absence of nonsense mediated decay. This may result in a dominant-
negative effect in colorectal cells compared to the nonsense mutation c.610_611delGinsTA 
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(p.Ala204X – lacking 377 amino acids). Although both the mutations in the C8monucleotide 
tract and the c.610_611delGinsTA mutation would result in loss of the C-terminus which 
contains the FNIP binding site, there may be other functions of FLCN (which is not fully 
understood currently) that may be altered differently by these different mutant proteins. 
It is known that these monucleotide repeat tracts are hypermutable and susceptible to 
instability. Defects in mismatch repair genes (e.g. in Lynch syndrome) can result in increased 
microsatellite instability and contribute to tumourigenesis by predisposing to somatic 
mutations in colorectal cancer tumour suppressor genes that contain short repeat coding 
sequences (Lynch et al., 2003; Markowitz et al., 1995). Although Kahnoski and colleagues 
(Kahnoski et al., 2003) did not detect any FLCN C8 monunucleotide tract mutation in 8 
microsatellite instable sporadic colorectal cancers, Nahorski found somatic FLCN C8 
monucleotide tract mutations in 23% of sporadic colorectal cancers which are microsatellite 
unstable (Nahorski et al., 2010). This is in keeping with Shin and colleagues who reported a 
detection rate of 16% in 32 sporadic microsatellite instable colorectal cancers (Shin et al., 
2003). 
In view of the finding by Woodward that 5% of patients with familial non-syndromic renal 
cell carcinoma have a germline FLCN mutation (Woodward et al., 2008), Nahorski also 
looked at the rate of detection of FLCN germline mutations in 50 unrelated individuals with 
familial non-syndromic colorectal cancer cases (with no evidence of familial adenomatous 
polyposis or germline mismatch repair genes). No germline FLCN mutations were detected. 
Therefore it is unlikely that patients with BHD would present with familial non-syndromic 
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colorectal cancer. In addition, as the age of diagnosis of colorectal cancer in this UK BHD 
cohort is 55 years, it is less likely that BHD patients who develop colorectal cancer would fall 
under the category of familial colorectal cancer as the criteria for this diagnosis is biased 
towards a younger age of diagnosis (e.g. the Amsterdam criteria in Lynch syndrome).  As a 
large proportion of older patients with FLCN mutations would be expected to have 
developed fibrofolliculomas, I suggest that in the absence of medical history or family 
history of BHD (skin fibrofolliculomas, history of pneumothorax or renal cancer) FLCN 
mutation testing is not indicated in this group of familial colorectal cancer patients.  
Like many other genodermatoses there is wide variability between patients in the severity 
of BHD syndrome. Analysis of renal tumours from patients with BHD syndrome 
demonstrates loss of the wild type allele in tumour tissue consistent with “recessive tumour 
suppressor gene” model of tumourigenesis (Vocke et al., 2005) and so stochastic factors will 
influence whether a patient develops RCC or not. In other inherited disorders with 
overlapping phenotypes such as VHL disease, both genotype-phenotype correlations 
associated with allelic heterogeneity and modifier effects may influence the risk of 
individual tumour types (Ong et al., 2007; Webster et al., 1998). No clear genotype-
phenotype correlations have been described in BHD syndrome. Previously Schmidt and 
colleagues reported the c.1062+2T>G (previously called IVS9+2) splice site mutation 
conferred a possible higher risk of renal cancer (Schmidt et al., 2005). However in a follow 
up study, this observation was not confirmed (Toro et al., 2008). Benhammou and 
colleagues reported a possible genotype-phenotype correlation in BHD where families with 
an intragenic deletion of exon 1 (possible promoter region) detected on MLPA may have a 
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lower risk for the development of renal cancer (Benhammou et al., 2011). However, the 
numbers were too small to make clear conclusions. None of the families in the UK cohort 
here and the Dutch cohort (Houweling et al., 2011) were found to have an exon 1 deletion. 
 We found that the Leu449PhefsX9 mutation,  identified in 4 families in our UK cohort, was 
associated with a high risk of RCC (8 mutation positive individuals from these 4 families 
developed renal cancer with a lifetime risk of renal cancer of 68%) compared to other FLCN 
mutation positive individuals. This candidate novel genotype-phenotype correlation will 
require confirmation in prospective analysis and in other cohorts of patients. Furthermore it 
would be of interest to know whether this mutation had differential effects on folliculin 
protein function compared to mutations with lower risks of RCC. However the function of 
the folliculin protein is not well defined. Both the Leu449PhefsX9 and the common 
His429ProfsX27 mutation would be expected to compromise binding of folliculin to FNIP1/2 
and though folliculin has been reported to have a number of cellular functions including 
regulation of mTOR (Baba et al., 2006; Hartman et al., 2009), TGFbeta (Hong et al., 2010), 
Rho (Nahorski et al., 2012), HIF (Preston et al., 2011) and other signalling pathways, it is not 
clear which functions are most relevant to folliculin renal tumour suppressor activity. 
Previously Webster demonstrated that genetic modifier effects can influence age at 
diagnosis in VHL disease (Webster et al., 1998). Here we found the first evidence of such 
effects in BHD syndrome with significantly better correlation of age at onset of 
fibrofolliculomas in close relatives than in more distantly related pairs. The strongest 
correlation was between first degree relatives (siblings and parent-child).  
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Patient BHD62-1 is one of four patients in the cohort who presented with more than one 
primary tumour type (rectal adenocarcinoma, oesophageal adenocarcinoma and 
chromophobe RCC). FLCN mutation testing identified a missense variant (c.715C>T, p. 
Arg239Cys) which has been shown to affect protein stability and therefore classified as a 
pathogenic mutation (Nahorski et al., 2011). (To further confirm pathogenicity, this 
missense mutation has also been reported in a female patient who was previously thought 
to have familial non-syndromic clear cell RCC with a clear cell RCC at age 46 and a 
contralateral multicentric clear cell RCC at age 55 years (Woodward et al., 2008). She would 
now be classified as having BHD in view of the diagnostic criteria proposed by the European 
BHD Consortium). The finding of a second likely pathogenic variant in a cancer 
predisposition gene, a TP53 missense variant (c.526C>T, p. Cys176Arg) could explain the 
multiple tumours and early age of onset of tumours in this patient. This patient has now 
been written up as part of a case series with Dr James Whitworth (Whitworth et al., 2015). 
Germline mutations in TP53 are associated with the cancer predisposition syndrome Li 
Fraumeni syndrome (LFS). Individuals with LFS have a high lifetime risk of developing cancer 
with an estimated risk of 50% by age 30 years and 90% by age 60 years (Lustbader et al., 
1992). The main cancers associated with LFS are soft tissue sarcomas, osteosarcomas, 
breast cancer, adrenocortical carcinomas, brain tumours and leukaemias. Among other 
tumours reported as also occurring more frequently in LFS are gastrointestinal cancers 
(including oesophageal cancers) and genitourinary cancers (including renal cell carcinoma) 
and affected individuals have a high risk of developing multiple primary cancers and cancers 
at a young age (Gonzalez et al., 2009; Lustbader et al., 1992). Although the patient’s 
146 
 
oesophageal cancer, rectal cancer (additional risk factor of ulcerative colitis) and RCC would 
be compatible with LFS, the chromophobe histology of the RCC would be more in keeping 
with the RCC seen in BHD. The TP53 missense variant found in this patient has been 
described before as a somatic mutation in multiple tumours including colorectal 
adenocarcinoma. In silico prediction tools also predict a damaging or function altering effect 
on the protein (see (Whitworth et al., 2015) and references within). Whitworth also 
identified a further two BHD FLCN mutation positive patients (not in this cohort) with 
multiple primary tumours harbouring a second cancer predisposition gene mutation (FLCN 
& NF1 and FLCN & MSH2). We proposed the name Multiple Inherited Neoplasia Alleles 
Syndrome (MINAS) to describe patients with 2 or more inherited cancer predisposition 
alleles causing multiple primary tumours. In the case series, a neurofibromatosis type 1 
patient with a NF1 mutation was also found to have a BRCA2 mutation and a patient with 
MLH1 mutation also was found to have a homozygous XPA splice mutation. Therefore 
another explanation for phenotypic variation in some patients with BHD syndrome could be 
the presence a second cancer predisposition gene allele. 
Environmental modifying factors can also be responsible for the phenotypic variability seen 
in BHD. Previous studies have shown that smoking increases the risk of cancers including 
kidney cancer as well as an increased risk of pneumothorax (Bense et al 1987, Cheng et al 
2009). Although in this study I collected data on smoking status, the data returned was not 
complete in sufficient numbers to calculate pack years to allow us to make direct analysis of 
correlation between cigarette smoking and risk of fibrofolliculomas, lung cysts, 
pneumothorax or kidney tumour.  Data collection on occupational sun exposure only 
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identified a small number of patients (n=3) with a high risk occupation (working long hours 
outdoors and/or significant time working in the middle-east). Therefore I was not able to 
study this with regards to either age of onset of fibrofolliculomas or severity of 
fibrofolliculomas in terms of number, distribution and growth. It would be interesting to 
compare this with a cohort of BHD patients in another country such as Australia with an 
increased sun exposure compared to the UK. 
At the start of this project, I established and curated variants into the FLCN Locus Specific 
Database (available at www.lovd.nl/flcn) and analysed the contents of the database. 
Mutations in the FLCN gene have been reported spanning all coding exons (Lim et al., 
2010a; Wei et al., 2009). Recently, large intragenic deletions and duplications have also 
been reported by using copy-number detection techniques such as MLPA (Benhammou et 
al., 2011; Kunogi et al., 2010; Sempau et al., 2010). Therefore, mutation negative patients 
with clinical features of BHD who were investigated a number of years ago only by 
sequencing of FLCN should have updated molecular testing by MLPA. This would be 
expected to increase the mutation detection rate by a further 5%. From my results although 
there appear to be no genotype-phenotype correlations evident with regards to the location 
of the mutation with a corresponding phenotype of BHD, PSP or FcRCC, however, this may 
reflect the criteria for diagnosis of these conditions and the effect of variability of the clinical 
phenotype. For example, from the results of our study, the skin manifestations can be quite 
mild or may not have manifested yet in a FLCN mutation carrier depending on the age 
whereby the patient has been assessed. In addition, using the new diagnostic criteria 
proposed by the European BHD consortium, individuals who have been diagnosed as having 
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PSP or FcRCC who have a germline FLCN mutation would now be classified as having BHD, 
despite the absence of the other features of BHD.  
In summary this BHD clinical and molecular study contributes a further 118 FLCN mutation 
positive BHD patients from 39 families to the medical literature and represent the largest 
cohort of BHD patients in the UK. It presents a total of 5985 patient years of natural history 
data with age related penetrance of the various manifestations of BHD. The study provides 
further evidence of allelic heterogeneity and modifying genetic factors as a potential cause 
of variability of the phenotype in BHD. 
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CHAPTER 4. OVERALL CONCLUSIONS 
4.1 CLINICAL AND EPIGENETIC INVESTIGATIONS OF BWS 
I studied a cohort of ART conceived BWS patients and found that the predominant (96%) 
molecular defect causing BWS in this group are IC2 epimutations (loss of methylation at 
KvDMR1). This is in contrast to naturally conceived sporadic BWS cases where 50% of cases 
have IC2 epimutations. Comparing the phenotypes of ART conceived and naturally 
conceived BWS patients with IC2 epimutations, I found phenotypic differences: a reduced 
incidence of exomphalos, increased facial naevus flammeus and an increased risk of non-
Wilms tumour neoplasia in the ART conceived cases. There were no incidences of Wilms 
tumour in both cohorts. I studied the possible cause of this variation by looking for evidence 
of additional loss of methylation (epimutations) at other imprinted loci that are normally 
methylated in the maternal allele at 6q24 (PLAGL1 DMR), 7q32 (PEG1 DMR) and 15q13 
(SNRPN DMR) and found additional loss of methylation cases in both cohorts. The frequency 
of additional loss of methylation were significantly higher in the ART conceived BWS cohort 
(37.5% vs 6.4% p=0.034). In the subgroup of BWS patients with additional loss of 
methylation at multiple imprinted loci I looked for evidence of loss or gain of methylation at 
the DLK1 DMR at 14q32 and found none. The observations in this study suggest that the 
process of ART act as an environmental modifier that increases the risk of epimutations at 
imprinted DMRs. The variation in phenotype between the ART conceived and naturally 
conceived BWS cases could be caused by these methylation abnormalities acting as 
epigenetic modifiers of the phenotype. 
150 
 
 
4.2 NATURAL HISTORY OF BIRT-HOGG-DUBE SYNDROME 
Studying the FLCN Mutation positive BHD patients in this UK cohort the following 
observations are made. The three main organ systems that are affected in BHD are the skin, 
lungs and kidneys. The most penetrant manifestation is the skin fibrofolliculomas with a 
lifetime risk of 97% and a mean age of onset of 34.1 years. The second most common 
manifestation are the lung cysts with a prevalence of 68%. The lifetime risk of developing a 
pneumothorax is 33%. The lifetime risk of renal cell carcinoma in this cohort is 36.8% with a 
median age of diagnosis of 52 years (range 25-85). The renal tumours that occur in BHD 
show features of other kidney cancer predisposition syndromes including the presence of 
bilateral and multifocal tumours. Therefore BHD patients will require annual surveillance for 
renal tumour by MRI scans. The lifetime risk of colon cancer is 13% with a median age of 
diagnosis of 55 years (range 27-64) and may be mutation-dependant. There is inter- and 
intra-familial variation in the various features of BHD that could be explained by allelic 
heterogeneity and modifying genetic factors. I also identified a novel genotype-phenotype 
correlation with the Leu449Phen frameshift mutation that increases the risk of renal cell 
carcinoma in BHD. 
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4.3 CAUSES OF PHENOTYPIC VARIABILITY IN BECKWITH-WIEDEMANN SYNDROME AND BIRT-
HOGG-DUBE SYNDROME 
Variability in the phenotype of genetic disorders can occur as a result of multiple causes 
including allelic heterogeneity, locus heterogeneity, genetic and epigenetic modifiers, 
environmental modifiers and chance. In my MD project, I studied two genetic kidney 
tumour predisposition syndromes Beckwith-Wiedemann syndrome (BWS) and Birt-Hogg-
Dube syndrome (BHD) to study factors that affect variability in these two conditions. 
4.3.1 BECKWITH WIEDEMAN SYNDROME 
4.3.1.1 Locus Heterogeneity 
In BWS, I have shown that in agreement with previous studies, locus heterogeneity at 
11p15.5 plays an important role in the variability of the phenotype in BWS. In the BWS IC2 
epimutation cohort (both ART and naturally conceived) studied here, there was no 
occurrence of Wilms tumour. This is in keeping with previous findings and studies suggesting 
that the increased Wilms tumour risk is associated with an overexpression of IGF2 due to 
upd(11)pat and IC1 epimutation (H19 DMR hypermethylation).   
Locus heterogeneity has also been demonstrated in other human imprinting syndromes. In 
Silver-Russell syndrome (SRS), phenotypic differences have been described between SRS 
cases with H19 DMR hypomethylation and upd(7)mat cases (Wakeling et al., 2010). Learning 
difficulties and speech delay were more frequent in the upd(7)mat group but congenital 
anomalies and fifth finger clinodactyly occurred more frequently in the H19 DMR 
hypomethylation group. 
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4.3.1.2 Epigenetic Modifiers 
I also demonstrated that trans- acting epigenetic modifiers (loss of methylation at various 
imprinted loci) can affect the phenotype in BWS. This study shows that there is variation in 
the phenotype of BWS cases conceived with ART compared to naturally conceived BWS 
cases with IC2 epimutations. There was a reduced incidence of exomphalos, an increased 
incidence of facial naevus flemmeus and more importantly a potentially increased incidence 
of non-Wilms tumour embryonal tumours in the ART conceived BWS cases. This difference 
in phenotype could be potentially explained by the presence of further epigenetic 
alterations by the finding of additional loss of methylation at other imprinted loci. This 
variation in phenotype due to additional loss of methylation at other imprinted loci has also 
been seen in another human imprinting syndrome Transient Neonatal Diabetes (TNDM) 
(Mackay et al., 2006a).  
4.3.1.3 Environmental modifiers 
The use of assisted reproductive technologies (ART) is a possible environmental factor that 
can affect phenotype by increasing the risk of loss of methylation at multiple imprinted loci. 
In BWS cases where sporadic naturally conceived cases have been shown to be due to IC2 
epimutation (KvDMR1 hypomethylation) in 50% of cases, in ART conceived BWS cases, 
almost all cases are due to this epimutation. The incidence of multi imprinted loci loss of 
methylation was also significantly higher in BWS cases conceived by ART. As discussed 
above, this could explain the difference in phenotype between the two groups of BWS 
patients. 
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4.3.2 BIRT-HOGG-DUBE SYNDROME 
4.3.2.1 Allelic Heterogeneity 
In BHD syndrome, I have showed that there is both intra and inter-familial variation in 
expression of the clinical phenotype as well as penetrance of the various features 
(fibrofolliculomas, lung cysts, pneumothorax, renal cancer and colorectal cancer).  I also 
found that different mutations can apparently influence the risk of specific tumours that 
occur in BHD syndrome. A particular frameshift mutation c.1318_1334dup17 
(p.Leu449PhenfsX27) conferred a higher risk of renal cancer in the UK cohort BHD patients 
compared to the exon 11 common mutation. In addition, the incidence of colorectal cancer 
appears to be higher in patients with the presence of the exon 11 common mutation and 
appears to segregate in some families. 
In another genetic kidney predisposition syndrome VHL disease, similar allelic heterogeneity 
has been described with the variable risk of certain tumour types. Phaechromocytoma is 
reported to be associated with an increased risk in the presence of certain missense 
mutations in the VHL gene and a decreased risk in the presence of truncating mutations or 
large deletions (Chen et al., 1995; Crossey et al., 1994; Maher et al., 1996). 
4.3.2.2 Genetic Modifiers 
In the BHD study I have shown evidence of the likely presence of genetic modifiers 
influencing the age of onset of the skin fibrofolliculomas in FLCN mutation positive BHD 
patients. By comparing the age of onset of fibrofolliculomas between different degrees of 
relationships between the FLCN mutation positive patients, I have shown a statistically 
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significant closer correlation of the age of onset of fibrofolliculomas in first degree relatives 
(siblings and parent-child) compared to more distantly related relatives. 
Similarly in VHL disease, pair wise analysis looking at the number of ocular angiomas that 
occurred identified evidence for genetic modifiers with first degree relative (siblings and 
parent-child) showing statistically significant correlation (Webster et al., 1998). 
The finding of a second genetic cancer predisposition allele (a TP53 missense variant) in one 
of the FLCN mutation positive BHD patients in this cohort with multiple primary tumours 
together with other reported FLCN mutation positive BHD patients with MINAS (multiple 
inherited neoplasia allele syndrome) developing multiple primary tumours reveals a “trans-
acting” genetic modifier. Other examples of these in the literature include children with 
more than one autosomal recessive condition due to consanguinity in the family (Marin et 
al.) and co-occurrence of rare genetic diseases in non-consanguineous families (Adams et 
al., 2014), both of which can causes overlapping or complex phenotypes. 
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CHAPTER 5. FUTURE DIRECTIONS 
5.1 BECKWITH-WIEDEMANN SYNDROME  
5.1.1 DISCOVERY OF NEW EPIGENETIC LOCI MODIFIERS 
Further analysis of a larger number of DMRs in more extensive cohorts of BWS patients 
should provide further information on the relative frequencies of abnormal methylation at 
different imprinted loci in ART conceived and naturally conceived BWS patients. Whole 
genome methylation array and whole genome bisulphite sequencing can be considered to 
determine extent of methylation disturbance on a larger scale. 
5.1.2 IDENTIFICATION OF GENETIC BASIS TO EXPLAIN RISK OF BWS IN ART 
The use of next generation sequencing techniques such as whole exome or genome 
sequencing of trios of parents and affected child in ART conceived BWS compared to 
controls may help elucidate the genetic basis of why only some children who are conceived 
with ART develop BWS. 
5.1.3 IDENTIFICATION OF TRANS-ACTING GENES THAT AFFECT IMPRINTING 
The occurrence of MLID is not restricted to ART conceived BWS cases but is also seen, albeit 
less frequently, in naturally conceived BWS cases. Currently there are 4 known trans-acting 
genes that can be associated with MLID (NLRP2, NRLP5, NRLP7 and ZFP57). Whole exome or 
genome sequencing of cohorts of BWS patients with multiple imprinted DMR 
hypomethylation (affected child and unaffected parent trio) can be undertaken to identify 
known or novel trans-acting genes that affect imprinting in the proband.  Sequencing the 
grandparents in addition can also help clarify significance of variants identified, clarify phase 
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and parent of origin effects, and help interpret variants in mothers of affected probands in 
potential maternal effect genes affecting imprinting in trans. 
5.2 BIRT-HOGG-DUBE SYNDROME 
5.2.1 LARGE PROSPECTIVE COHORT STUDIES 
The observations in this MD project provide a basis for large collaborative studies to further 
delineate the natural history as well as investigate the molecular basis of our findings in a 
large cohort of BHD patients. As BHD remains a rare and under-recognised condition, such a 
study would have to be collaborative and multinational to achieve such an objective. 
International consensus on management of the cancer risk and surveillance can be guided 
by the results of such studies. 
5.2.2 MULTIPLE PRIMARY TUMOUR STUDY 
Another avenue for investigation in BHD is to undertake exome or whole genome 
sequencing of constitutional and tumour DNA in affected patients with multiple primary 
tumours (and tumours that do not fit with a single genetic cause) to detect cohorts that may 
have multiple inherited neoplasia allele syndrome (MINAS).  
5.2.3 IDENTIFICATION OF MOLECULAR CAUSE OF BHD IN FLCN MUTATION NEGATIVE CASES 
In a cohort of families with a clinical diagnosis of BHD who test negative for FLCN mutations 
and copy number changes, further studies by whole exome or genome sequencing have the 
potential to identify the molecular cause of their disease. This could be a novel gene or a 
mutation not currently detectable using current techniques of sequencing and copy number 
detection. 
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Appendix C  FOLLICULIN (FLCN) CODING DNA REFERENCE SEQUENCE 
 (used for mutation description) (last modified June 18, 2009) 
 
The sequence was taken from NM_144997.5  Please note that introns are available by 
clicking on the exon numbers above the sequence.  
 
 (upstream sequence) 
                                         .         .                g.5024 
                                     gagtcacgcgcctgggtgtcggcg       c.-481 
 
 .         .         .         .         .         .                g.5084 
 gggctgcgggaccgcgagtgagtgtggtcgctcctggttctgccagctcccctgagagcc       c.-421 
 
 .         .         .         .         .         .                g.5144 
 tgaacccgggcttgagagcctcgccaccccgggtgacatccctgccgtgggcttgggggc       c.-361 
 
 .         .         .         .         .         .                g.5204 
 tctgggtgtgattccgccggtccgggtcccgcagcgaccacctacccagcgcagtcaggg       c.-301 
 
 .         .         .         .         .         .                g.5264 
 gcggggctgggacccagagcgggaccccggctgccgagtccaggtgtcccgcgggcctcg       c.-241 
 
 .         .   | 02     .         .         .         .             g.9334 
 atttggggagcag | aaaacgccaggtcttcaagggtgtctgccaccaccatgcctgaccca    c.-181 
 
 .         .         .         .         .         .                g.9394 
 tttggcagcagcctcgtgtgtggtggtctggtgtggacggtggaagcgtgattctgctga       c.-121 
 
 .       | 03 .         .         .         .         .             g.10359 
 gtgtcag | tgtgaccactcgtgctcagccgtatctcagcaggaggacaggtgccggagcag    c.-61 
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 .         .         .         .      | 04  .         .             g.14051 
 ctcgtgcagctaagcagccaactgcagaaacgtcag | gcctgttgcagtctccaaggcacc    c.-1 
 
          .         .         .         .         .         .       g.14111 
 ATGAATGCCATCGTGGCTCTCTGCCACTTCTGCGAGCTCCACGGCCCCCGCACTCTCTTC       c.60 
 M  N  A  I  V  A  L  C  H  F  C  E  L  H  G  P  R  T  L  F         p.20 
 
          .         .         .         .         .         .       g.14171 
 TGCACGGAGGTGCTGCACGCCCCACTTCCTCAAGGGGATGGGAATGAGGACAGTCCTGGC       c.120 
 C  T  E  V  L  H  A  P  L  P  Q  G  D  G  N  E  D  S  P  G         p.40 
 
          .         .         .         .         .         .       g.14231 
 CAGGGTGAGCAGGCGGAAGAAGAGGAAGGTGGCATTCAGATGAACAGTCGGATGCGTGCG       c.180 
 Q  G  E  Q  A  E  E  E  E  G  G  I  Q  M  N  S  R  M  R  A         p.60 
 
          .         .         .         .         .         .       g.14291 
 CACAGCCCCGCAGAGGGGGCCAGCGTCGAGTCCAGCAGCCCGGGGCCCAAAAAGTCGGAC       c.240 
 H  S  P  A  E  G  A  S  V  E  S  S  S  P  G  P  K  K  S  D         p.80 
 
           | 05        .         .         .         .         .    g.15917 
 ATGTGCGAG | GGCTGCCGGTCACTTGCTGCAGGGCACCCGGGATATATCAGCCATGATAAA    c.300 
 M  C  E   | G  C  R  S  L  A  A  G  H  P  G  Y  I  S  H  D  K      p.100 
 
          .         .         .         .         .         .       g.15977 
 GAGACCTCCATTAAATACGTCAGCCACCAGCACCCCAGCCACCCCCAGCTCTTCAGCATT       c.360 
 E  T  S  I  K  Y  V  S  H  Q  H  P  S  H  P  Q  L  F  S  I         p.120 
 
          .         .         .       | 06 .         .         .    g.18069 
 GTCCGCCAGGCCTGTGTCCGGAGCCTGAGCTGTGAG | GTCTGCCCTGGCCGTGAAGGCCCC    c.420 
 V  R  Q  A  C  V  R  S  L  S  C  E   | V  C  P  G  R  E  G  P      p.140 
184 
 
 
          .         .         .         .         .         .       g.18129 
 ATCTTCTTCGGAGATGAGCAGCACGGCTTTGTGTTCAGCCACACCTTCTTCATCAAGGAC       c.480 
 I  F  F  G  D  E  Q  H  G  F  V  F  S  H  T  F  F  I  K  D         p.160 
 
          .         .         .         .         .         .       g.18189 
 AGCCTGGCCAGGGGCTTCCAGCGCTGGTACAGCATCATCACCATCATGATGGACCGGATC       c.540 
 S  L  A  R  G  F  Q  R  W  Y  S  I  I  T  I  M  M  D  R  I         p.180 
 
          .         .         .         .         .         .       g.18249 
 TACCTCATCAACTCCTGGCCCTTCCTGCTGGGGAAGGTCCGGGGAATCATCGATGAGCTC       c.600 
 Y  L  I  N  S  W  P  F  L  L  G  K  V  R  G  I  I  D  E  L         p.200 
 
          .         | 07         .         .         .         .    g.19569 
 CAGGGCAAGGCGCTCAAG | GTGTTTGAGGCAGAGCAGTTTGGATGCCCACAGCGTGCTCAG    c.660 
 Q  G  K  A  L  K   | V  F  E  A  E  Q  F  G  C  P  Q  R  A  Q      p.220 
 
          .         .         .         .         .         .       g.19629 
 AGGATGAACACAGCCTTCACGCCATTCCTACACCAGAGGAACGGCAACGCCGCCCGCTCG       c.720 
 R  M  N  T  A  F  T  P  F  L  H  Q  R  N  G  N  A  A  R  S         p.240 
 
          .         .         .         .         .          | 08    
g.20561 
 CTGACATCGCTGACAAGTGATGACAACCTGTGGGCGTGCCTGCACACCTCCTTTGCCTG | G    c.780 
 L  T  S  L  T  S  D  D  N  L  W  A  C  L  H  T  S  F  A  W  |      p.260 
 
          .         .         .         .         .         .       g.20621 
 CTCCTGAAGGCGTGTGGCAGCCGGCTGACCGAGAAGCTCCTGGAAGGTGCTCCGACCGAG       c.840 
 L  L  K  A  C  G  S  R  L  T  E  K  L  L  E  G  A  P  T  E         p.280 
 
          .         .         .  | 09      .         .         .    g.23008 
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 GATACCTTGGTCCAGATGGAGAAGCTCGCTG | ATTTAGAAGAGGAATCAGAAAGCTGGGAC    c.900 
 D  T  L  V  Q  M  E  K  L  A  D |   L  E  E  E  S  E  S  W  D      p.300 
 
          .         .         .         .         .         .       g.23068 
 AACTCTGAGGCTGAAGAGGAGGAGAAAGCCCCTGTGTTGCCAGAGAGTACAGAAGGGCGG       c.960 
 N  S  E  A  E  E  E  E  K  A  P  V  L  P  E  S  T  E  G  R         p.320 
 
          .         .         .         .         .         .       g.23128 
 GAGCTGACCCAGGGCCCGGCAGAGTCCTCCTCTCTCTCAGGCTGTGGGAGCTGGCAGCCC       c.1020 
 E  L  T  Q  G  P  A  E  S  S  S  L  S  G  C  G  S  W  Q  P         p.340 
 
          .         .         .         .   | 10     .         .    g.25024 
 CGGAAGCTGCCAGTCTTCAAGTCCCTCCGGCACATGAGGCAG | GTCCTGGGTGCCCCTTCT    c.1080 
 R  K  L  P  V  F  K  S  L  R  H  M  R  Q   | V  L  G  A  P  S      p.360 
 
          .         .         .         .         .         .       g.25084 
 TTCCGCATGCTGGCCTGGCACGTTCTCATGGGGAACCAGGTGATCTGGAAAAGCAGAGAC       c.1140 
 F  R  M  L  A  W  H  V  L  M  G  N  Q  V  I  W  K  S  R  D         p.380 
 
          .         .         .       | 11 .         .         .    g.25709 
 GTGGACCTCGTCCAGTCAGCTTTTGAAGTACTTCGG | ACCATGCTTCCCGTGGGCTGCGTC    c.1200 
 V  D  L  V  Q  S  A  F  E  V  L  R   | T  M  L  P  V  G  C  V      p.400 
 
          .         .         .         .         .         .       g.25769 
 CGCATCATCCCATACAGCAGCCAGTACGAGGAGGCCTATCGGTGCAACTTCCTGGGGCTC       c.1260 
 R  I  I  P  Y  S  S  Q  Y  E  E  A  Y  R  C  N  F  L  G  L         p.420 
 
          .         .         .         . | 12       .         .    g.26892 
 AGCCCGCACGTGCAGATCCCCCCCCACGTGCTCTCCTCAG | AGTTTGCTGTCATCGTGGAG    c.1320 
 S  P  H  V  Q  I  P  P  H  V  L  S  S  E |   F  A  V  I  V  E      p.440 
186 
 
 
          .         .         .         .         .         .       g.26952 
 GTCCACGCAGCCGCACGTTCCACCCTCCACCCTGTGGGGTGTGAGGATGACCAGTCTCTC       c.1380 
 V  H  A  A  A  R  S  T  L  H  P  V  G  C  E  D  D  Q  S  L         p.460 
 
          .         .         .         .         .   | 13     .    g.27106 
 AGCAAGTACGAGTTTGTGGTGACCAGTGGGAGCCCTGTAGCTGCAGACCGAG | TGGGCCCC    c.1440 
 S  K  Y  E  F  V  V  T  S  G  S  P  V  A  A  D  R  V |   G  P      p.480 
 
          .         .         .         .         .         .       g.27166 
 ACCATCCTGAATAAGATTGAAGCGGCTCTGACCAACCAGAACCTGTCTGTGGATGTGGTG       c.1500 
 T  I  L  N  K  I  E  A  A  L  T  N  Q  N  L  S  V  D  V  V         p.500 
 
          .         .         .         | 14         .         .    g.28354 
 GACCAGTGCCTCGTCTGCCTCAAGGAGGAGTGGATGAA | CAAAGTGAAGGTGCTTTTTAAG    c.1560 
 D  Q  C  L  V  C  L  K  E  E  W  M  N  |  K  V  K  V  L  F  K      p.520 
 
          .         .         .         .         .         .       g.28414 
 TTCACCAAGGTGGACAGTCGACCCAAAGAGGACACACAGAAGCTGCTGAGCATCCTGGGT       c.1620 
 F  T  K  V  D  S  R  P  K  E  D  T  Q  K  L  L  S  I  L  G         p.540 
 
          .         .         .         .         .         .       g.28474 
 GCGTCCGAGGAGGACAATGTCAAGCTGCTGAAGTTCTGGATGACTGGCCTGAGCAAGACC       c.1680 
 A  S  E  E  D  N  V  K  L  L  K  F  W  M  T  G  L  S  K  T         p.560 
 
          .         .         .         .         .         .       g.28534 
 TACAAGTCACACCTCATGTCCACGGTCCGCAGCCCCACAGCCTCGGAGTCTCGGAACTGA       c.1740 
 Y  K  S  H  L  M  S  T  V  R  S  P  T  A  S  E  S  R  N  X         p.579 
 
          .         .         .         .         .         .       g.28594 
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 cccgtcacacacacctgcctaaagacagggatggctgtccacaggatcctccagccccgt       c.*60 
 
          .         .         .         .         .         .       g.28654 
 gagagggactgtcccttgagtttctcaactgctggaaggagctgtgtcccagcaaggaag       c.*120 
 
          .         .         .         .         .         .       g.28714 
 ggaaaccatcagggctgggctcggccctgtcaggtttggggcctgtgtgcttcccagact       c.*180 
 
          .         .         .         .         .         .       g.28774 
 ctccctccagccgttggaatcgctgaagatggcaatgaaaggcggagggatgatgggctc       c.*240 
 
          .         .         .         .         .         .       g.28834 
 tctctgtgttcaaactccttggagagacgactaggaggacagcttgcctcccaggcccct       c.*300 
 
          .         .         .         .         .         .       g.28894 
 tgtggacttagactcaaaacccgcaggagaaacaggtccgactcagtatgcagtcgcaat       c.*360 
 
          .         .         .         .         .         .       g.28954 
 aacatgtctgctcccgaggttaacattcaagcgtttctactttgaaattcagcaagagtt       c.*420 
 
          .         .         .         .         .         .       g.29014 
 tctgggccttatgtttgagggtaccttttgctgcagttgtgaatattcagtacattgcca       c.*480 
 
          .         .         .         .         .         .       g.29074 
 gctcttggtcactgagtgattgagttagggctccgcaagagactttggggagtgaagtgg       c.*540 
 
          .         .         .         .         .         .       g.29134 
 atctcttcctcatcttttggtcctctgaaatgtgtgttctgaagccatggggctcgtctt       c.*600 
 
          .         .         .         .         .         .       g.29194 
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 ctggggtgttcccctgcaggtgctggtgaaggtaacctggggcttaatgatggagtccct       c.*660 
 
          .         .         .         .         .         .       g.29254 
 gatcatttttgcacaagacaggttgctgaggggtcggcaagcatctgacttgcccaatcc       c.*720 
 
          .         .         .         .         .         .       g.29314 
 cctggatatggtgagccccgccatgcttttattctgtatcgcttttgtctttattgctgc       c.*780 
 
          .         .         .         .         .         .       g.29374 
 tttcaacatttacgtttggttacagttaactattttcggagtgtggtgattgaagacaat       c.*840 
 
          .         .         .         .         .         .       g.29434 
 ttcatcatcccactgtacttttttttttgagagggagtttcactcttgttgcccaggctg       c.*900 
 
          .         .         .         .         .         .       g.29494 
 gagtgcaatggcacgatcttggctcactgcaacctctgcctcctgggttcaagcaattct       c.*960 
 
          .         .         .         .         .         .       g.29554 
 cctgcctcagcctccagagtagctggaactacaggtgcccgccactatgcccagctaatt       c.*1020 
 
          .         .         .         .         .         .       g.29614 
 tttgtattttttagtagagacggggtttcaccgtgttggccgggctggtctcaaactcct       c.*1080 
 
          .         .         .         .         .         .       g.29674 
 gacctcaggtgatccacccacctcagcctcccaaagtgctgggattacaagcgtgagcca       c.*1140 
 
          .         .         .         .         .         .       g.29734 
 ctgtgcctggcccttttttttttttttttttttttttttaaagagatggcatcttgctat       c.*1200 
 
          .         .         .         .         .         .       g.29794 
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 gtcgtccaggctggtcttgaactcctgagttcaagcagtcctcctgcttcaacatacagc       c.*1260 
 
          .         .         .         .         .         .       g.29854 
 tacaggtaccccccactatacatttttaataaggattcatggctcagagggattttctga       c.*1320 
 
          .         .         .         .         .         .       g.29914 
 tggttttgctgatttgtttctagtttttttgtgtttatatttaacatgaagaccaagttt       c.*1380 
 
          .         .         .         .         .         .       g.29974 
 atataactaggtatctgtataatgcaacaacattggaacacaataaagatgtatttttgt       c.*1440 
 
                                                                    g.29977 
 aaa                                                                c.*1443 
 (downstream sequence) 
Legend: 
Nucleotide numbering (following the rules of the HGVS for a 'Coding DNA Reference 
Sequence') is indicated at the right of the sequence, counting the A of the ATG 
translation initiating Methionine as 1. Every 10th nucleotide is indicated by a "." above the 
sequence. The Folliculin protein sequence is shown below the coding DNA sequence, with 
numbering indicated at the right starting with 1 for the translation initiating Methionine. 
Every 10th amino acid is shown in bold. The position of introns is indicated by a vertical 
line, splitting the two exons. The start of the first exon (transcription initiation site) is 
indicated by a '\', the end of the last exon (poly-A addition site) by a '/'. The exon 
number is indicated above the first nucleotide(s) of the exon. To aid the description of 
frame shift mutations, all stop codons in the +1 frame are shown in bold while all 
stop codons in the +2 frame are underlined. 
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Appendix E  PRESENTATIONS ARISING FROM THIS THESIS 
Platform presentations: 
Clinical investigation of the UK cohort of FLCN mutation positive Birt-Hogg-Dube syndrome 
patients: 
1. The 91st Annual Meeting of the British Association of Dermatologist (BAD):  London 
July 2011 (Plenary session) 
2. American Society of Human Genetics (ASHG) conference: Washington DC November 
2010 (Concurrent session) 
3. British Human Genetics Conference: Warwick September 2010 (Concurrent session) 
Investigating the Folliculin (FLCN) mutation positive Birt-Hogg-Dube syndrome patients in 
the UK: Clinical and Molecular Genetic analysis: 
1. 3rd International Birt-Hogg-Dube syndrome Symposium: Maastricht May 2011  
Germline mutation in NLRP2 (NALP2) in a familial imprinting disorder (Beckwith-
Wiedeman Syndrome): 
1. European Society of Human Genetics:  Human Genetics Conference: Vienna May 
2009 (Concurrent session) 
2. Epigenome Network of Excellence (NOE) meeting: Edinburgh June 2009 
Clinical and molecular genetic features of Beckwith-Wiedemann Syndrome associated 
with Assisted Reproductive Technologies: 
1. UK Clinical Genetics Society (CGS) Spring meeting: Liverpool May 2008 
Seminars: 
Clinical and molecular genetic investigation of Birt-Hogg-Dube syndrome: 
1. West Midlands Regional Genetics Service – Genetics  Directorate lunchtime Seminar 
September 2010 
2. Department of Genetic Medicine Manchester – Genetics seminar October 2012 
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3. West Midlands Dermatogenetics meeting  - Seminar November 2009 
 
Clinical and molecular genetic features of Beckwith-Wiedemann Syndrome associated 
with Assisted Reproductive Technologies: 
1. West Midlands Regional Genetics Service – Genetics  Directorate lunchtime Seminar 
September 2009 
Poster presentations: 
The Folliculin (FLCN) mutation database: an online resource for FLCN sequence variants 
involved in Birt-Hogg-Dube syndrome 
1. The 5th National Cancer Research Institute (NCRI) Cancer Conference: – Birmingham 
October  2009 
2. UK Cancer Genetics Group (CGG) Spring Meeting – Glasgow May 2009 – BEST 
POSTER PRIZE  
Clinical and molecular genetic features of Beckwith-Wiedemann Syndrome associated 
with Assisted Reproductive Technologies: 
1. University of Birmingham College of Medical and Dental Sciences Research & 
Enterprise Gala April 2010 
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Appendix F  PATIENT INFORMATION SHEETS AND CONSENT FORMS CREATED 
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Appendix G  PATIENT INFORMATION LEAFLETS REVIEWED FOR WWW.BHDSYNDROME.ORG 
 
Birt-Hogg-Dube syndrome: Clinical Introduction 
www.bhdsyndrome.org/wp-content/uploads/2012/05/pamphlet-clinician-info-2015.pdf 
Birt-Hogg-Dube syndrome: Diagnosis Information 
www.bhdsyndrome.org/wp-content/uploads/2013/11/BHD-pamphlet-diagnosis-2015.pdf 
Birt-Hogg-Dube syndrome: Skin Symptoms and Treatment Options 
www.bhdsyndrome.org/wp-content/uploads/2013/11/BHD-pamphlet-skin-2015.pdf 
Birt-Hogg-Dube syndrome: Kidney Symptoms 
www.bhdsyndrome.org/wp-content/uploads/2013/11/BHD-pamphlet-kidney-symp-
2015.pdf 
Birt-Hogg-Dube syndrome: Kidney Treatment Options 
www.bhdsyndrome.org/wp-content/uploads/2013/11/BHD-pamphlet-kidney-treatment-
2015.pdf 
Birt-Hogg-Dube syndrome: Lung Symptoms and Treatment Options 
www.bhdsyndrome.org/wp-content/uploads/2013/11/BHD-pamphlet-lung-v61.pdf 
 
